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There	  is	  substantial	  evidence	  of	  considerable	  insensitivity	  affecting	  the	  current	  tests	  
used	  to	  screen	  for	  urinary	  infection.	  The	  studies	  within	  this	  thesis	  provide	  original	  work	  
in	  examining	  the	  performance	  of	  recommended	  diagnostic	  tests	  for	  urinary	  tract	  
infection,	  and	  explore	  the	  bacterial	  ecology	  of	  urinary	  infection	  and	  its	  associated	  
urothelial	  inflammatory	  response	  in	  patients	  with	  symptoms	  of	  overactive	  bladder.	  	  
	  
The	  association	  between	  lower	  urinary	  tract	  inflammation,	  bacterial	  colonisation	  and	  
the	  generation	  of	  overactive	  bladder	  symptoms	  was	  explored.	  An	  enhanced	  bacterial	  
culture	  method	  was	  used	  and	  quantitative	  thresholds	  discredited.	  Comparative	  data	  
from	  patients	  and	  controls	  demonstrated	  that	  bacterial	  urinary	  infection	  was	  evident	  in	  
ninety	  percent	  of	  patients.	  Quantitative	  and	  qualitative	  differences	  in	  the	  bacterial	  
ecology	  were	  found	  amongst	  patients	  and	  controls.	  These	  were	  associated	  with	  
increased	  urothelial	  inflammation	  amongst	  patients.	  
	  
Adenosine-­‐5'-­‐triphosphate	  (ATP)	  is	  a	  neurotransmitter	  and	  inflammatory	  cytokine	  
implicated	  in	  the	  pathophysiology	  of	  lower	  urinary	  tract	  disease.	  ATP	  additionally	  
reflects	  microbial	  biomass,	  thus	  may	  function	  as	  a	  surrogate	  marker	  of	  urinary	  tract	  
infection	  (UTI).	  The	  potential	  of	  urinary	  ATP	  in	  the	  assessment	  of	  lower	  urinary	  tract	  
symptoms,	  infection	  and	  inflammation	  was	  tested.	  Sampling	  techniques	  suitable	  for	  
clinical	  practice	  were	  validated.	  Urinary	  ATP	  was	  reviewed	  as	  a	  marker	  of	  infection	  in	  
patients	  with	  lower	  urinary	  tract	  symptoms.	  Though	  it	  may	  have	  a	  role	  as	  a	  research	  
tool,	  it	  was	  unconvincing	  as	  a	  surrogate,	  clinical	  diagnostic	  marker.	  Several	  urinary	  
cytokines	  were	  explored	  and	  urinary	  IL6	  and	  Lactoferrin	  varied	  in	  relation	  to	  surrogate	  
markers	  of	  infection	  in	  patients	  with	  overactive	  bladder	  symptoms.	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1 Chapter	  1	  –	  Introduction	  
1.1 Epidemiology	  of	  lower	  urinary	  tract	  symptoms	  
Lower	  urinary	  tract	  symptoms	  (LUTS)	  is	  a	  collective	  term	  describing;	  1)	  urinary	  storage	  
problems	  such	  as	  frequency,	  urgency	  and	  urge	  incontinence;	  2)	  voiding	  difficulties	  such	  
as	  hesitancy,	  reduced	  stream,	  intermittency	  and	  incomplete	  voiding;	  3)	  sensory	  
symptoms	  that	  include	  experiences	  of	  pain;	  and	  4)	  stress	  urinary	  incontinence	  (1,	  2).	  	  
Large	  population	  based	  studies	  have	  shown	  that	  LUTS	  is	  a	  global	  problem,	  affecting	  
men	  and	  women,	  and	  increases	  with	  age.	  The	  EpiLUTS	  study	  collected	  data	  from	  30,000	  
volunteers	  from	  US,	  UK	  and	  Sweden	  and	  reported	  the	  prevalence	  of	  at	  least	  one	  LUTS,	  
at	  least	  ‘sometimes’,	  as	  72.3%	  for	  men	  and	  76.3%	  for	  women,	  and	  at	  least	  ‘often’	  for	  
47.9%	  of	  men	  and	  52.5%	  of	  women.	  	  The	  study	  reported	  that	  for	  most	  LUTS,	  at	  least	  
half	  of	  the	  participants	  were	  bothered	  ‘somewhat’	  or	  more	  and	  hence	  such	  symptoms	  
have	  a	  significant	  impact	  on	  quality	  of	  life	  (3).	  Irwin	  et	  al	  estimated	  that	  in	  2008,	  45.2%	  
of	  the	  world	  population	  was	  affected	  by	  at	  least	  one	  LUTS	  with	  an	  estimated	  rise	  to	  2.3	  
billon	  (18.4%	  increase)	  by	  2018	  (4).	  In	  addition	  there	  is	  considerable	  overlap	  between	  
these	  symptoms	  (3,	  5)	  so	  that	  diagnostic	  categorisation	  may	  be	  difficult.	  	  These	  
conditions	  are	  stigmatising	  (6)	  and	  are	  associated	  with	  a	  substantial	  economic	  burden	  
(7,	  8)	  with	  an	  estimated	  annual	  cost	  of	  £80	  million	  to	  the	  NHS	  on	  continence	  products	  
alone.	  	  
	  
In	  women,	  risk	  factors	  for	  LUTS	  include	  the	  menopause,	  pregnancy	  and	  parity,	  mode	  of	  
delivery	  and	  obesity.	  Women	  are	  more	  likely	  than	  men	  to	  have	  stress	  incontinence.	  
Pregnancy,	  childbirth,	  menopause	  and	  normal	  female	  anatomy	  may	  account	  for	  this	  
difference.	  However,	  men	  with	  prostate	  gland	  problems	  are	  at	  increased	  risk	  of	  urge	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and	  overflow	  incontinence.	  	  Other	  risk	  factors	  include	  age,	  obesity,	  smoking	  and	  chronic	  
cough,	  constipation	  and	  other	  medical	  conditions	  that	  may	  affect	  kidney	  function.	  	  
	  
In	  patients	  presenting	  with	  LUTS,	  whatever	  the	  symptom	  mix,	  the	  exclusion	  of	  UTI	  is	  a	  
mandatory	  first	  step	  in	  the	  assessment	  of	  all	  LUTS	  (9).	  Whilst	  acute	  UTI	  is	  not	  
diagnostically	  challenging	  (10),	  in	  the	  case	  of	  LUTS	  without	  acute	  frequency	  and	  dysuria,	  
exclusion	  of	  infection	  poses	  a	  diagnostic	  challenge.	  	  	  
	  
1.2 Urinary	  tract	  system	  –	  Anatomy	  and	  function	  	  	  
The	  lower	  urinary	  tract	  contains	  the	  bladder	  and	  urethra.	  The	  micturition	  cycle	  
describes	  the	  filling,	  storage	  and	  voluntary	  emptying	  of	  the	  bladder.	  The	  bladder	  is	  a	  
muscular	  organ,	  which	  is	  situated	  below	  the	  peritoneal	  cavity	  near	  the	  pelvic	  floor.	  In	  
men,	  it	  lies	  in	  front	  of	  the	  rectum	  and	  in	  women	  it	  lies	  in	  front	  of	  the	  uterus.	  	  Urine	  
collects	  in	  the	  bladder	  from	  the	  kidneys	  via	  both	  ureters,	  which	  open	  into	  the	  bladder	  
though	  ureteric	  orifices.	  Urine	  is	  expelled	  from	  the	  bladder	  through	  the	  urethra,	  a	  single	  
muscular	  tube,	  which	  ends	  in	  the	  urethral	  orifice.	  Anatomically,	  the	  bladder	  is	  divided	  
into	  a	  dome,	  two	  ureteric	  orifices,	  and	  an	  opening	  for	  the	  urethra,	  which	  surrounds	  the	  
trigone	  at	  the	  base	  of	  the	  bladder.	  In	  men,	  the	  prostate	  gland	  lies	  outside	  the	  opening	  
for	  the	  urethra	  (11).	  
	  
The	  bladder	  is	  composed	  of	  three	  layers	  consisting	  of	  the	  mucosal	  layer,	  the	  smooth	  
muscle	  known	  as	  the	  detrusor	  and	  the	  serosal	  surface.	  	  The	  mucosa	  has	  been	  described	  
to	  consist	  of	  the	  urothelium,	  which	  is	  exposed	  to	  urine,	  a	  single	  layer	  of	  cells	  known	  the	  
basement	  membrane	  and	  the	  lamina	  propria,	  which	  is	  an	  interface	  between	  the	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mucosa	  and	  bladder	  muscle	  (12,	  13).	  	  The	  muscular	  layer	  of	  the	  bladder	  is	  known	  as	  the	  
detrusor,	  which	  consists	  of	  smooth	  muscle,	  with	  bundles	  know	  as	  fascicles.	  	  	  	  	  
	  
The	  innervation	  of	  the	  body	  of	  the	  bladder	  differs	  from	  the	  bladder	  outlet,	  where	  the	  
body	  is	  rich	  in	  beta-­‐adrenergic	  receptors.	  These	  receptors	  are	  stimulated	  by	  the	  
sympathetic	  component	  of	  the	  autonomic	  nervous	  system	  (ANS).	  Beta	  stimulation,	  via	  
fibres	  of	  the	  hypogastric	  nerve,	  suppresses	  contraction	  of	  the	  detrusor.	  Conversely,	  
parasympathetic	  stimulation,	  by	  fibres	  from	  the	  pelvic	  nerve	  and	  plexus,	  causes	  the	  
detrusor	  to	  contract.	  Sympathetic	  stimulation	  is	  thought	  to	  be	  predominant	  during	  
bladder	  filling,	  and	  the	  parasympathetic	  thought	  to	  cause	  emptying	  (14).	  	  The	  urethra,	  
though	  anatomically	  differ	  in	  males	  and	  females,	  functions	  similarly.	  	  The	  bladder	  outlet	  
is	  composed	  of	  the	  urethral	  sphincter	  consisting	  of	  the	  internal	  and	  external	  sphincter.	  
The	  internal	  sphincter	  is	  composed	  of	  smooth	  muscle	  like	  the	  detrusor	  and	  extends	  into	  
the	  bladder	  neck.	  Like	  the	  detrusor,	  the	  internal	  sphincter	  is	  controlled	  by	  the	  ANS	  and	  
is	  normally	  closed.	  The	  primary	  receptors	  in	  the	  bladder	  neck	  are	  alpha-­‐adrenergic.	  
Sympathetic	  stimulation	  of	  these	  alpha-­‐receptors,	  via	  fibres	  in	  the	  hypogastric	  nerve,	  is	  
thought	  to	  contribute	  to	  urinary	  continence.	  The	  external	  sphincter	  is	  histologically	  
different	  from	  the	  detrusor	  and	  internal	  sphincter,	  and	  consists	  of	  striated	  muscle	  
under	  voluntary	  control.	  It	  receives	  its	  innervation	  from	  the	  pudendal	  nerve,	  arising	  
from	  the	  ventral	  horns	  of	  the	  sacral	  cord	  (15)	  (16).	  	  During	  micturition,	  supraspinal	  
centres	  block	  stimulation	  by	  the	  hypogastric	  and	  pudendal	  nerves.	  This	  relaxes	  the	  
internal	  and	  external	  sphincters	  and	  removes	  the	  sympathetic	  inhibition	  of	  the	  
parasympathetic	  receptors.	  This	  results	  in	  the	  voluntary	  passage	  of	  urine	  when	  the	  




1.3 Overactive	  bladder	  	  
	  
1.3.1 Definition	  
The	  definition	  of	  overactive	  bladder	  (OAB)	  has	  changed	  over	  time	  and	  is	  now	  expressed	  
as	  a	  condition	  where	  there	  is	  urgency,	  the	  sudden	  overwhelming	  desire	  to	  pass	  urine	  
(1).	  It	  may	  present	  with	  or	  without	  urge	  incontinence	  and	  a	  frequency	  of	  greater	  than	  8	  
voids	  per	  day	  and	  nocturia	  of	  more	  than	  1	  (19).	  	  The	  prevalence	  of	  OAB	  is	  thought	  to	  be	  
16%	  and	  is	  commonly	  associated	  with	  other	  LUTS.	  	  It	  poses	  a	  substantial	  social-­‐
economic	  burden,	  which	  is	  ever	  growing	  with	  the	  aging	  population	  (8).	  	  It	  has	  a	  negative	  
impact	  on	  quality	  of	  life	  affecting	  social,	  psychological,	  occupational,	  physical,	  and	  
sexual	  aspects	  of	  those	  who	  suffer	  from	  it.	  	  
	  
1.3.2 Symptom	  complex	  and	  assessment	  
The	  lower	  urinary	  tract	  symptoms	  expressed	  by	  patients	  with	  overactive	  bladder	  
overlap	  with	  other	  lower	  urinary	  tract	  disease	  such	  as	  interstitial	  cystitis,	  painful	  bladder	  
syndrome	  and	  acute	  urinary	  tract	  infection.	  The	  National	  Institute	  of	  Clinical	  Excellence	  
(NICE	  2015)	  states	  that	  the	  clinical	  history	  should	  be	  sufficient	  to	  diagnose	  and	  
differentiate	  between	  lower	  urinary	  tract	  syndromes.	  There	  are	  many	  validated	  urgency	  
questionnaires	  in	  the	  literature	  that	  help	  to	  diagnose	  OAB	  (20-­‐24).	  Other	  validated	  
questionnaires	  commonly	  used	  to	  assess	  lower	  urinary	  tract	  symptoms	  include	  the	  
ICIQ–FLUTS,	  ICIQ-­‐MLUTS	  and	  pain	  scores.	  
	  
1.3.3 Anatomy	  and	  physiology	  of	  normal	  bladder	  and	  the	  OAB	  bladder	  	  
The	  urinary	  bladder	  is	  a	  musculomembranous	  sac,	  which	  acts	  as	  a	  reservoir	  for	  urine	  
and	  lies	  in	  the	  anterior	  pelvis,	  behind	  the	  pubic	  symphysis,	  in	  both	  sexes.	  The	  urine	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enters	  via	  the	  ureters	  and	  is	  expelled	  via	  the	  urethra.	  	  	  Superiorly	  the	  bladder	  is	  covered	  
by	  peritoneum	  and	  lies	  anterior	  to	  the	  rectum,	  and	  uterus	  in	  females.	  	  The	  bladder	  wall,	  
also	  known	  as	  the	  detrusor	  muscle,	  is	  made	  up	  of	  smooth	  muscle	  fibres	  arranged	  in	  
spiral,	  longitudinal	  and	  circular	  bundles.	  The	  base	  of	  the	  bladder,	  known	  as	  the	  trigone,	  
is	  bound	  laterally	  by	  the	  urethral	  orifices,	  with	  the	  internal	  urethral	  meatus	  anteriorly.	  	  
The	  bladder	  is	  lined	  by	  a	  layer	  of	  transitional	  epithelium	  known	  as	  the	  urothelium.	  	  	  
	  
The	  male	  and	  female	  urethra	  show	  marked	  anatomical	  differences,	  though	  function	  in	  a	  
similar	  way.	  	  The	  male	  urethra	  is	  longer,	  approximately	  20cm,	  encased	  by	  the	  prostate	  
gland	  at	  the	  base	  of	  the	  bladder	  and	  the	  urethral	  sphincter.	  	  The	  female	  urethra	  is	  
shorter,	  only	  3-­‐4cm	  long	  and	  descend	  through	  the	  pelvic	  floor.	  	  The	  urethra	  has	  both	  
smooth	  and	  striated	  muscle	  types	  and	  continence	  is	  achieved	  by	  voluntary	  contraction	  
of	  the	  external	  urethral	  sphincter.	  The	  normal	  bladder	  functions	  through	  a	  complex	  
coordination	  of	  musculoskeletal,	  neurologic,	  and	  psychological	  functions	  that	  allow	  
filling	  and	  emptying	  of	  the	  bladder	  contents.	  Continence	  is	  achieved	  by	  the	  synergistic	  
relaxation	  of	  detrusor	  muscles	  and	  contraction	  of	  the	  external	  urethral	  sphincter.	  	  
	  
1.3.3.1 Neurological	  control	  of	  micturition	  	  
Parasympathetic	  fibres,	  arising	  as	  preganglionic	  axons	  from	  S2	  to	  S4,	  relay	  through	  
ganglia	  mostly	  within	  the	  detrusor	  muscle.	  	  Postganglionic	  cholingeric	  nerves	  supply	  the	  
detrusor	  muscle	  and	  stimulate	  detrusor	  contractions.	  	  Sympathetic	  nerves	  arise	  from	  
T10	  to	  L2	  and	  relay	  in	  the	  pelvic	  ganglia.	  	  Their	  exact	  role	  in	  the	  control	  of	  micturition	  is	  
unclear.	  	  It	  is	  known	  that	  α-­‐adrenergic	  receptors	  and	  their	  nerve	  terminals	  are	  found	  
mainly	  in	  the	  smooth	  muscle	  of	  the	  bladder	  neck	  and	  proximal	  urethra,	  where	  as	  β-­‐
receptors	  are	  found	  in	  the	  fundus	  of	  the	  bladder.	  	  The	  α-­‐receptors	  respond	  to	  
noradrenalin	  by	  stimulating	  contraction,	  where	  as	  the	  β-­‐receptors	  relax	  the	  smooth	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muscle.	  	  It	  is	  possible	  that	  the	  sympathetic	  neurons	  play	  a	  role	  in	  both	  urethral	  closure	  
and	  detrusor	  relaxation	  during	  the	  filling	  phase	  of	  the	  micturition	  cycle.	  	  	  
	  
The	  distal	  sphincter	  mechanism	  is	  innervated	  from	  the	  sacral	  segments	  S2-­‐S4	  by	  
somatic	  motor	  fibres	  that	  reach	  the	  sphincter	  either	  by	  the	  pelvic	  plexus	  or	  via	  the	  
pudendal	  nerves.	  	  Afferent	  nerves	  are	  carried	  in	  both	  the	  parasympathetic	  and	  
pudendal	  pathways	  and	  transmit	  sensory	  impulses	  from	  the	  bladder,	  urethra	  and	  pelvic	  
floor.	  	  These	  sensory	  impulses	  pass	  to	  the	  cerebral	  cortex	  and	  the	  micturition	  centre,	  
where	  they	  produce	  reflex	  bladder	  relaxation	  and	  increased	  tone	  in	  the	  distal	  sphincter	  
to	  maintain	  continence.	  	  Cortical	  control	  is	  a	  basic	  part	  of	  the	  micturition	  cycle.	  	  The	  
higher	  centres	  suppress	  detrusor	  contractions	  and	  their	  main	  function	  is	  to	  inhibit	  
micturition.	  	  Afferent	  impulses	  pass	  to	  the	  brain	  via	  the	  posterior	  columns	  to	  the	  pons,	  
periaqueducatal	  grey,	  the	  anterior	  cingulate	  gyrus	  and	  the	  preioptic	  area	  of	  the	  
hypothalamus.	  
	  	  	  
1.3.3.2 The	  Micturition	  Cycle	  
The	  bladder	  alternates	  between	  a	  storage/filling	  phase	  and	  an	  emptying/micturition	  
phase.	  During	  the	  storage	  phase	  the	  bladder	  is	  able	  to	  fill	  steadily	  without	  rise	  in	  the	  
intravesical	  pressure	  due	  to	  the	  high	  compliance	  of	  the	  detrusor	  muscle.	  	  As	  the	  volume	  
of	  urine	  increases,	  stretch	  receptors	  in	  the	  bladder	  are	  stimulated	  resulting	  in	  reflex	  
bladder	  relaxation	  and	  reflex	  increase	  in	  sphincter	  tone.	  	  At	  75%	  capacity	  there	  is	  the	  
first	  desire	  to	  void	  but	  voluntary	  control	  is	  exerted	  over	  the	  desire,	  which	  then	  
temporarily	  disappears.	  	  Compliance	  of	  the	  detrusor	  muscle	  allows	  further	  filling	  until	  
the	  next	  desire	  to	  void	  and	  the	  emptying	  phase.	  	  Micturition	  is	  coordinated	  by	  the	  
pontine	  micturition	  centre	  (PMC)	  in	  the	  pons.	  	  It	  is	  initiated	  first	  by	  voluntary	  and	  then	  
by	  reflex	  relaxation	  of	  the	  pelvic	  floor	  and	  distal	  sphincter	  mechanisms,	  followed	  by	  
 24	  
reflex	  detrusor	  contraction.	  	  Intravesical	  pressure	  remains	  greater	  than	  urethral	  
pressure	  until	  the	  bladder	  is	  empty.	  	  The	  normal	  control	  of	  micturition	  requires	  
coordinated	  reflex	  activity	  of	  the	  autonomic	  and	  somatic	  nerves.	  	  These	  responses	  
depend	  on	  normal	  anatomical	  structures	  and	  normal	  innervation.	  	  Hence	  structural	  or	  
neurogenic	  lesions	  can	  lead	  to	  disorders	  of	  micturition.	  	  
	  
Symptoms	  of	  overactive	  bladder	  were	  previously	  thought	  to	  be	  synonymous	  with	  
urodynamic	  detrusor	  overactivity.	  	  	  Hashim	  et	  al	  found	  that	  only	  64%	  of	  patients	  with	  
symptoms	  of	  overactive	  bladder	  demonstrated	  urodynamic	  detrusor	  overactive	  (DO)	  
with	  more	  than	  30%	  of	  patients	  with	  no	  OAB	  showing	  DO	  on	  filling	  cystometry	  (25).	  	  	  It	  
has	  more	  recently	  been	  proposed	  that	  OAB	  is	  a	  symptom	  complex	  and	  several	  
theoretical	  propitiations	  are	  published	  regarding	  the	  underlying	  pathology.	  
	  
1.3.3.3 OAB	  –	  Myogenic	  proposition	  
The	  myogenic	  proposition	  states	  that	  changes	  in	  the	  detrusor	  muscle	  are	  responsible	  
for	  involuntary	  detrusor	  contractions.	  It	  is	  thought	  that	  a	  local	  contraction	  is	  able	  to	  
spread	  and	  cause	  a	  co-­‐ordinated	  contraction	  of	  the	  bladder	  wall.	  Detrusor	  overactivity	  
has	  also	  been	  associated	  with	  changes	  in	  the	  muscle	  architecture	  including	  increased	  
gap-­‐junctions,	  which	  could	  influence	  spread	  of	  muscle	  contractions.	  These	  changes	  have	  
also	  been	  observed	  in	  the	  bladder	  as	  part	  of	  aging	  and	  also	  in	  conditions	  such	  as	  
bladder	  outlet	  obstruction	  leading	  to	  detrusor	  hypertrophy	  (26).	  
1.3.3.4 OAB	  –	  Neurogenic	  proposition	  
It	  has	  been	  suggested	  that	  damage	  to	  the	  central	  pathways	  or	  sensitisation	  of	  
peripheral	  afferent	  nerve	  may	  induce	  voiding	  reflexes	  which	  trigger	  detrusor	  
overactivity	  (27).	  	  Mechanism	  that	  have	  been	  proposed	  in	  the	  generation	  of	  DO	  include	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insult	  to	  the	  brain	  or	  spinal	  cord	  resulting	  in	  reduction	  in	  the	  suprapontine	  suppression,	  
expression	  of	  primitive	  spinal	  bladder	  reflexes,	  synaptic	  plasticity,	  and	  sensitisation	  of	  
peripheral	  afferent	  terminals	  in	  the	  bladder.	  
1.3.3.5 OAB	  –	  Autonomous	  proposition	  
The	  autonomous	  proposition	  proposes	  that	  the	  detrusor	  is	  modular,	  with	  each	  module	  
being	  supplied	  by	  an	  individual	  bladder	  ganglia	  or	  by	  a	  node	  of	  interstitial	  cells	  known	  as	  
a	  myovescial	  plexus.	  	  During	  normal	  filling	  there	  is	  autonomous	  activity	  with	  non-­‐
micturition	  contractions	  and	  phasic	  sensory	  discharge.	  In	  pathological	  conditions	  there	  
is	  thought	  to	  be	  augmentation	  of	  autonomous	  activity	  resulting	  in	  detrusor	  overactivity.	  
In	  addition	  increased	  communication	  between	  modules	  is	  also	  thought	  to	  result	  in	  
increased	  detrusor	  activity.	  In	  summary	  the	  pathophysiology	  of	  DO	  included	  damage	  to	  
the	  afferent	  and	  efferent	  pathways	  to	  and	  from	  the	  bladder.	  	  The	  true	  aetiology	  of	  
OAB/DO	  may	  vary	  in	  different	  individuals	  and	  co-­‐exist,	  as	  well	  as	  including	  other	  
mechanisms,	  which	  have	  not	  yet	  been	  found.	  
1.3.3.6 The	  role	  of	  the	  urothelium	  in	  OAB	  	  
The	  urothelium	  is	  no	  longer	  thought	  to	  be	  an	  inert	  structure	  but	  is	  recognised	  to	  have	  
an	  important	  sensory	  role	  in	  bladder	  function.	  The	  urothelium	  is	  thought	  to	  exhibit	  
neuron	  like	  properties	  with	  expression	  of	  messenger	  molecule	  receptors	  and	  is	  the	  site	  
of	  action	  of	  various	  neurotransmitters	  that	  play	  a	  role	  in	  the	  peripheral	  control	  
mechanism	  of	  bladder	  activity	  (28).	  In	  addition,	  it	  has	  been	  suggested	  that	  there	  is	  
direct	  communication	  with	  sub-­‐urothelial	  afferents.	  Ferguson	  et	  al	  showed	  that	  when	  
mouse	  detrusor	  muscle	  is	  stretched,	  flux	  of	  calcium	  intracellularly	  results	  in	  the	  release	  
of	  ATP	  on	  the	  serosal	  aspect	  of	  the	  urothelium	  (29).	  It	  is	  now	  thought	  that	  ATP	  is	  
released	  by	  both	  surfaces	  of	  the	  urothelium	  (30).	  ATP	  activation	  of	  purinergic	  receptors,	  
P2X3	  and/or	  P2X2/3,	  on	  suburothelial	  afferent	  nerves	  leads	  to	  relay	  of	  information	  to	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the	  central	  nervous	  system	  to	  produce	  a	  sensation	  of	  bladder	  fullness	  and	  urgency	  (31).	  
Therefore	  it	  is	  thought	  that	  purinergic	  signalling	  has	  a	  function	  in	  the	  mechano-­‐sensory	  
transduction	  in	  the	  bladder	  (32,	  33).	  
	  
The	  role	  of	  ATP	  in	  bladder	  pain	  has	  been	  studied	  using	  the	  mouse	  model.	  	  P2X3	  
receptor	  knock	  out	  mice	  have	  displayed	  reduced	  pain	  related	  behaviour	  in	  response	  to	  
chemical	  irritation	  of	  the	  bladder	  with	  formalin	  and	  ATP	  injection.	  Furthermore,	  these	  
mice	  also	  exhibited	  marked	  bladder	  hyporeflexia	  characterised	  by	  a	  decreased	  
micturition	  frequency	  and	  an	  increased	  bladder	  capacity	  under	  normal	  bladder	  
pressures	  (34).	  Vlaskovska	  et	  al	  also	  found	  that	  the	  P2X3	  knockout	  mice,	  ATP	  release	  
was	  proportional	  to	  the	  extent	  of	  bladder	  distension	  with	  distension	  resulting	  in	  a	  
progressive	  increase	  in	  the	  activity	  of	  afferent	  nerves	  (35).	  Intravesical	  ATP,	  in	  the	  
presence	  of	  a	  compromised	  urothelium,	  has	  also	  been	  shown	  to	  induce	  detrusor	  
overactivity	  via	  the	  P2X	  receptor	  (36).	  
	  
During	  inflammation,	  ATP	  is	  also	  thought	  to	  play	  a	  role	  with	  an	  increase	  in	  ATP	  release.	  
In	  patients	  with	  interstitial	  cystitis,	  increased	  ATP	  secretion	  has	  been	  found	  as	  well	  as	  an	  
augmented	  release	  of	  ATP	  in	  response	  to	  stretch	  (37).	  	  
	  
It	  has	  therefore	  been	  suggested	  that	  Inflammation	  of	  the	  urothelium	  may	  play	  a	  part	  in	  
the	  pathophysiology	  of	  OAB	  by	  not	  only	  disrupting	  the	  integrity	  of	  the	  urothelial	  barrier	  
but	  also	  by	  leading	  to	  an	  increased	  release	  of	  ATP	  by	  the	  urothelium.	  	  An	  aberrant	  ATP	  
response	  induced	  by	  an	  inflammatory	  reaction	  may	  also	  play	  a	  role	  in	  the	  
pathophysiology	  of	  OAB	  by	  increasing	  sensory	  nerve	  excitation.	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1.4 Diagnosis	  of	  OAB	  and	  Exclusion	  of	  UTI	  
When	  assessing	  all	  patients	  with	  LUTS	  it	  is	  universally	  agreed	  that	  the	  mandatory	  first	  
step	  is	  the	  exclusion	  of	  UTI.	  In	  patients	  presenting	  with	  acute	  frequency	  and	  dysuria,	  
diagnosis	  is	  based	  on	  history	  alone.	  	  However,	  in	  patients	  presenting	  without	  dysuria	  we	  
rely	  on	  investigations	  to	  help	  exclude	  UTI.	  	  Internationally	  and	  nationally	  these	  include	  
the	  quantitative	  clean-­‐catch	  midstream	  urine	  culture,	  which	  is	  ubiquitous	  as	  the	  gold	  
standard	  for	  diagnosis,	  as	  recommended	  by	  NICE	  (2015)	  in	  the	  UK.	  	  NICE	  and	  the	  
International	  Continence	  Society	  (ICS)	  (2002,	  2010)	  also	  recommended	  the	  use	  of	  
surrogate	  markers	  of	  infection	  which	  include	  microscopy	  of	  urine	  and	  the	  use	  of	  urinary	  
dipstick	  tests.	  	  
	  
Published	  guidelines	  across	  Europe,	  USA	  and	  the	  UK	  reveal	  significant	  discrepancies	  in	  
the	  choice	  of	  a	  quantitative	  threshold	  used	  to	  define	  significant	  bacteriuria.	  The	  clean-­‐
catch,	  midstream	  urine	  (MSU)	  sample	  culture	  in	  the	  UK	  and	  Europe	  commonly	  uses	  the	  
Kass	  (1957)	  criterion	  of	  105	  colony	  forming	  units	  (cfu)	  ml-­‐1	  of	  a	  single	  species	  of	  a	  known	  
urinary	  pathogen	  (38,	  39).	  Kass	  drew	  these	  data	  from	  74	  women	  with	  acute	  
pyelonephritis	  and	  337	  normal	  controls,	  a	  select	  sample	  unrepresentative	  of	  wider	  
lower	  urinary	  tract	  symptoms	  (LUTS).	  Despite	  its	  limitations,	  this	  criterion	  has	  become	  a	  
ubiquitous	  reference	  standard	  and	  has	  been	  challenged	  by	  several	  groups	  (40,	  41).	  The	  
Associate	  of	  Urology	  (EUA)	  guidelines	  for	  urological	  infections	  emphasise	  that	  no	  single	  
threshold	  can	  be	  applied	  in	  all	  clinical	  situations.	  The	  urinary	  dipstick	  tests	  for	  nitrite	  
and	  leucocyte	  esterase,	  which	  have	  been	  validated	  against	  the	  Kass	  criterion,	  have	  also	  
recently	  been	  found	  to	  be	  unreliable	  (42-­‐45).	  
 28	  
1.4.1 Quantitative	  MSU	  culture	  
The	  quantitative	  microbiological	  bacterial	  culture	  remains	  the	  reference	  gold	  standard	  
in	  diagnosis	  of	  significant	  bacteria.	  	  Currently	  in	  the	  UK	  the	  proposed	  threshold	  that	  
discriminates	  normal	  from	  pathology	  is	  105	  cfu	  ml-­‐1.	  	  This	  threshold	  is	  based	  on	  work	  by	  
Kass	  with	  data	  from	  74	  patients	  with	  acute	  pyelonephritis	  and	  334	  asymptomatic	  
controls.	  	  He	  proposed	  that	  bacterial	  growth	  of	  greater	  than	  105	  cfu	  ml-­‐1	  of	  a	  single	  
known	  urinary	  pathogen	  was	  significant	  of	  urinary	  tract	  infection	  in	  this	  group	  of	  
patients.	  	  This	  work	  has	  formed	  the	  basis	  of	  the	  current	  quantitative	  threshold	  used	  to	  
exclude	  UTI	  in	  patients	  presenting	  with	  LUTS.	  	  There	  has	  since	  been	  other	  work	  in	  
patients	  presenting	  with	  classic	  symptoms	  of	  acute	  cystitis	  with	  sudden	  onset	  of	  pain,	  
frequency	  and	  urgency.	  	  It	  was	  found	  that	  a	  threshold	  of	  105	  cfu	  ml-­‐1	  missed	  nearly	  50%	  
of	  genuine	  coliform	  infections.	  	  It	  was	  proposed	  that	  in	  patients	  with	  symptoms	  of	  acute	  
cystitis,	  bacterial	  growth	  of	  greater	  than	  102	  cfu	  ml-­‐1	  of	  a	  known	  urinary	  pathogen	  was	  a	  
more	  appropriate	  threshold	  in	  this	  group	  of	  patients	  (40,	  46).	  Unfortunately	  however	  
much	  of	  this	  work	  has	  been	  overlooked	  and	  many	  laboratories	  still	  use	  the	  threshold	  of	  
105	  cfu	  ml-­‐1	  when	  assessing	  urine	  samples	  from	  patients	  with	  lower	  urinary	  tract	  
symptoms.	  	  
	  
In	  clinical	  medicine,	  to	  aid	  diagnosis	  we	  frequently	  use	  abolute	  terms	  to	  desribe	  the	  
existence	  or	  absence	  of	  disease.	  However	  nature	  and	  biology	  do	  not	  allow	  such	  distinct	  
entites	  and	  commonly	  disease	  manifests	  across	  a	  spectrum	  (2).	  	  Diagnostic	  test	  
performance	  is	  influenced	  by	  spectrum	  bias	  where	  the	  test	  properties	  are	  qualified	  by	  
the	  spectrum	  of	  disease	  under	  scrutiny	  (47).	  The	  quantitative	  routine	  MSU	  is	  an	  
example	  of	  this.	  	  In	  patients	  describing	  symptoms	  of	  acute	  frequency	  and	  dysuria	  the	  
diagnosis	  of	  UTI	  is	  not	  challenging	  and	  should	  be	  based	  on	  history	  alone.	  However	  in	  
patients	  presenting	  with	  non-­‐dysuric	  symptoms	  we	  still	  rely	  on	  the	  use	  of	  current	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investigations	  to	  help	  exclude	  urinary	  infection.	  	  It	  is	  now	  widely	  appreciated	  that	  in	  
patients	  with	  lower	  urinary	  tract	  symptoms,	  a	  midstream	  urine	  sample	  that	  is	  reported	  
as	  negative	  based	  on	  the	  105	  cfu	  µl-­‐1	  threshold	  does	  not	  exclude	  significant	  UTI	  (40,	  45,	  
48-­‐51).	  	  The	  use	  of	  test	  boundaries	  and	  a	  dichotomous	  threshold	  to	  define	  the	  
presence/absence	  of	  disease	  is	  artificial,	  and	  distorts	  our	  understanding	  of	  the	  
underlying	  pathology.	  	  
	  
The	  work	  by	  Kass	  also	  only	  addressed	  pathogenic	  coliform	  organisms,	  and	  mixed	  growth	  
was	  thought	  to	  be	  likely	  due	  to	  contamination	  and	  was	  dismissed.	  	  There	  is	  now	  
evidence	  to	  support	  polymicrobial	  infection	  in	  human	  disease,	  with	  work	  exploring	  this	  
in	  the	  bladder	  (41).	  The	  culture	  methods	  used	  today	  also	  assume	  dominant	  
pathogenicity	  from	  the	  Enterobacteriaceae	  species,	  notably	  E	  coli.	  Because	  of	  this	  
assumption,	  the	  MSU	  culture	  is	  performed	  on	  a	  selective	  medium	  (selective	  
chromogenic	  medium)	  for	  Enterobacteriaceae	  under	  aerobic	  conditions.	  No	  anaerobic	  
bacteria	  are	  sought	  and	  some	  aerobic	  bacteria	  can	  be	  missed	  because	  of	  the	  choice	  of	  
medium.	  Whilst	  this	  might	  be	  appropriate	  for	  diagnosing	  acute	  infection,	  there	  is	  no	  
evidence	  that	  the	  same	  bacteria	  are	  implicated	  in	  chronic	  infections	  or	  patients	  
presenting	  with	  non-­‐dysuric	  lower	  urinary	  tract	  symptoms	  such	  as	  in	  the	  overactive	  
bladder.	  Thus,	  there	  are	  no	  data	  to	  inform	  the	  selection	  of	  a	  suitable	  gold	  standard	  for	  
diagnosing	  UTI	  in	  this	  context.	  
	  
1.4.2 Microscopy	  for	  pyuria	  	  
Microscopy	  of	  urine	  for	  the	  detection	  of	  urinary	  leucocytes	  is	  widely	  used	  as	  a	  surrogate	  
marker	  of	  urinary	  infection.	  	  Many	  laboratories	  also	  use	  it	  as	  a	  screening	  tool	  for	  all	  
urine	  samples	  received	  and	  only	  those	  deemed	  to	  have	  a	  significant	  pyuria	  are	  cultured.	  
This	  technique	  stems	  from	  Dukes	  work	  in	  1927	  (52)	  which	  predates	  Kass’	  work.	  	  His	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work	  reviewed	  midstream	  urine	  samples	  from	  300	  asymptomatic	  volunteers	  and	  found	  
a	  mean	  leucocyte	  counts	  of	  1.6	  wbc	  μl-­‐1	  	  in	  males	  and	  5.4	  wbc	  μl-­‐1	  in	  females	  with	  a	  
range	  of	  0-­‐50	  wbc	  μl-­‐1	  	  (52).	  From	  this,	  he	  proposed	  an	  arbitrary	  cut	  off	  of	  <10	  wbc	  μl-­‐1	  
as	  the	  limit	  for	  normal	  pyuria.	  	  As	  a	  consequence	  we	  now	  use	  a	  microscopic	  pyuria	  ≥10	  
wbc	  μl-­‐1	  to	  suggest	  urinary	  infection.	  	  The	  work	  by	  Dukes	  is	  open	  to	  similar	  criticism	  to	  
Kass’	  work	  of	  spectrum	  bias.	  	  Here	  a	  healthy	  population	  has	  been	  used	  to	  define	  disease	  
in	  a	  symptomatic	  population.	  	  In	  addition	  the	  data	  from	  Dukes	  work	  shows	  a	  wide	  range	  
of	  pyuria	  and	  hence	  the	  data	  would	  be	  skewed	  and	  not	  normally	  distributed.	  	  Therefore	  
use	  of	  the	  median	  would	  have	  been	  a	  more	  appropriate	  measure	  of	  central	  tendency	  
and	  had	  that	  occurred,	  zero	  pyuria	  would	  have	  been	  promoted	  as	  the	  normal	  state.	  The	  
samples	  collected	  in	  Dukes’	  work	  were	  also	  voided	  samples	  and	  without	  careful	  
sampling	  may	  be	  subject	  to	  contamination.	  Studies	  comparing	  catheter	  sampling	  do	  not	  
report	  any	  differences	  in	  leucocyte	  excretion	  between	  the	  sexes.	  
	  
Microscopic	  pyuria	  is	  commonly	  used	  to	  exclude	  infection	  and	  many	  studies	  have	  
reviewed	  its	  performace	  against	  quantitative	  bacterial	  culture.	  Some	  studies	  have	  
however	  found	  that	  those	  with	  symptoms	  of	  acute	  UTI	  were	  culture	  negative,	  against	  a	  
threshold	  of	  ≥105	  cfu	  ml-­‐1.as	  diagnostic	  of	  infection,	  nearly	  half	  demonstrated	  leucocyte	  
excretion	  of	  ≥10	  wbc	  μl-­‐1	  (53,	  54).	  	  These	  data	  support	  pyuria	  excretion	  ≤10	  wbc	  μl-­‐1	  as	  a	  
common	  finding	  amongst	  women	  with	  acute	  cystitis	  symptoms,	  and	  questions	  the	  
microbiological	  definition	  of	  UTI,	  long	  before	  Kass’	  work	  was	  re-­‐evaluated.	  This	  history	  
illustrates	  the	  error	  of	  propositions	  being	  accepted	  as	  explanatory	  in	  the	  absence	  of	  
empirical	  support.	  	  
	  
There	  are	  limited	  data	  evaluating	  the	  role	  of	  microscopic	  pyuria	  as	  a	  surrogate	  marker	  
of	  infection	  in	  patients	  with	  non-­‐acute	  symptoms.	  	  In	  patients	  with	  painless	  LUTS	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microscopic	  pyuria	  has	  been	  reported	  to	  have	  a	  sensitivity	  of	  56%	  (95%	  CI	  46-­‐60%)	  and	  
specificity	  of	  72%	  (95%	  CI	  67-­‐76%)	  for	  midstream	  urine	  (MSU)	  cultures	  at	  ≥105	  cfu	  ml-­‐1,	  
and	  66%	  (95%	  CI	  54-­‐77%)	  and	  73%	  (95%	  CI	  69-­‐78%)	  respectively	  for	  catheter	  specimen	  
of	  urine	  (CSU)	  culture	  at	  ≥105	  cfu	  ml-­‐1	  (55).	  In	  patients	  presenting	  with	  non-­‐acute	  
symptoms	  Kupelian	  et	  al	  found	  the	  positive	  predictive	  value	  (PPV)	  and	  negative	  
predictive	  valve	  (NPV)	  of	  pyuria	  as	  a	  surrogate	  marker	  of	  UTI	  to	  be	  0.40	  (CI	  0.37-­‐0.43)	  
and	  0.75	  (CI	  0.73-­‐0.76)	  respectively.	  They	  found	  that	  40%	  of	  the	  inflammatory	  signal	  
was	  lost	  by	  4	  hours	  after	  sample	  collection	  which	  is	  a	  common	  delay	  between	  patients	  
providing	  samples	  and	  time	  taken	  to	  arrive	  at	  laboratories	  for	  analysis	  (56).	  Given	  that	  
microscopy	  of	  urine	  is	  performed	  by	  laboratories	  so	  that	  only	  those	  with	  ≥10	  wbc	  μl-­‐1	  
require	  culture	  samples	  may	  be	  wrongly	  dismissed	  as	  negative	  for	  infection.	  
	  	  	  	  	  	  	  	  	  
1.4.3 Urinary	  dipstick	  
Urinary	  dipsticks	  are	  commonly	  used	  in	  clinical	  practice	  to	  help	  in	  the	  diagnosis	  of	  
urinary	  tract	  infection.	  	  They	  were	  introduced	  as	  part	  of	  ‘point	  of	  care	  testing’	  to	  aid	  in	  
diagnosis	  of	  UTI	  and	  reduce	  the	  need	  for	  urine	  microscopy	  and	  urine	  culture	  and	  allow	  
for	  earlier	  treatment.	  Modern	  reagent	  strips	  are	  able	  to	  provide	  information	  on	  a	  
variety	  of	  physical	  and	  biochemical	  variables.	  The	  principle	  measure	  of	  UTI	  includes	  the	  
presence	  of	  leucocyte	  esterase	  and	  nitrites.	  	  Leucocyte	  esterase	  is	  an	  enzymic	  leucocyte	  
product	  and	  so	  a	  potential	  measure	  of	  pyuria.	  The	  Nitrite	  test	  uses	  the	  Greiss	  reaction	  
to	  detect	  a	  nitrate	  reduction	  product	  of	  some	  uropathogenic	  bacteria.	  The	  chemical	  
basis	  of	  this	  reaction	  is	  that	  in	  an	  acid	  environment	  nitrite	  reacts	  with	  an	  aromatic	  
amine	  (sulfanilamide)	  to	  form	  a	  coloured	  diazonium	  salt	  that	  in	  turn	  reacts	  with	  
hydroxybenzoquinolone	  to	  provide	  a	  pink	  colour.	  It	  requires	  the	  presence	  of	  bacteria	  
that	  can	  convert	  nitrate	  in	  the	  urine	  to	  nitrite	  (57).	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The	  International	  Consultation	  on	  Incontinence	  guidelines	  on	  LUTS	  emphasises	  the	  
need	  to	  exclude	  UTI	  and	  recommends	  dipstick	  testing	  as	  a	  screening	  method	  (58).	  NICE	  
also	  recommends	  the	  use	  of	  urinary	  dipstick	  for	  screening	  patients	  with	  lower	  urinary	  
tract	  symptoms	  (59).	  However,	  there	  are	  no	  published	  data	  to	  support	  dipstick	  as	  a	  
valid	  screening	  tool	  for	  patients	  with	  non-­‐acute,	  non-­‐dysuric	  symptoms.	  On	  reviewing	  
the	  literature	  there	  is	  considerable	  evidence	  to	  question	  the	  accuracy	  of	  urinary	  
dipsticks	  (42,	  43,	  60,	  61).	  	  The	  sensitivity	  of	  leucocyte	  esterase	  has	  been	  suggested	  to	  be	  
around	  60%	  and	  specificity	  of	  around	  70%.	  The	  sensitivity	  of	  nitrite	  is	  approximately	  
18%	  -­‐	  50%,	  with	  reported	  specificities	  of	  90%	  (42,	  61).	  Again,	  these	  estimates	  relate	  to	  
patients	  with	  acute	  symptoms,	  with	  positive	  reference	  cultures	  at	  ≥105	  cfu	  ml-­‐1.	  	  
	  
1.5 Acute	  Urinary	  Tract	  Infection	  
1.5.1 Aetiology	  and	  Pathophysiology	  UTI	  
	  Urinary	  tract	  infection	  is	  one	  of	  the	  commonest	  bacterial	  infections	  worldwide.	  The	  
American	  Foundation	  for	  Urological	  Diseases	  reports	  that	  acute	  bacterial	  cystitis	  affects	  
8–10	  million	  Americans	  a	  year	  and	  most	  of	  these	  patients	  are	  female	  with	  an	  annual	  
cost	  of	  $2.14	  billion(10,	  62).	  One	  in	  three	  women	  will	  develop	  a	  UTI	  requiring	  antibiotic	  
treatment	  by	  age	  24,	  and	  50%	  experience	  at	  least	  one	  during	  their	  lifetime	  (62,	  63).	  	  It	  
has	  been	  suggested	  that	  predisposing	  factors	  include	  urinary	  tract	  obstruction,	  
incomplete	  voiding,	  and	  aberrant	  structural	  anatomy.	  Additional	  risk	  factors	  include	  
prior	  history	  of	  UTIs,	  vaginal	  intercourse	  within	  the	  past	  two	  weeks,	  use	  of	  
contraception	  with	  spermicide,	  low	  vaginal	  oestrogen	  level,	  and	  individual	  genetic	  
background	  (10).	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The	  incidence	  of	  cystitis	  is	  significantly	  higher	  in	  women	  than	  men,	  possibly	  the	  result	  of	  
anatomical	  differences.	  The	  shorter	  female	  urethra	  might	  facilitate	  bacterial	  transit	  
from	  the	  urethral	  opening	  to	  the	  bladder	  and	  colonisation	  of	  the	  vaginal	  introitus	  by	  
gastrointestinal	  pathogens,	  which	  are	  usually	  part	  of	  the	  normal	  faecal	  microbiota	  (50).	  
This	  could	  also	  be	  influenced	  by	  sexual	  activity.	  The	  role	  of	  the	  normal	  vaginal	  
microbiota	  in	  the	  defence	  against	  genital	  colonisation	  with	  potentially	  pathogenic	  
adhering	  E.	  coli	  has	  been	  suggested	  in	  some	  studies.	  The	  reported	  vaginal	  colonisation	  
rate	  of	  E.	  coli	  varies	  from	  6	  to	  26%	  (64).	  
	  
Defensive	  properties	  of	  the	  commensal	  microbiota	  against	  colonisation	  by	  bowel	  
organisms	  include	  the	  production	  of	  inhibitory	  substances	  against	  pathogens,	  
colonisation	  of	  epithelial	  surfaces,	  and	  competition	  with	  potential	  pathogens	  for	  sites	  of	  
adhesion.	  The	  relationship	  of	  vaginal	  E.	  coli	  load	  with	  phases	  of	  the	  menstrual	  cycle	  also	  
indicates	  hormonal	  influence	  on	  vaginal	  colonisation	  with	  E.	  coli	  (65).	  Local	  trauma,	  
such	  as	  sexual	  intercourse	  or	  urethral	  massage,	  promotes	  invasion	  of	  the	  urinary	  tract.	  
A	  vaginal	  pH	  of	  5	  or	  less	  protects	  against	  vaginal	  colonisation	  and	  urogenital	  infections.	  
Lactobacillus	  species	  usually	  colonise	  the	  vagina	  and	  generate	  an	  acidic	  vaginal	  pH,	  
which	  interferes	  with	  the	  adhesion	  of	  E.	  coli,	  one	  of	  the	  most	  common	  uropathogens	  in	  
otherwise	  normal	  women.	  It	  is	  also	  likely	  that	  use	  of	  soaps	  to	  clean	  the	  genital	  tract	  
alters	  the	  pH	  and	  normal	  microbiota.	  In	  addition,	  the	  use	  of	  diaphragms,	  cervical	  caps,	  
or	  spermicides	  for	  contraception	  is	  associated	  with	  a	  higher	  incidence	  of	  UTI.	  Most	  
spermicides	  contain	  Nonoxynol-­‐9,	  which	  appears	  to	  be	  active	  against	  hydrogen	  
producing	  Lactobacillus	  in	  the	  vagina	  (64).	  	  
	  
In	  females	  with	  recurrent	  UTI,	  hormonal	  factors	  are	  thought	  to	  influence	  bacterial	  
attachment	  to	  epithelial	  cells.	  Genitourinary	  mucosal	  cells	  have	  oestrogen	  receptors	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(66).	  Adherence	  changes	  during	  the	  menstrual	  cycle	  and	  is	  maximal	  during	  peak	  
oestrogen	  stimulation.	  Oestrogen	  deficiency	  in	  postmenopausal	  women	  is	  associated	  
with	  a	  higher	  risk	  of	  UTI.	  The	  suggested	  mechanism	  is	  that	  mucosal	  atrophy	  leads	  to	  
lower	  levels	  of	  lactobacilli	  in	  the	  vaginal	  microbiota	  with	  increases	  in	  vaginal	  pH,	  
promoting	  colonisation	  by	  Enterobacteriaceae.	  	  	  The	  Cochrane	  review	  2008	  found	  two	  
studies	  showing	  vaginal	  oestrogens	  to	  be	  superior	  to	  antibiotics	  for	  treatment	  (67,	  68).	  
Raz	  et	  al	  reported	  both	  a	  lower	  vaginal	  pH	  in	  the	  oestrogen	  treatment	  group	  and	  a	  
higher	  proportion	  of	  vaginal	  Lactobacillus	  spp.	  as	  compared	  to	  controls	  (68).	  	  
	  
1.5.2 Uropathogens	  
There	  are	  many	  studies	  reviewing	  the	  organisms	  responsible	  for	  urinary	  tract	  infection.	  	  
Much	  of	  this	  work	  has	  been	  from	  patients	  with	  acute	  UTI	  or	  pyelonephritis.	  	  Known	  
uropathogens	  have	  been	  described	  but	  much	  of	  this	  work	  has	  used	  quantitative	  
thresholds	  and	  hence	  this	  will	  contribute	  to	  our	  current	  understanding	  of	  urinary	  
ecology.	  The	  dismissal	  of	  polymicrobial	  cultures	  as	  likely	  contamination,	  and	  uncertainty	  
relating	  to	  the	  uropathogenic	  potential	  of	  specific	  genera/species,	  also	  question	  
established	  thoughts	  on	  uropathogens.	  Whether	  the	  bacterial	  ecology	  of	  urinary	  tract	  
infection	  differs	  across	  the	  spectrum	  of	  clinical	  syndromes	  is	  unknown.	  
	  
The	  ECO·∙SENS	  project	  (60)	  was	  large	  study	  that	  included	  all	  community	  patients	  with	  
symptoms	  of	  acute	  cystitis	  and	  used	  a	  threshold	  for	  women	  with	  acute	  cystitis	  with	  a	  
positive	  growth	  reported	  as	  growth	  ≥103	  cfu	  ml-­‐1.	  The	  study	  reported	  all	  uropathogens	  
and	  included	  polymicrobial	  growth	  of	  two	  isolates.	  Uropathogenic	  E.coli	  (UPEC)	  was	  the	  
commonest	  bacterium	  accounting	  for	  approximately	  75%	  of	  samples.	  Other	  
Enterobacteriaceae,	  including	  P.	  mirabilis,	  Klebsiella,	  Enterobacter,	  and	  Citrobacter,	  
were	  reported	  in	  15%;	  Staphylococcus	  saprophyticus	  in	  5%,	  with	  other	  Staphylococci	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and	  Enterococci	  in	  the	  remaining	  5%.	  Within	  the	  literature	  Group	  B	  streptococcus	  has	  
also	  been	  associated	  with	  UTI	  in	  pregnancy	  and	  Proteus	  and	  Pseudomonas	  with	  hospital	  
acquired	  UTI	  (69).	  
	  
There	  is	  limited	  data	  on	  the	  presence	  on	  anaerobic	  bacteria	  in	  the	  urinary	  tract.	  	  In	  one	  
large	  study	  only	  1.3%	  of	  samples	  grew	  anaerobic	  organisms,	  predominately	  
Lactobacillus	  spp	  and	  Clostridium	  	  (70).	  	  Similarly	  another	  study	  found	  positive	  growth	  
of	  anaerobic	  bacteria	  in	  only	  0.03%	  of	  samples,	  with	  positive	  growth	  as	  more	  than	  108	  
cfu	  ml-­‐1	  of	  a	  single	  organism,	  which	  may	  explain	  the	  lower	  prevalence	  (71).	  On	  
reviewing	  the	  literature	  it	  can	  be	  suggested	  that	  anaerobic	  bacteria	  may	  have	  a	  role	  in	  a	  
small	  number	  of	  urinary	  tract	  infection.	  	  However	  the	  limited	  date	  may	  be	  a	  reflection	  
of	  the	  difficulty	  in	  culturing	  these	  bacteria	  and	  that	  Anaerobic	  culture	  methods	  are	  not	  
routinely	  used	  clinical	  practice	  and	  that	  there	  is	  need	  for	  further	  work	  to	  reach	  a	  
probably	  conclusion.	  	  
	  
Atypical	  bacteria	  such	  as	  Mycoplasma	  spp,	  Ureaplasma	  spp	  and	  Chlamydia	  spp	  have	  
also	  been	  implicated	  in	  causing	  UTI.	  However	  again	  these	  were	  from	  smaller	  studies	  
where	  there	  was	  also	  presence	  of	  uropathogenic	  bacteria.	  	  Hence	  it	  is	  difficult	  to	  
ascertain	  what	  role	  these	  organism	  my	  play	  in	  the	  generation	  of	  symptoms	  (72,	  73).	  	  
	  
1.5.3 Bacterial	  urothelial	  invasion	  and	  intracellular	  growth	  
For	  pathogen	  host	  interaction	  to	  occur,	  bacteria	  must	  be	  able	  to	  attach	  and	  adhere	  to	  
host	  tissues.	  	  Much	  of	  the	  work	  has	  centred	  on	  the	  murine	  model	  of	  acute	  UTI	  with	  
UPEC	  (74)	  (50).	  The	  urothelium	  has	  been	  described	  to	  have	  a	  surface	  layer	  of	  umbrella	  
cells,	  which	  act	  as	  a	  protective	  barrier.	  	  In	  the	  murine	  model	  of	  acute	  model,	  
colonisation	  of	  the	  bladder	  by	  UPEC	  is	  dependent	  upon	  the	  mannose-­‐binding	  adhesion,	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FimH,	  at	  the	  tip	  of	  type	  1	  pili	  (75).	  FimH	  binds	  to	  uroplakins	  on	  the	  superficial	  umbrella	  
cells	  of	  the	  urothelium,	  mediating	  colonisation	  and	  triggering	  subsequent	  bacterial	  
internalisation	  into	  the	  bladder	  epithelial	  cells	  (76).	  Once	  inside	  the	  epithelial	  cells,	  
UPEC	  bacteria	  are	  protected	  from	  the	  host’s	  innate	  immune	  defences.	  	  This	  allows	  the	  
bacterium	  the	  ability	  to	  replicate	  rapidly	  forming	  biofilm-­‐like	  intracellular	  bacterial	  
communities	  (IBCs)	  (74).	  Similarly	  to	  extracellular	  biofilms,	  IBC	  formation	  is	  transient	  
and	  terminates	  in	  a	  dispersal	  stage,	  during	  which	  bacteria	  escape	  the	  infected	  host	  cell,	  
spreading	  to	  neighbouring	  (naive)	  host	  cells,	  where	  the	  IBC	  cycle	  can	  be	  repeated	  (77).	  
Numerous	  host	  defences	  against	  this	  process,	  including	  inflammasome	  activation	  and	  
programmed	  urothelial	  exfoliation	  have	  been	  suggested	  (76).	  	  UPEC	  strains	  have	  been	  
shown	  to	  form	  IBCs	  in	  murine	  mouse	  models.	  	  This	  allows	  UPEC	  to	  persist	  and	  form	  
quiescent	  intracellular	  reservoirs	  (QIRs)	  or	  the	  development	  of	  chronic	  cystitis	  (77).	  
	  
1.5.4 Host	  defence	  against	  infection	  
The	  first	  defences	  against	  bacterial	  infection	  and	  adhesion	  to	  the	  urothelium	  are	  the	  
physical	  and	  chemical	  properties	  of	  the	  urine.	  Invading	  bacteria	  stimulate	  micturition.	  
Voiding	  washes	  out	  bacteria	  from	  the	  bladder	  and	  urethra	  and	  urine	  dilutes	  the	  
bacterial	  load.	  Bacterial	  growth	  is	  impeded	  by	  low	  pH	  and	  the	  high	  urea	  and	  organic	  
acid	  concentrations	  and	  the	  extremes	  of	  high	  and	  low	  osmolality	  discourage	  less	  
adapted	  bacteria	  (77).	  Nevertheless,	  aggressive	  bacterial	  species	  have	  evolved	  
mechanisms	  to	  overcome	  these	  obstacles.	  There	  are	  a	  number	  of	  interrelated	  
anatomical/	  physiological	  factors	  that	  influence	  the	  maintenance	  of	  bacterial	  numbers	  
in	  urine	  once	  infection	  is	  established.	  These	  include	  the	  flow	  rate	  of	  urine	  into	  the	  
bladder;	  the	  volume	  of	  residual	  urine	  remaining	  in	  the	  bladder	  after	  micturition	  and	  the	  
frequency	  with	  which	  micturition	  occurs.	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The	  flow	  rate	  of	  urine	  into	  the	  bladder	  is	  inevitably	  variable,	  but	  averages	  at	  about	  1	  
ml/min	  during	  the	  day	  and	  at	  about	  0.25	  ml/min	  during	  the	  night	  (78).	  The	  flow	  rate	  is	  
increased	  by	  high	  fluid	  intake	  and	  diuretics,	  so	  the	  urine	  produced	  may	  be	  dilute	  and	  
less	  suitable	  for	  supporting	  bacterial	  growth.	  Providing	  the	  urine	  is	  not	  carrying	  bacteria	  
from	  a	  focus	  of	  infection	  in	  the	  kidney,	  the	  influence	  of	  urine	  flow	  on	  bacterial	  numbers	  
in	  bladder	  is	  a	  dilution	  effect.	  However,	  this	  dilutional	  effect	  also	  influences	  the	  immune	  
response,	  by	  diluting	  immune	  cells	  at	  the	  site	  of	  infection.	  Furthermore,	  post	  
micturition	  residual	  urine	  can	  vary	  enormously	  in	  the	  infected	  bladder	  (79)	  .	  The	  interval	  
between	  episodes	  of	  micturition	  will	  fluctuate	  during	  the	  day	  and	  vary	  with	  fluid	  intake.	  
Most	  people	  micturate	  only	  once,	  or	  not	  at	  all,	  during	  the	  night,	  but	  urinary	  infection	  
may	  alter	  this	  habit.	  In	  acute	  cystitis	  frequency	  of	  micturition	  is	  a	  common	  presenting	  
symptom.	  This	  may	  be	  invoked	  as	  a	  natural	  defence	  mechanism	  until	  the	  resolution	  of	  
infection.	  In	  addition,	  higher	  residual	  volumes	  are	  also	  associated	  with	  urinary	  tract	  
infection,	  particularly	  in	  the	  postmenopausal	  group.	  	  
	  
As	  a	  result	  of	  normal	  kidney	  function,	  the	  variability	  in	  the	  chemical	  characteristics	  of	  
urine	  such	  as	  pH	  and	  osmolality	  can	  promote	  or	  suppress	  bacterial	  growth.	  Any	  
reduction	  in	  the	  bacterial	  growth	  rate	  will	  be	  to	  the	  patient's	  advantage,	  but	  this	  does	  
not	  necessarily	  equate	  to	  elimination	  of	  infection.	  The	  situation	  may	  be	  complicated	  by	  
the	  fact	  that	  the	  bacteria	  may	  fix	  themselves	  to	  the	  surface	  of	  the	  bladder	  mucosa	  or	  
reside	  in	  foci	  within	  the	  urinary	  system	  where	  they	  are	  unaffected	  by	  hydrokinetic	  
forces.	  	  
	  
The	  importance	  of	  'bound'	  organisms	  in	  the	  persistence	  of	  infection	  has	  been	  
investigated,	  through	  mathematical	  modelling,	  by	  Mackintosh	  et	  al.	  (80).	  They	  
calculated	  that	  if	  10	  'bound'	  bacteria	  continuously	  seed	  the	  urine	  with	  fresh	  organisms,	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infection	  would	  be	  maintained	  at	  around	  the	  10	  bacteria	  per	  ml	  level,	  even	  in	  the	  most	  
favourable	  washout	  conditions	  in	  which	  a	  patient	  with	  a	  normal	  residual	  bladder	  
volume	  micturates	  every	  hour.	  	  This	  synthetic	  data	  are	  supported	  by	  clinical	  studies	  
which	  have	  shown	  that	  infection	  will	  persist	  in	  a	  proportion	  of	  women	  despite	  adequate	  
diuresis	  and	  any	  impairment	  of	  the	  efficiency	  of	  the	  washout	  mechanism	  will	  
exacerbate	  the	  situation	  (81).	  	  
	  
1.5.5 The	  inflammatory	  response	  to	  UTI	  	  	  
It	  was	  initially	  thought	  that	  urinary	  defence	  may	  be	  dependent	  on	  specific	  soluble	  
epithelial	  cell-­‐derived	  mediators	  such	  as	  Tamm-­‐Horsfall	  protein	  (THP),	  soluble	  IgA,	  
Lactoferrin,	  lipocalin,	  antimicrobial	  peptides	  such	  as	  α-­‐	  and	  β-­‐defensins	  and	  cathelicidin	  
that	  have	  evolved	  under	  microbial	  pressure	  to	  combat	  uropathogenic	  bacteria	  (82).	  
These	  identified	  molecules	  may	  exert	  multiple	  functions	  including	  mechanical	  
elimination	  of	  bacteria	  and	  inhibition	  of	  invasion.	  Microbes	  evade	  these	  early	  defences	  
and	  adhere	  and	  initiate	  an	  immune	  response.	  	  
	  
Urothelial	  damage	  by	  infection	  leads	  to	  the	  release	  of	  inflammatory	  mediators	  including	  
platelet	  derived	  growth	  factor	  (PDGF),	  tumour	  necrosis	  factor-­‐α	  (TNF-­‐α),	  interleukin	  6	  
(IL6)	  and	  interleukin	  8	  (CXCL	  8).	  Infection	  by	  UPEC	  has	  been	  well	  studied	  in	  which	  a	  
rapid	  cytokine	  response	  has	  been	  seen	  by	  adhering	  P	  or	  type-­‐1	  fimbriated	  E.coli	  (83-­‐85).	  
In	  urinary	  tract	  cell	  lines,	  epithelial	  cell	  activation	  by	  fimbriated	  E.	  coli	  requires	  primary	  
recognition	  receptors	  for	  fimbrial	  adhesins	  and	  Toll-­‐like	  receptor	  4	  (TLR4)	  for	  
transmembrane	  signalling	  (86).	  	  Human	  urinary	  tract	  epithelial	  cells	  express	  both	  
glycosphingolipid	  and	  mannosylated	  surface	  glycoprotein	  receptors,	  which	  recognize	  
the	  P	  fimbrial	  adhesions	  and	  the	  type1	  fimbriae,	  respectively	  (83,	  87).	  	  	  	  Bacterial	  
components	  bind	  to	  Toll-­‐like	  receptors	  (TLR)	  and	  thereby	  activate	  an	  intracellular	  innate	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immune	  cascade.	  A	  key	  player	  in	  the	  bladder	  is	  TLR-­‐4,	  which	  is	  assisted	  by	  CD14	  to	  bind	  
lipopolysaccharide	  (LPS)	  (88).	  TLR-­‐4,	  -­‐2,	  and	  -­‐5	  binding	  activates	  the	  MyD88	  pathway,	  
which	  ultimately	  leads	  to	  NF-­‐κβ	  transcription	  and	  proinflammatory	  cytokine	  production.	  
The	  six	  key	  cytokines	  that	  are	  induced	  are	  notably	  IL-­‐6,	  CXCL8	  (IL-­‐8)	  as	  well	  as	  ICAM-­‐1,	  
CXCL-­‐1,	  CXCL-­‐5	  and	  CXCL-­‐6.	  IL-­‐6	  may	  cause	  fever	  and	  trigger	  the	  acute-­‐phase	  response,	  
while	  chemokines	  such	  as	  IL-­‐8	  recruit	  inflammatory	  cells	  to	  the	  site	  of	  infection	  (88).	  IL6	  
has	  also	  been	  implicated	  in	  a	  chronic	  inflammatory	  response	  (89,	  90).	  
	  
Urinary	  cytokines	  are	  elevated	  in	  patients	  with	  UTI	  and	  epithelial	  cells	  have	  been	  
identified	  as	  early	  producers	  of	  cytokines	  in	  the	  murine	  UTI	  model	  (91)	  (92,	  93)	  (94).	  	  
Uroepithelial	  cell	  lines	  of	  bladder	  and	  kidney	  origin	  constitutively	  make	  IL-­‐6	  and	  respond	  
with	  elevated	  IL-­‐6	  production	  to	  exogenous	  stimuli	  like	  bacteria	  or	  cytokines	  (91,	  95,	  
96).	  Studies	  of	  patients	  with	  UTI	  have	  shown	  rapid	  increases	  in	  urine	  IL6	  levels	  after	  the	  
onset	  of	  infection	  or	  instillation	  of	  bacteria	  into	  the	  urinary	  tract	  but	  serum	  IL6	  levels	  
are	  only	  elevated	  in	  those	  with	  acute	  pyelonephritis	  (97-­‐99).	  Through	  the	  release	  of	  
cytokines,	  epithelial	  cells	  establish	  a	  network	  with	  local	  and	  distant	  host	  cells	  (95).	  Cell	  
recruitment	  follows	  after	  the	  secretion	  of	  chemokines	  like	  IL-­‐8.	  Studies	  have	  shown	  that	  
IL-­‐8	  is	  present	  in	  epithelial	  cells	  of	  the	  healthy	  urinary	  tract	  and	  that	  IL-­‐8	  is	  secreted	  in	  
response	  to	  infection.	  IL-­‐8	  then	  returns	  to	  non-­‐detectable	  levels	  after	  treatment,	  and	  is	  
absent	  from	  normal	  urine	  (100).	  	  	  
	  
1.6 OAB	  and	  the	  role	  of	  infection	  
In	  assessing	  anyone	  who	  presents	  with	  LUTS	  a	  mandatory	  step	  is	  the	  expulsion	  of	  UTI.	  
Routine	  urinalysis	  and	  culture	  are	  unreliable	  in	  excluding	  infection	  in	  this	  group	  of	  
patients	  and	  hence	  significant	  infective	  pathology	  may	  have	  been	  missed.	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In	  patients	  with	  OAB	  symptoms	  there	  are	  studies	  that	  suggest	  increased	  inflammatory	  
activity	  and	  bacterial	  colonisation,	  not	  seen	  in	  asymptomatic	  control	  subjects.	  This	  
evidence	  postulates	  that	  bacterial	  infection	  and	  associated	  urothelial	  inflammation	  may	  
be	  responsible	  for	  the	  generation	  of	  chronic	  lower	  urinary	  tract	  symptoms.	  Khasryia	  et	  
al	  found	  that	  patients	  with	  chronic	  lower	  urinary	  tract	  symptoms	  have	  higher	  urinary	  
pyuria	  and	  microbial	  growth	  when	  compared	  to	  controls	  (55).	  	  Bacterial	  strains	  from	  
symptomatic	  patients	  were	  also	  shown	  to	  invade	  urothelial	  cell	  lines	  whilst	  bacteria	  
isolated	  from	  controls	  did	  not.	  	  It	  was	  hypothesised	  that	  patients	  with	  chronic	  lower	  
urinary	  tract	  symptoms	  have	  intracellular	  bacterial	  colonies	  that	  are	  responsible	  for	  an	  
inflammatory	  response	  and	  generation	  of	  symptoms.	  	  This	  group	  of	  patients	  also	  
showed	  increase	  urothelial	  cell	  shedding.	  	  These	  cells	  were	  harvested	  from	  the	  urine	  
and	  underwent	  an	  antibiotic	  protection	  assay	  where	  the	  cells	  where	  incubated	  with	  a	  
lethal	  cocktail	  of	  antibiotics	  to	  kill	  any	  extra	  cellular	  bacteria.	  	  On	  lysis	  of	  these	  cells	  after	  
24	  hours	  there	  was	  an	  increase	  in	  bacterial	  growth	  suggestive	  that	  these	  urothelial	  cells	  
were	  harbouring	  intracellular	  or	  cell	  associated	  infection,	  which	  was	  not	  killed	  by	  
extracellular	  antibiotics.	  	  	  
	  
Horsley	  et	  al	  2013,	  have	  also	  suggested	  the	  presence	  of	  intracellular	  bacterial	  colonies	  
and	  bacterial	  pods	  protected	  by	  biofilms,	  in	  urothelial	  cells	  from	  patients	  with	  chronic	  
lower	  urinary	  tract	  symptoms	  (101).	  	  The	  authors	  used	  methods	  including	  fluorescent	  
confocal	  microscopy	  and	  electron	  microscopy	  to	  confirm	  that	  these	  were	  intracellular	  
bacterial	  communities.	  	  	  
	  
There	  is	  also	  histological	  evidence	  to	  support	  infection	  in	  patients	  with	  OAB	  and	  
elevated	  pro-­‐inflammatory	  urinary	  cytokine	  release.	  Lunawat	  et	  al	  found	  that	  in	  all	  61	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patients	  with	  OAB	  and	  pyuria,	  but	  negative	  routine	  microbial	  culture,	  bladder	  biopsies	  
manifested	  all	  the	  uroepithelial	  features	  of	  chronic	  cystitis;	  no	  features	  of	  inflammation	  
were	  identified	  in	  control	  samples	  (102).	  	  Vijaya	  et	  al	  found	  increased	  bacterial	  growth	  
on	  culturing	  bladder	  biopsies	  obtained	  at	  cystoscopy	  from	  patient	  with	  overactive	  
bladder	  (103).	  	  The	  routine	  MSU	  in	  all	  these	  patients	  was	  negative	  but	  culture	  of	  
bladder	  biopsies	  showed	  significant	  microbial	  growth	  and	  elevated	  urinary	  NGF	  levels	  as	  
compared	  to	  controls.	  	  These	  patients	  were	  then	  treated	  with	  antibiotics	  and	  the	  
urinary	  NGF	  levels	  were	  shown	  to	  decrease	  after	  treatment.	  	  
	  
1.6.1 OAB	  and	  urinary	  cytokines	  	  
There	  are	  limited	  and	  conflicting	  data	  on	  the	  expression	  of	  inflammatory	  mediators	  in	  
OAB.	  Other	  lower	  urinary	  tract	  syndromes	  such	  as,	  interstitial	  cystitis	  and	  painful	  
bladder	  syndrome	  have	  been	  linked	  to	  an	  inflammatory	  aetiology.	  	  Interstitial	  cystitis	  
and	  the	  painful	  bladder	  syndrome	  are	  associated	  with	  increased	  mast	  cells	  on	  bladder	  
biopsy	  and	  raised	  inflammatory	  markers	  in	  the	  urine	  including	  histamine,	  
methylhistamine	  and	  IL6	  (104).	  Erickson	  et	  al.	  found	  elevated	  levels	  of	  IL6	  and	  
epidermal	  growth	  factor	  (EGF)	  in	  patients	  with	  interstitial	  cystitis	  (105).	  Bouchelouche	  
et	  al.	  showed	  that	  IL-­‐1β	  and	  TNFα	  stimulate	  the	  secretion	  of	  IL6	  in	  cultured	  human	  
detrusor	  smooth	  muscle	  cells	  (106,	  107).	  	  The	  regulatory	  effect	  of	  cytokines	  in	  
inflammation	  has	  been	  shown	  in	  animal	  models,	  particularly	  the	  stimulation	  with	  
bacterial	  endotoxin	  lipopolysaccharide,	  leading	  to	  the	  secretion	  of	  IL6.	  Heinrich	  et	  al	  
showed	  an	  upregulation	  in	  the	  gap	  junction	  proteins	  connexin	  43	  and	  45,	  secondary	  to	  
stimulation	  by	  IL6	  (108).	  They	  suggested	  that	  this	  modification	  of	  cell-­‐cell	  
communication	  by	  IL6	  could	  be	  pivotal	  in	  the	  pathophysiology	  of	  the	  overactive	  bladder	  
and	  interstitial	  cystitis.	  Conversely,	  Ghoniem	  et	  al	  have	  shown	  a	  down	  regulation	  of	  IL6	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in	  the	  urine	  of	  patients	  with	  OAB,	  however,	  they	  do	  not	  describe	  the	  minimum	  level	  of	  
detection	  of	  the	  cytokine	  in	  their	  micro-­‐array	  (109).	  
	  
Recently,	  there	  has	  been	  much	  interest	  in	  other	  inflammatory	  markers	  in	  OAB,	  
particularly	  for	  use	  as	  biomarkers	  of	  the	  disease.	  Neurotrophins	  such	  as	  Nerve	  growth	  
factor	  (NGF)	  and	  Brain	  derived	  growth	  factor	  (BDGF)	  and	  prostaglandins	  have	  been	  
studied	  in	  OAB	  (110).	  	  Tyagi	  et	  al.	  studied	  IL-­‐5,	  IL6,	  IL-­‐10,	  IL-­‐12p70/p40,	  IL-­‐1	  receptor	  
antagonist	  (IL-­‐1Ra),	  Epidermal	  growth	  factor	  (EGF)	  and	  soluble	  IL-­‐2	  receptor	  a	  (sIL-­‐2Ra)	  
in	  the	  urine	  of	  patients	  diagnosed	  with	  OAB	  compared	  to	  control	  volunteers.	  	  They	  
found	  a	  significant	  increase	  in	  IL-­‐10,	  IL-­‐12,	  EGF	  and	  IL-­‐12p70/p40.	  They	  suggested	  a	  
relationship	  with	  inflammation	  in	  OAB,	  possibly	  secondary	  to	  irritation	  or	  stress	  (111).	  	  
Increased	  urinary	  CXCL	  8	  has	  been	  shown	  in	  interstitial	  cystitis	  but	  not	  in	  the	  overactive	  
bladder	  (86,	  99,	  112).	  	  
	  	  
1.7 Hypothesis	  and	  Aims	  
When	  assessing	  anyone	  who	  presents	  with	  lower	  urinary	  tract	  symptoms,	  excluding	  a	  
urinary	  tract	  infection	  is	  key.	  	  However	  there	  is	  substantial	  evidence	  that	  refutes	  the	  
ability	  of	  current	  diagnostic	  tests	  to	  detect	  and	  exclude	  UTI.	  	  Therefore	  the	  role	  of	  
infection	  in	  the	  generation	  of	  LUTS	  merits	  scrutiny.	  	  It	  has	  been	  suggested	  in	  
epidemiological	  studies	  that	  advancing	  age	  and	  female	  sex	  may	  be	  associated	  with	  
bacteriuria	  and	  pyuria,	  which	  is	  thought	  to	  be	  in	  the	  absence	  of	  infection	  as	  measured	  
by	  current	  standards	  (113-­‐115).	  There	  is	  however	  some	  data	  to	  suggest	  bacterial	  
infection,	  urothelial	  inflammation	  and	  immune	  activation	  in	  patients	  with	  OAB	  
symptoms	  that	  is	  undetected	  by	  routine	  tests	  (51,	  102).	  Observational	  data	  also	  suggest	  
a	  response	  to	  antibiotic	  treatment	  in	  patients	  with	  OAB,	  although	  further	  data	  are	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awaited.	  	  However,	  these	  studies	  can	  be	  criticised	  due	  to	  a	  younger	  control	  population,	  
use	  of	  limited	  of	  markers	  and	  small	  sample	  size.	  There	  is	  therefore	  a	  need	  for	  future	  
studies	  to	  match	  patients	  and	  control	  subjects	  for	  key	  demographic	  characteristics.	  In	  
addition	  it	  would	  be	  important	  to	  evaluate	  the	  presence	  and	  role	  of	  infection	  in	  patients	  
presenting	  with	  overactive	  bladder.	  Prospective	  data	  evaluating	  the	  interaction	  
between	  symptoms,	  bacterial	  ecology	  and	  urothelial	  inflammatory	  response	  would	  add	  
to	  support	  a	  causal	  relationship.	  
	  
1.7.1 Hypothesis	  to	  be	  tested	  	  
Bacterial	  infection	  of	  the	  lower	  urinary	  tract	  goes	  undetected	  by	  routine	  diagnostic	  
testing	  and	  contributes	  to	  the	  generation	  of	  LUTS	  in	  patients	  with	  symptoms	  of	  OAB.	  
	  
1.7.2 Thesis	  Aims	  
1. To	  explore	  the	  urinary	  inflammatory	  response	  in	  patients	  with	  symptoms	  of	  
overactive	  bladder.	  
	  
2. To	  determine	  the	  relationship	  between	  urothelial	  inflammation,	  manifested	  by	  
pyuria,	  epithelial	  shedding	  and	  microbial	  growth,	  and	  symptom	  variation	  in	  
patients	  with	  symptoms	  of	  OAB.	  
	  
3. To	  determine	  the	  urinary	  cytokine	  and	  inflammatory	  response	  in	  relation	  to	  





1.7.3 Thesis	  Outline	  
	  
Chapter	  1	  provides	  a	  comprehensive	  introduction	  to	  urinary	  tract	  infection	  and	  an	  
overview	  of	  its	  role	  in	  LUTS	  and	  OAB.	  The	  common	  processes	  and	  methodologies	  used	  
in	  this	  research	  have	  been	  described	  in	  chapter	  2.	  	  Chapter	  3	  is	  an	  evaluation	  of	  urinary	  
ATP	  in	  relation	  to	  infection	  and	  inflammation	  in	  patients	  with	  LUTS.	  	  Chapter	  4	  is	  a	  
review	  of	  key	  inflammatory	  cytokines	  in	  patients	  with	  symptoms	  of	  OAB	  as	  compared	  to	  
asymptomatic	  controls.	  	  Longitudinal	  studies	  exploring	  the	  role	  of	  infection	  and	  
inflammation	  in	  patients	  with	  OAB	  symptoms	  has	  been	  addressed	  in	  Chapter	  5	  and	  6.	  	  




2 Chapter	  2	  –	  Patient	  recruitment	  and	  common	  methods	  of	  
measuring	  urinary	  infection	  
2.1 Ethical	  approval	  
Studies	  included	  in	  this	  work	  had	  ethical	  approval	  by	  the	  National	  Research	  Ethics	  
Service	  (NRES)	  -­‐	  East	  Central	  Research	  Ethical	  Committee	  1	  (REC	  Reference	  number	  
11/H0721/7).	  
	  	  
2.2 Patient	  recruitment	  and	  consent	  
Patients	  were	  recruited	  from	  urological	  clinics	  at	  the	  Department	  of	  Medicine,	  
University	  College	  London	  Archway	  Campus.	  The	  patients	  who	  expressed	  interest	  were	  
given	  written	  information	  regarding	  the	  study	  and	  then	  contacted	  two	  weeks	  later	  and	  
if	  agreeable,	  invited	  for	  an	  initial	  visit	  where	  written	  informed	  consent	  was	  obtained.	  
Control	  subjects	  were	  recruited	  from	  the	  staff	  at	  the	  Whittington	  hospital	  and	  
University	  College	  London.	  	  
	  
2.3 Data	  management	  and	  protection	  
Study	  data	  were	  stored	  in	  the	  Department	  of	  Medicine,	  UCL	  Archway	  Campus,	  as	  per	  
Good	  Clinical	  Practice	  (GCP)	  guidance.	  All	  samples	  and	  recoded	  data	  were	  identifiable	  
by	  study	  numbers	  and	  participant	  initials.	  Any	  patient	  identifiable	  data	  was	  stored	  on	  
only	  a	  secure	  NHS	  database,	  which	  was	  protected	  by	  encryption	  and	  daily	  backup.	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2.4 Statistical	  methods	  
IBM®	  SPSS®	  Statistics	  20	  (IBM,	  New	  York,	  USA)	  was	  used	  for	  statistical	  analysis.	  Data	  
were	  described	  using	  standard	  descriptive	  statistics.	  Specific	  statistical	  analysis	  for	  each	  
study	  has	  been	  described	  in	  each	  relevant	  section.	  	  
	  
2.5 Study	  design	  	  
Prospective	  observational	  cross-­‐sectional	  and	  longitudinal	  cohort	  studies	  were	  
conducted	  using	  standard	  methods.	  Patient	  and	  control	  groups	  were	  matched	  by	  key	  
demographic	  characteristics.	  
	  
2.6 Study	  groups	  
Subject	  Inclusion	  Criteria	  
1. Adult	  Women	  aged	  >=18	  years	  	  
2. Able	  to	  complete	  a	  symptom	  questionnaire	  	  
3. Diagnosed	  with	  OAB	  with	  or	  without	  pyuria	  (≥	  1	  wbc	  µl-­‐1)	  
4. Post-­‐menopausal	  women	  or	  women	  using	  adequate	  contraception	  
	  
Subject	  Exclusion	  Criteria	  
1. Age	  less	  than	  18	  years	  	  
2. Inability	  to	  consent	  	  
3. Pregnant	  women	  or	  women	  planning	  to	  conceive	  
4. Patients	  with	  concurrent	  illnesses	  that	  in	  the	  opinion	  of	  the	  investigator	  




The	  study	  groups	  were	  	  
1)	  Female	  adult	  patients	  with	  OAB	  (1),	  describing:	  	  
a. Urgency,	  the	  sudden	  compelling	  desire	  to	  urinate,	  a	  sensation	  that	  is	  
difficult	  to	  defer.	  
b. Urinary	  frequency,	  voiding	  eight	  or	  more	  times	  in	  a	  24-­‐hour	  period.	  	  
c. Nocturia,	  the	  need	  to	  wake	  one	  or	  more	  times	  per	  night	  to	  void.	  
d. They	  may	  or	  may	  not	  experience	  urinary	  incontinence.	  
e. With	  or	  without	  pyuria	  (≥1	  wbc	  µL-­‐1)	  and/or	  a	  history	  of	  acute	  symptom	  
exacerbations.	  
	  
2)	  Female	  adults	  without	  OAB	  and	  without	  other	  LUTS.	  
	  
2.7 Symptom	  collection	  
2.7.1 ICIQ	  Questionnaires	  
The	  International	  Consultation	  on	  Incontinence	  Questionnaires	  (ICIQ)	  were	  selected	  to	  
evaluate	  symptomatology	  (19).	  The	  ICIQ-­‐LUTS	  questionnaire	  is	  a	  well-­‐validated	  tool	  and	  
was	  selected	  to	  quantify	  and	  characterise	  symptoms	  and	  to	  assess	  patients’	  perception	  
of	  bother	  by	  such	  symptoms.	  The	  questionnaire	  consists	  of	  a	  total	  of	  12	  questions;	  four	  
questions	  on	  filling,	  three	  on	  voiding	  and	  five	  questions	  on	  incontinence.	  Each	  question	  
is	  scored	  1–4;	  thus,	  range	  of	  overall	  scores	  from	  0	  to	  16,	  12	  and	  20	  for	  filling,	  voiding	  
and	  incontinence	  scales,	  respectively.	  The	  overall	  score	  is	  0	  to	  48	  with	  higher	  scores	  
indicating	  greater	  impact	  of	  individual	  symptoms	  for	  the	  patient.	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2.7.2 Whittington	  Urgency	  Score	  
The	  symptoms	  of	  urinary	  urgency	  were	  measured	  in	  detail	  using	  a	  validated	  tool.	  The	  
Whittington	  Urgency	  Score	  is	  a	  ten-­‐item	  scale	  completed	  by	  participants	  that	  records	  
characteristics	  and	  the	  degree	  of	  urinary	  urgency	  (116).	  	  The	  questionnaire	  has	  been	  
fully	  validated	  (116,	  117).	  
2.7.3 Whittington	  Pain	  Score	  
The	  Whittington	  Pain	  Questionnaire,	  developed	  from	  a	  large	  symptom	  dataset	  provided	  
by	  patients	  with	  interstitial	  cystitis	  (IC),	  was	  selected	  for	  use	  in	  these	  studies.	  It	  is	  a	  
validated,	  eight-­‐item	  scale	  which	  records	  the	  most	  prevalent	  dysaesthetic/pain	  
symptoms	  associated	  with	  the	  lower	  urinary	  tract	  (20).	  
	  
2.8 MSU	  sample	  collection	  
Participants	  were	  asked	  to	  provide	  midstream	  clean-­‐catch	  method.	  	  Patients	  were	  given	  
verbal	  and	  written	  instructions	  (118)	  to	  try	  and	  avoid	  contamination.	  Participants	  were	  
instructed	  to	  first	  clean	  their	  hands,	  and	  clean	  the	  genital	  area	  with	  an	  antibacterial	  
wipe	  prior	  to	  sample	  collection.	  Female	  subjects	  were	  instructed	  to	  hold	  the	  labia	  apart	  
and	  cleanse	  the	  genial	  region	  from	  front	  to	  back	  with	  an	  antibacterial	  wipe.	  
Uncircumcised	  males	  were	  asked	  to	  retract	  the	  foreskin	  and	  cleanse	  the	  glans.	  
Participants	  were	  then	  asked	  to	  begin	  urinating.	  	  A	  sterile	  bowl	  was	  put	  into	  the	  
continuous	  stream	  to	  collect	  the	  middle	  part	  of	  the	  void	  and	  then	  removed.	  	  This	  
continuous	  stream	  of	  urine,	  as	  opposed	  to	  stopping	  and	  starting,	  reduced	  
contamination	  from	  the	  perineum.	  The	  urine	  was	  decanted	  into	  three	  30	  ml	  sterile	  
universal	  specimen	  tubes.	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2.9 Urine	  dipstick	  testing	  
Multistix®	  8	  SG	  reagent	  strips	  were	  used	  to	  test	  urine	  sample	  and	  analysed	  using	  the	  	  	  
paired	  with	  a	  Clinitek®	  Status	  analyser	  (Siemens,	  Munich,	  Germany).	  Leucocyte	  esterase	  
was	  reported	  as:	  ‘negative’,	  ‘trace’,	  ‘one	  1	  +’,	  ‘two	  2+’,	  or	  ‘three	  3+’;	  nitrite	  was	  
reported	  as	  ‘negative’	  or	  ‘positive’.	  
	  
2.10 Cytological	  assessment	  
	  
2.10.1 Inflammation:	  Microscopy	  for	  pyuria	  
Fresh	  urine	  samples	  were	  collected	  as	  described	  above	  and	  immediate	  microscopy	  was	  
performed	  on	  fresh	  unspun,	  unstained	  urine.	  A	  disposable	  pipette	  was	  used	  to	  place	  a	  
drop	  of	  urine	  in	  the	  filling	  chamber	  of	  a	  Neubauer	  haemocytometer	  and	  covered	  with	  a	  
glass	  cover	  slip.	  	  Olympus	  CX41	  light	  microscope	  (x200)	  (Olympus,	  Southend-­‐on-­‐Sea,	  
UK)	  was	  used	  to	  analyse	  the	  sample.	  The	  leucocyte	  count	  was	  enumerated	  using	  a	  
standard	  operating	  procedure	  in	  triplicate.	  	  All	  three	  measures	  were	  recorded	  and	  the	  
mean	  value	  calculated.	  	  	  	  
	  
2.10.2 Immune	  response:	  Urothelial	  cell	  shedding	  
Fresh,	  unspun,	  unstained	  urine	  samples	  were	  analysed	  immediately	  after	  sample	  
collection.	  A	  disposable	  pipette	  was	  used	  to	  place	  a	  drop	  of	  urine	  in	  the	  filling	  chamber	  
of	  a	  Neubauer	  haemocytometer	  and	  covered	  with	  a	  glass	  cover	  slip.	  	  Olympus	  CX41	  
light	  microscope	  (x200)	  (Olympus,	  Southend-­‐on-­‐Sea,	  UK)	  was	  used	  to	  analyse	  the	  
sample.	  The	  epithelial	  cell	  count	  was	  enumerated	  using	  a	  standard	  operating	  procedure	  
in	  triplicate.	  	  All	  three	  measures	  were	  recorded	  and	  the	  mean	  value	  calculated.	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2.10.3 Bacterial	  colonisation:	  Urothelial	  clue	  cell	  analysis	  
Urine	  samples	  were	  processed	  within	  I	  hour	  of	  sample	  collection,	  and	  were	  refrigerated	  
at	  4°C	  until	  assessment.	  A	  collection	  chamber	  consisted	  of	  a	  single	  channel	  cuvette	  and	  
retainer,	  a	  Shandon	  filter	  card	  (Fisher	  Scientific,	  Loughborough,	  UK),	  and	  a	  Superfrost	  
Ultra	  Plus	  glass	  microscope	  slide.	  80	  μl	  of	  urine	  was	  transferred	  into	  the	  collection	  
chamber	  for	  centrifugation.	  The	  sample	  was	  spun	  at	  75	  g	  for	  five	  minutes	  in	  a	  Shandon	  
Cytospin	  2	  cytocentrifuge	  (Thermo	  Scientific,	  Basingstoke,	  UK).	  The	  cellular	  components	  
of	  the	  sample	  formed	  a	  visible	  deposit	  on	  the	  slide.	  	  A	  hydrophobic	  barrier	  pen	  (Vector	  
Laboratories,	  Peterborough,	  UK)	  was	  used	  to	  outline	  the	  area	  and	  create	  a	  barrier.	  	  	  
	  
The	  cells	  were	  then	  fixed	  by	  adding	  100	  μl	  of	  4%	  formaldehyde	  (Thermo	  Scientific,	  
Fisher	  Scientific)	  in	  PBS	  at	  room	  temperature	  for	  15	  minutes.	  The	  formaldehyde	  was	  
aspirated	  and	  the	  preparation	  washed	  three	  times	  with	  PBS	  at	  5	  minute	  intervals.	  The	  
cell	  membranes	  were	  stained	  with	  wheat	  germ	  agglutinin	  (WGA)	  conjugated	  to	  Alexa	  
Fluor	  488	  (Invitrogen).	  	  Wheat	  germ	  agglutinin	  stock	  solution	  (1.0mg/mL)	  was	  prepared	  
by	  dissolving	  5mg	  of	  Alexa	  Fluor	  488	  WGA	  conjugate	  into	  5ml	  of	  sterile	  PBS.	  	  The	  stock	  
solution	  was	  stored	  in	  aluminium	  foil	  to	  protect	  from	  light	  at	  -­‐20°C	  for	  up	  to	  1	  month.	  
To	  prepare	  the	  Alexa	  Fluor	  488	  WGA	  conjugate	  working	  solution,	  the	  stock	  solution	  was	  
further	  diluted	  with	  Hank’s	  balanced	  salt	  solution	  (HBSS)	  minus	  phenol	  red	  (Invitrogen).	  	  
This	  gave	  a	  working	  solution	  of	  WGA	  conjugated	  to	  Alexa	  Fluor	  488	  of	  5.0μg/mL	  and	  
100μl	  of	  this	  was	  added	  to	  the	  cell	  deposit	  ensuring	  complete	  coverage	  of	  the	  cells.	  The	  
cellular	  deposit	  was	  incubated	  for	  15	  minutes	  at	  room	  temperature.	  	  The	  labelling	  
solution	  was	  then	  carefully	  aspirated	  and	  the	  cells	  washed	  4	  times	  at	  5	  minute	  intervals	  
with	  HBSS.	  Alexa	  Fluor	  488	  excites	  at	  a	  wavelength	  of	  495nm	  and	  emits	  at	  519nm,	  
hence	  the	  cell	  membranes	  appeared	  green	  under	  fluorescent	  microscopy.	  The	  host	  and	  
bacterial	  DNA	  were	  stained	  using	  the	  DNA	  stain,	  DAPI.	  100μl	  of	  DAPI	  (4’’,6-­‐diamidino-­‐2-­‐
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phenylindole,	  Sigma-­‐Aldrich)	  at	  concentration	  of	  1μg/ml	  in	  PBS	  was	  added	  to	  the	  
cellular	  deposit.	  	  The	  cells	  were	  incubated	  for	  15	  minutes	  at	  room	  temperature.	  	  The	  
DAPI	  solution	  was	  then	  aspirated	  and	  cells	  washed	  4	  times	  at	  5	  minute	  intervals	  with	  
PBS.	  DAPI	  solution	  (1μg/ml)	  were	  stored	  with	  protection	  from	  light	  at	  -­‐20°C.	  The	  cells	  
were	  immediately	  mounted	  with	  FluorSave	  reagent	  (Calbiochem)	  and	  a	  coverslip	  
carefully	  applied	  ensuring	  no	  air	  bubbles.	  	  The	  coverslip	  was	  fixed	  with	  clear	  nail	  varnish	  
and	  the	  slide	  was	  left	  to	  dry	  for	  at	  least	  one	  hour	  with	  protection	  from	  light.	  DAPI	  gives	  
mammalian	  nuclei	  and	  bacteria	  a	  blue	  appearance	  under	  fluorescent	  microscopy;	  it	  
excites	  at	  a	  wavelength	  of	  360nm	  and	  emits	  at	  460nm.	  DAPI	  is	  able	  to	  label	  intracellular	  
and	  extracellularly	  attached	  bacteria	  without	  the	  need	  for	  permeabilisation.	  All	  slides	  
were	  stored	  at	  4°C	  in	  a	  light-­‐protective	  box.	  The	  slides	  were	  examined	  under	  a	  
fluorescent	  microscope	  Olympus	  CX41	  upright	  epi-­‐fluorescence	  microscope	  (Olympus),	  
at	  the	  Department	  of	  Medicine,	  UCL	  Archway	  Campus.	  Images	  were	  processed	  using	  
ImageJ	  1.44P	  and	  Axiovision	  Rel.	  4.8	  software	  (Carl	  Zeiss,	  Cambridge,	  UK).	  	  The	  
proportion	  of	  clue	  cells	  were	  calculated	  by	  counting	  the	  total	  number	  of	  cells	  present	  
and	  then	  the	  proportion	  of	  cells	  with	  associated	  bacteria.	  	  Counts	  were	  performed	  in	  
triplicate	  and	  an	  average	  clue	  cell	  proportion	  recorded.	  
	  
2.11 Urothelial	  cytokine	  response	  
Urine	  samples	  were	  centrifuged	  using	  a	  Denley	  BR401	  centrifuge	  (RMAX=140mm)	  
(Denley,	  Heckmondwike,	  UK)	  at	  627	  g	  for	  5	  minutes.	  The	  supernatant	  was	  carefully	  
removed	  into	  20,	  1ml	  freezing	  microtubes	  (Sigma-­‐Aldrich)	  for	  immediate	  storage	  at	  	  	  	  	  	  	  	  
-­‐80°C.	  	  For	  each	  experiment	  a	  new	  aliquot	  of	  urine	  was	  used	  to	  ensure	  that	  each	  sample	  
only	  underwent	  one	  freeze	  thaw	  cycle.	  Details	  of	  methods	  used	  for	  individual	  cytokines	  
are	  described	  in	  relevant	  chapters.	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2.11.1 Concentration	  correction:	  Urinary	  creatinine	  
The	  measurement	  of	  urinary	  cytokines	  may	  be	  influenced	  by	  urinary	  concentration.	  	  
Urinary	  creatinine,	  a	  measure	  of	  glomerular	  filtration	  rate,	  was	  used	  as	  a	  correction	  
factor	  and	  concentration	  of	  cytokines	  expressed	  as	  a	  ratio	  of	  the	  creatinine	  
concentration.	  Thirty	  milliliters	  of	  urine	  in	  a	  sterile	  universal	  specimen	  tube	  was	  sent	  to	  
the	  Whittington	  Hospital	  biochemistry	  laboratory	  for	  analysis.	  Samples	  were	  processed	  
immediately	  upon	  receipt,	  or	  after	  overnight	  refrigeration	  at	  4°C.	  Urinary	  creatinine	  was	  
measured	  using	  an	  automated	  Jaffe	  technique,	  in	  which	  creatinine	  and	  alkaline	  picric	  
acid	  produce	  a	  red/orange	  complex	  measured	  by	  spectrophotometry.	  
	  
2.12 Microbiological	  assessment	  	  
2.12.1 Enhanced	  Sediment	  culture	  
Enhanced	  sediment	  cultures	  were	  processed	  within	  two	  hours	  of	  urine	  sample	  
collection.	  Samples	  were	  refrigerated	  at	  4°C	  until	  processed.	  All	  sediment	  cultures	  were	  
conducted	  in	  the	  research	  laboratory	  at	  the	  Department	  of	  Medicine,	  UCL	  Archway	  
Campus.	  
	  
2.12.1.1 Preparation	  and	  inoculation	  
Five	  millilitres	  of	  fresh	  unspun	  unstained	  urine	  was	  transferred	  into	  a	  sterile	  centrifuge	  
tube.	  	  The	  sample	  was	  centrifuged	  at	  627g	  for	  5	  minutes	  in	  a	  Denley	  BR401	  centrifuge	  
(RMAX=140mm)	  (Denley,	  Heckmondwike,	  UK).	  The	  supernatant	  was	  carefully	  removed,	  
leaving	  the	  urinary	  sediment.	  The	  sediment	  was	  resuspended	  in	  400	  μl	  of	  1%	  sterile	  PBS	  
solution.	  Four,	  1:10	  serial	  dilutions	  were	  performed	  for	  accurate	  quantitative	  bacterial	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counting.	  	  Serial	  dilutions	  were	  performed	  by	  resuspending	  100μl	  of	  the	  sediment	  
solution	  into	  900μl	  of	  1%	  sterile	  PBS,	  for	  a	  1:10	  dilution.	  This	  was	  then	  further	  diluted	  by	  
taking	  100μl	  of	  the	  1:10	  solution	  and	  resuspending	  this	  in	  a	  sterile	  Eppendorf	  containing	  
900μl	  of	  1%	  sterile	  PBS	  for	  a	  1:100	  dilution.	  This	  was	  repeated	  a	  further	  two	  times	  to	  
produce	  five	  sediment	  suspensions	  of	  concentration	  neat	  to	  10-­‐4.	  
	  
Chromogenic	  CPS3	  agar	  plates	  (bioMérieux,	  Basingstoke,	  UK)	  were	  used	  for	  culture.	  	  
The	  plate	  was	  divided	  into	  5	  subsections	  and	  50μl	  of	  the	  resuspended	  sediment	  and	  
serial	  dilution	  pipetted	  and	  spread	  onto	  each	  area.	  In	  addition	  50μl	  of	  the	  stock	  1%	  PBS	  
solution	  was	  plated	  onto	  a	  Columbia	  Blood	  Agar	  (CBA)	  plate	  (Oxoid,	  Basingstoke,	  UK).	  
All	  culture	  plates	  were	  incubated	  aerobically	  for	  24	  hours	  at	  37°C	  in	  a	  CO2	  dependant	  
incubator.	  	  If	  there	  was	  growth	  on	  the	  CBA	  plate,	  all	  samples	  where	  that	  stock	  PBS	  was	  
used,	  were	  discarded	  as	  this	  implied	  contamination	  of	  the	  stock	  1%	  PBS.	  
	  
2.12.1.2 Bacterial	  Quantification	  
Each	  bacterial	  isolate	  was	  quantified.	  	  No	  threshold	  was	  used	  to	  discriminate	  positive	  or	  
negative	  growth.	  The	  number	  of	  colonies	  of	  each	  isolate	  was	  determined	  in	  each	  sector	  
of	  the	  CPS3	  plate,	  corresponding	  to	  one	  of	  five	  serial	  bacterial	  dilutions.	  The	  mean	  
colony	  count	  from	  all	  sectors	  was	  calculated.	  
	  
2.12.1.3 Colour	  identification	  of	  colonies	  
The	  CPS3	  chromogenic	  medium	  allows	  bacterial	  identification	  of	  uropathogens	  to	  genus	  
or	  species	  level,	  dependent	  on	  the	  microbe.	  The	  growth	  of	  distinct	  bacteria	  is	  colour	  
specific	  to	  allow	  easy	  and	  fast	  enumeration.	  Colour	  identification	  was	  based	  on	  the	  
manufacturer’s	  standardized	  colour	  guide.	  Colour-­‐based	  identification	  was	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supplemented	  with	  Gram	  staining	  and	  rapid	  biochemical	  tests	  for	  further	  
characterisation.	  Analytical	  Profile	  Index	  (API)	  testing	  could	  be	  used	  when	  these	  
methods	  were	  unable	  to	  conclusively	  identify	  an	  isolate.	  
	  
2.12.1.4 Bacterial	  identification:	  Gram	  Stain	  
Gram	  staining	  was	  used	  to	  determine	  the	  morphological	  characteristics	  and	  cell	  wall	  
composition	  of	  bacteria	  where	  further	  classification	  was	  required.	  A	  single	  pure	  colony	  
was	  picked	  with	  a	  sterile	  loop	  and	  mixed	  on	  a	  glass	  slide	  with	  20µl	  of	  PBS.	  The	  solutions	  
were	  allowed	  to	  dry	  in	  air.	  Crystal	  violet	  stain	  (Sigma)	  was	  added	  over	  the	  slide.	  This	  was	  
allowed	  to	  stand	  for	  30	  seconds.	  The	  slide	  was	  then	  gently	  rinsed	  with	  a	  stream	  of	  
water.	  Iodine	  solution	  (Sigma)	  was	  added	  on	  the	  smear,	  enough	  to	  cover	  the	  slide.	  This	  
was	  allowed	  to	  stand	  for	  30	  seconds.	  The	  iodine	  solution	  was	  rinsed	  off	  the	  slide	  with	  
running	  water.	  	  A	  few	  drops	  of	  acetone	  (Sigma)	  were	  added	  so	  the	  solution	  trickled	  
down	  the	  slide	  and	  rinsed	  off	  with	  water	  after	  5	  seconds.	  A	  counter	  stain	  of	  1%	  neutral	  
red	  solution	  carbol	  fuchsin	  (Sigma)	  was	  added	  for	  30	  seconds.	  The	  solution	  was	  washed	  
off	  with	  water.	  The	  slide	  was	  air-­‐dried	  after	  blotting	  off	  excess	  water.	  	  
	  
Gram-­‐positive	  bacteria	  exhibited	  a	  dark	  purple	  colour	  due	  to	  their	  ability	  to	  retain	  
crystal	  violet	  within	  their	  peptidoglycan	  exoskeleton.	  In	  contrast,	  Gram-­‐negative	  
bacteria	  were	  unable	  to	  hold	  crystal	  violet.	  Instead,	  the	  counter	  stain	  dilute	  carbol	  
fuchsin	  (pink)	  was	  displayed.	  The	  morphology	  was	  characterised	  as	  either	  rod	  or	  bacillus	  
(cylindrical	  in	  shape)	  or	  coccus	  (spherical	  in	  shape).	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2.12.1.5 Bacterial	  identification:	  ‘Spot’	  biochemical	  testing	  
Rapid	  reagent	  testing	  (‘spot	  testing’)	  using	  catalase,	  indole,	  oxidase,	  bile	  esculin	  and	  
coagulase	  tests	  (Remel,	  Basingstoke,	  UK)	  were	  employed	  to	  supplement	  colour-­‐based	  
bacterial	  identification.	  
	  
2.12.1.5.1 Catalyse	  test	  
Using	  a	  sterile	  disposable	  loop,	  growth	  from	  the	  centre	  of	  a	  colony	  was	  transferred	  to	  a	  
clean	  glass	  slide.	  20µL	  of	  3%	  hydrogen	  peroxide	  (Sigma)	  was	  added	  to	  the	  colony.	  The	  
sample	  was	  observed	  for	  effervescence.	  A	  sustained	  appearance	  of	  effervescence	  was	  
reported	  as	  positive.	  
	  
2.12.1.5.2 Indole	  test	  
Indole	  spot	  reagent	  is	  used	  to	  detect	  the	  presence	  of	  indole,	  which	  is	  one	  of	  the	  
degradation	  products	  of	  the	  bacterial	  metabolism	  of	  tryptophan.	  	  	  It	  is	  used	  to	  
differentiate	  E	  coli	  from	  other	  bacterial	  genera	  such	  as	  Klebsiella,	  Enterobacter	  and	  
Serratia.	  Using	  a	  sterile	  disposal	  loop,	  growth	  from	  the	  centre	  of	  a	  colony	  was	  
transferred	  into	  sterile	  blotting	  paper	  containing	  a	  drop	  of	  indole	  and	  observed	  for	  
30seconds.	  	  A	  positive	  result	  was	  demonstrated	  by	  a	  blue	  to	  blue-­‐green	  colour,	  and	  a	  
negative	  result	  was	  demonstrated	  by	  a	  clear	  or	  light	  pink	  colour.	  
2.12.1.5.3 Oxidase	  test	  
A	  solution	  of	  tetramethyl-­‐p-­‐phenylenediamine	  (Sigma)	  was	  prepared	  in	  1ml	  of	  sterile	  
distilled	  water.	  A	  sterile	  swab	  was	  placed	  into	  the	  solution	  and	  soaked.	  The	  cotton	  bud	  
was	  then	  touched	  onto	  the	  surface	  of	  the	  test	  colony.	  A	  positive	  reaction	  was	  taken	  as	  
the	  development	  of	  a	  purple	  colour	  within	  20	  seconds.	  	  Pseudomonas	  aeruginosa	  (NCTC	  
10662)	  was	  used	  as	  a	  positive	  control.	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2.12.1.5.4 Bile	  Esculin	  	  
Bile	  Esculin	  agar,	  a	  selective	  differential	  agar,	  was	  used	  to	  confirm	  the	  identity	  of	  
Enterococcus.	  	  Members	  of	  the	  genus	  Enterococcus	  are	  able	  to	  grow	  in	  the	  presence	  of	  
4%	  bile	  (oxgall)	  and	  hydrolyzing	  esculin	  to	  glucose	  and	  esculetin.	  Esculetin	  combines	  
with	  ferric	  ions	  to	  produce	  a	  characteristic	  black	  complex,	  which	  constitutes	  a	  positive	  
result.	  
2.12.1.5.5 Co-­‐agulase	  test	  
The	  coagulase	  test	  was	  used	  to	  differentiate	  Staphylococcus	  aureus	  from	  coagulase-­‐
negative	  staphylococci.	  Two	  drops	  of	  saline	  were	  put	  onto	  the	  slide	  and	  emulsified	  with	  
the	  test	  organism	  using	  a	  sterile	  loop.	  A	  drop	  of	  plasma	  (rabbit	  plasma	  anticoagulated	  
with	  EDTA)	  was	  placed	  on	  one	  of	  the	  inoculated	  saline	  drop	  and	  mixed	  well	  and	  the	  
slide	  is	  rocked	  gently	  for	  about	  10	  seconds.	  If	  'positive',	  macroscopic	  clumping	  was	  
observed	  in	  the	  plasma	  within	  10	  seconds,	  with	  no	  clumping	  in	  the	  saline	  drop.	  	  If	  
'negative',	  no	  clumping	  was	  observed.	  
	  
2.12.1.6 Bacterial	  sub-­‐culture	  and	  isolate	  storage	  
Each	  bacterial	  isolate	  identified	  on	  chromogenic	  agar	  was	  sub-­‐cultured.	  A	  single	  colony	  
of	  bacteria	  was	  plated	  on	  a	  CBA	  plate	  using	  a	  sterile	  1μl	  inoculation	  loo	  to	  allow	  pure	  
growth.	  	  The	  plate	  was	  incubated	  for	  24	  hours	  at	  37°C.	  Each	  Bacterial	  isolate	  was	  
labelled	  stored	  in	  2	  ml	  cryopreservation	  vials	  (Thermo	  Scientific)	  as	  per	  the	  




2.12.2 Routine	  MSU	  culture	  
All	  routine	  microbiological	  cultures	  were	  undertaken	  in	  the	  Whittington	  Hospital	  
microbiology	  laboratory.	  Thirty	  millilitres	  of	  urine	  in	  a	  sterile	  universal	  specimen	  tube	  
was	  cultured	  immediately	  upon	  receipt,	  or	  after	  overnight	  refrigeration	  at	  4°C.	  Trained	  
biomedical	  scientists	  undertook	  all	  analyses.	  
2.12.2.1 Preparation	  and	  inoculation	  
One	  microlitre	  of	  the	  urine	  sample	  was	  inoculated	  onto	  a	  CPS3	  agar	  plate	  using	  a	  sterile	  
1µl	  loop.	  	  	  Inoculation	  was	  achieved	  by	  streaking	  the	  loop	  across	  the	  plate.	  The	  culture	  
plate	  was	  then	  incubated	  aerobically	  for	  24	  hrs	  at	  37°C.	  Bacterial	  colonies	  were	  
identified	  by	  colour	  and	  morphologic	  characteristics,	  as	  described	  previously.	  Rapid	  
reagent	  testing	  (‘spot	  testing’)	  was	  employed	  to	  supplement	  colour-­‐based	  bacterial	  
identification.	  	  	  
2.12.2.2 Bacterial	  Quantification	  
Routine	  culture	  techniques	  are	  semi-­‐quantitative,	  and	  bacterial	  growth	  is	  estimated	  by	  
visual	  assessment	  of	  colony	  density.	  A	  ‘positive’	  culture	  was	  defined	  as	  the	  growth	  of	  a	  
single	  recognised	  uropathogen	  at	  ≥105	  cfu	  ml-­‐1.	  Polymicrobial	  growth	  above	  this	  
threshold	  was	  reported	  as	  ‘mixed	  growth’.	  Any	  bacterial	  growth	  below	  105	  cfu	  ml-­‐1	  was	  




3 Chapter	  3	  –	  Urinary	  ATP	  as	  marker	  of	  urinary	  infection	  in	  
patients	  with	  LUTS	  –	  cross	  sectional	  data	  
	  
LUTS	  is	  a	  collective	  term	  describing	  (1)	  urinary	  storage	  problems	  such	  as	  frequency,	  
urgency	  and	  urge	  incontinence	  described	  as	  OAB	  and	  the	  main	  focus	  of	  this	  thesis;	  	  (2)	  
voiding	  difficulties	  such	  as	  hesitancy,	  reduced	  stream,	  intermittency	  and	  incomplete	  
voiding;	  	  (3)	  sensory	  symptoms	  that	  include	  various	  experiences	  of	  pain;	  and	  (4)	  stress	  
urinary	  incontinence.	  There	  is	  considerable	  overlap	  between	  these	  symptoms	  (Coyne	  
2009)	  so	  that	  diagnostic	  categorisation	  is	  difficult	  and	  it	  is	  impossible	  to	  consider	  OAB	  
without	  reference	  to	  the	  other	  symptom	  sets.	  	  Part	  of	  the	  process	  of	  discerning	  the	  
dominant	  problem	  is	  the	  exclusion	  of	  urinary	  tract	  infection;	  whatever	  the	  symptom	  
mix,	  it	  is	  a	  mandatory	  first	  step	  in	  the	  assessment	  of	  all	  LUTS	  (119).	  Whilst	  acute	  UTI	  is	  
not	  diagnostically	  challenging,	  in	  the	  case	  of	  LUTS	  without	  acute	  frequency	  and	  dysuria,	  
exclusion	  of	  infection	  poses	  a	  diagnostic	  challenge.	  	  	  
	  
There	  are	  good	  reasons	  to	  scrutinise	  urinary	  adenosine-­‐5'-­‐triphosphate	  (ATP)	  as	  a	  
possible	  surrogate	  marker	  of	  UTI	  since	  the	  reliability	  of	  popular	  diagnostic	  methods	  
used	  to	  exclude	  UTI	  have	  been	  questioned	  (40,	  42,	  45,	  120).	  Published	  guidelines	  across	  
Europe,	  USA	  and	  the	  UK	  reveal	  significant	  discrepancies	  in	  the	  choice	  of	  a	  quantitative	  
threshold	  used	  to	  define	  significant	  bacteriuria.	  The	  clean-­‐catch,	  midstream	  urine	  (MSU)	  
sample	  culture	  in	  the	  UK	  and	  Europe	  commonly	  uses	  the	  Kass	  (1957)	  criterion	  of	  105	  
colony	  forming	  units	  (cfu)	  ml-­‐1	  of	  a	  single	  species	  of	  a	  known	  urinary	  pathogen	  (38).	  	  
Kass	  drew	  these	  data	  from	  74	  women	  with	  acute	  pyelonephritis	  and	  337	  normal	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controls,	  a	  select	  sample	  unrepresentative	  of	  wider	  lower	  urinary	  tract	  symptoms	  
(LUTS).	  Despite	  its	  limitations,	  this	  criterion	  has	  become	  a	  ubiquitous	  reference	  
standard	  and	  has	  been	  challenged	  by	  several	  groups	  (40,	  41).	  The	  European	  Associate	  of	  
Urology	  (EUA)	  guidelines	  for	  urological	  infections	  emphasise	  that	  no	  single	  threshold	  
can	  be	  applied	  in	  all	  clinical	  situations.	  The	  urinary	  dipstick	  tests	  for	  nitrite	  and	  
leucocyte	  esterase	  are	  also	  commonly	  used	  as	  a	  bedside	  screening	  test	  for	  infection	  and	  
as	  a	  measure	  of	  a	  positive	  urine	  culture.	  	  However,	  the	  use	  of	  urinary	  dipstick	  has	  been	  
validated	  against	  the	  urine	  culture	  to	  a	  threshold	  of	  105	  colony	  forming	  units	  (cfu)	  ml-­‐1	  
and	  following	  the	  recent	  criticism	  of	  the	  Kass	  criterion,	  urinary	  dipstick	  have	  also	  been	  
found	  to	  be	  unreliable	  (42,	  43,	  45).	  
	  
Urinary	  tract	  ATP	  has	  attracted	  intense	  interest	  in	  the	  last	  30	  years	  for	  its	  
pharmacological	  and	  pathophysiological	  associations.	  There	  are	  great	  hopes	  that	  
purinergic	  receptor	  manipulation	  might	  influence	  detrusor	  motor	  function	  and	  
urothelial	  afferents	  (121)	  achieving	  therapeutic	  benefit	  for	  patients	  with	  OAB.	  	  ATP	  is	  an	  
important	  urothelial	  cell	  distress	  signal	  (122)	  and	  is	  released	  by	  inflammatory	  cells	  and	  
bacteria	  (123).	  	  Urinary	  tract	  infection,	  featuring	  bacterial	  invasion,	  urothelial	  distress	  
and	  an	  innate	  immune	  response	  involving	  recruitment	  of	  inflammatory	  cells,	  should	  be	  
associated	  with	  increased	  urinary	  ATP	  levels.	  	  Indeed,	  high	  levels	  of	  ATP	  have	  been	  
detected	  in	  the	  urine	  of	  patients	  with	  interstitial	  cystitis	  and	  acute	  UTI	  with	  a	  positive	  
urine	  culture	  (124).	  Increased	  ATP	  has	  also	  been	  shown	  to	  be	  released	  from	  cultured	  
urothelial	  cells	  infected	  with	  uropathogenic	  E.coli	  (UPEC)	  (125)	  and	  UPEC	  also	  produce	  
ATP	  when	  cultured	  in	  vitro	  (126).	  It	  has	  been	  postulated	  that	  ATP	  may	  reflect	  microbial	  
biomass	  and	  hence	  ATP	  increases	  as	  the	  amount	  of	  bacteria	  present	  increases.	  	  	  
Currently	  ATP	  levels	  are	  used	  widely	  in	  the	  food,	  water	  and	  sanitation	  industry	  as	  a	  




Given	  the	  problems	  with	  current	  tests	  developing	  alternative	  diagnostic	  assays	  is	  a	  high	  
priority.	  I	  sought	  to	  scrutinise	  the	  performance	  of	  urinary	  ATP	  as	  a	  potential	  surrogate	  
marker	  for	  urinary	  infection	  in	  patients	  with	  lower	  urinary	  tract	  symptoms.	  	  
	  
The	  hypothesis	  to	  be	  tested	  was:	  
	  
1)	  Patients	  with	  OAB	  show	  a	  higher	  urinary	  inflammatory	  signal	  as	  compared	  to	  controls	  
with	  higher	  concentrations	  of	  urinary	  ATP.	  	  
	  
2)	  Urinary	  ATP	  has	  the	  potential	  as	  a	  surrogate	  marker	  of	  urinary	  infection	  in	  patients	  
with	  chronic	  lower	  urinary	  tract	  symptoms.	  
	  
3.2 Study	  Design	  	  
The	  study	  was	  divided	  into	  two	  parts;	  (1)	  a	  clinical	  experiment	  that	  evaluated	  urinary	  
ATP	  in	  patients	  with	  LUTS	  and	  controls,	  comparing	  urinary	  ATP	  with	  symptoms,	  
microscopic	  pyuria	  and	  urine	  culture	  results;	  and	  (2)	  a	  laboratory	  experimental	  series	  
that	  explored	  the	  factors	  that	  could	  influence	  sample	  collection,	  storage	  and	  
preservation.	  As	  urine	  contains	  native	  ATPase	  activity,	  the	  time-­‐decay	  curve	  of	  urinary	  
ATP	  from	  collection	  to	  processing	  was	  evaluated.	  	  Boric	  acid	  crystals,	  which	  are	  
commonly	  used	  as	  a	  urinary	  preservative,	  have	  been	  shown	  to	  prevent	  microbial	  
swarming	  (128)	  and	  boric	  acid	  has	  a	  preservative	  influence	  on	  white	  cells	  (129).	  The	  
effect	  of	  the	  use	  of	  urinary	  preservative	  boric	  acid,	  storage	  temperature	  and	  the	  effect	  
of	  centrifugation	  on	  urinary	  ATP	  concentration	  was	  studied.	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3.3 Ethical	  Approval	  
All	  of	  the	  studies	  included	  in	  this	  work	  were	  subject	  to	  approval	  by	  the	  National	  
Research	  Ethics	  Service	  (NRES).	  This	  study	  was	  approved	  by	  East	  Central	  Research	  
Ethical	  Committee	  1	  (REC	  Reference	  number	  11/H0721/7).	  
	  
3.4 Inclusion	  and	  exclusion	  criteria	  
Subject	  Inclusion	  Criteria	  
5. Adults	  aged	  >=18	  years	  	  
6. Able	  to	  complete	  a	  symptom	  questionnaire	  	  
7. Diagnosed	  with	  LUTS	  with	  or	  without	  pyuria	  (≥	  1	  wbc	  µl-­‐1)	  
8. Post-­‐menopausal	  women	  or	  women	  using	  adequate	  contraception	  
	  
Subject	  Exclusion	  Criteria	  
5. Age	  less	  than	  18	  years	  	  
6. Inability	  to	  consent	  	  
7. Pregnant	  women	  or	  women	  planning	  to	  conceive	  
8. Patients	  with	  concurrent	  illnesses	  that	  in	  the	  opinion	  of	  the	  investigator	  are	  
likely	  to	  compromise	  the	  validity	  of	  the	  data	  
	  
There	  were	  two	  study	  groups	  1)	  adult	  patients	  with	  LUTS	  and	  2)	  control	  group	  of	  adults	  
without	  any	  LUTS.	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3.5 Study	  Population	  
3.5.1 Recruitment	  
Patients	  with	  lower	  urinary	  tract	  symptoms	  and	  healthy	  volunteers	  were	  recruited	  as	  
described	  in	  chapter	  2.	  	  
3.5.2 Consent	  	  
Written	  consent	  was	  obtained	  from	  all	  participating	  individuals	  as	  described	  in	  chapter	  
2.	  
	  
3.6 Safety	  considerations	  	  
There	  were	  no	  safety	  considerations	  for	  patients	  providing	  MSU	  samples	  only.	  	  
	  
3.7 Study	  Method	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  as	  
described	  in	  chapter	  2.	  	  
	  
An	  ATP	  Bioluminescent	  Assay	  Kit	  was	  used	  to	  quantify	  ATP	  expression	  in	  sampled	  urine	  
(Sigma-­‐Aldrich).	  	  Standard	  solutions	  were	  prepared	  using	  the	  supplied	  ATP	  standard	  
(2x10-­‐6	  M	  ATP)	  and	  sterile	  1%	  PBS	  as	  a	  diluent.	  Five	  serial	  dilutions	  of	  the	  ATP	  standard	  
were	  prepared,	  producing	  solutions	  between	  2x10-­‐7	  and	  2x10-­‐12	  M	  ATP;	  the	  stock	  ATP	  
standard	  and	  PBS	  used	  as	  2x10-­‐6	  M	  and	  zero	  standards	  respectively.	  	  
	  
Urine	  samples	  underwent	  only	  once	  freeze	  thaw	  cycle.	  Urine	  samples	  were	  thawed	  to	  
room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  (Scientific	  Industries,	  New	  York,	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USA).	  	  The	  thawed	  samples	  were	  buffered	  to	  approximately	  pH	  7.8	  to	  optimise	  
luciferase	  enzymic	  action.	  Sixteen	  wells	  in	  a	  96	  well	  microplate	  were	  each	  filled	  with	  50	  
µl	  of	  the	  eight	  ATP	  standard	  solutions	  in	  duplicate;	  the	  remaining	  wells	  were	  filled	  with	  
50	  µl	  of	  each	  urine	  test	  sample.	  The	  luciferin/luciferase	  reagent	  was	  reconstituted	  in	  the	  
supplied	  diluent	  immediately	  prior	  to	  use.	  Fifty	  microlitres	  of	  the	  solution	  was	  added	  to	  
each	  of	  the	  wells	  and	  bioluminescence	  measurements	  made	  immediately	  using	  a	  
Synergy	  3	  luminometer	  (Biotek,	  Potton,	  UK)	  set	  at	  570	  nm.	  
	  
3.7.1 Blinding	  	  
Microscopy	  and	  ATP	  analysis	  were	  performed	  with	  blinding	  to	  patient	  details	  and	  
symptoms	  of	  participants.	  Samples	  presented	  for	  analysis	  were	  identified	  only	  by	  a	  
randomly	  generated	  four-­‐digit	  study	  number.	  	  	  
	  
3.7.2 Evaluation	  of	  the	  effect	  of	  time	  on	  urinary	  ATP	  
Urine	  samples	  used	  to	  assess	  stability	  of	  ATP	  over	  time	  were	  stored	  at	  room	  
temperature	  (23°C).	  	  Aliquots	  were	  taken	  at	  0	  hours	  (immediately),	  12	  hours,	  24	  hours,	  
48	  hours,	  168	  hours	  and	  frozen	  at	  -­‐80°C.	  	  	  
	  
3.7.3 Evaluation	  of	  the	  effect	  of	  storage	  temperature	  on	  urinary	  ATP	  
The	  literature	  tends	  to	  recommend	  storage	  at	  -­‐80°C;	  however,	  this	  is	  not	  convenient	  for	  
many	  clinical	  services.	  The	  effects	  of	  freezing	  at	  -­‐80°C	  and	  -­‐20°C	  were	  therefore	  studied.	  
2ml	  aliquots	  of	  fresh	  urine	  were	  taken	  from	  each	  participant.	  One	  aliquot	  was	  frozen	  
immediately	  after	  microscopy	  and	  stored	  at	  -­‐80°C	  and	  another	  at	  -­‐20°C.	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3.7.4 Evaluation	  of	  the	  use	  of	  boric	  acid	  preservative	  on	  urinary	  ATP	  
The	  effects	  of	  boric	  acid	  preservation	  on	  decay	  of	  urinary	  ATP	  were	  studied.	  	  10	  mls	  of	  
urine	  was	  introduced	  into	  pre-­‐prepared	  boric	  acid	  tubes	  (Becton	  Dickinson	  Vacutainer®	  
C&S	  Preservative	  Urine	  Tubes	  for	  Culture	  and	  Sensitivity)	  and	  stored	  at	  room	  
temperature.	  Aliquots	  were	  taken	  at	  0	  hours	  (immediately),	  12	  hours,	  24	  hours,	  48	  
hours,	  168	  hours	  and	  frozen	  at	  -­‐80°C.	  	  
	  
3.7.5 Evaluation	  of	  the	  effect	  of	  centrifugation	  on	  urinary	  ATP	  
Urinary	  ATP	  may	  originate	  from	  several	  sources	  including	  bacteria,	  urothelial	  cells	  and	  
white	  cells.	  Therefore,	  I	  sought	  to	  discover	  whether	  centrifuging	  the	  urine	  altered	  the	  
assay	  result,	  either	  by	  removing	  cells	  from	  the	  supernatant,	  or	  by	  lysing	  cells	  in	  the	  
process.	  An	  aliquot	  of	  urine	  was	  spun	  at	  620	  g	  for	  5	  minutes	  and	  the	  supernatant	  was	  
frozen	  at	  -­‐80°C.	  	  
	  
All	  of	  the	  urine	  aliquots	  were	  frozen	  immediately	  at	  -­‐80°C.	  These	  samples	  were	  
processed	  for	  urinary	  ATP	  between	  eight	  to	  twelve	  weeks	  after	  collection	  and	  storage.	  
The	  frozen	  urine	  aliquots	  were	  thawed	  to	  room	  temperature	  (23°C)	  using	  a	  water	  bath	  
and	  then	  immediately	  analysed	  using	  the	  standard	  luciferin-­‐luciferase	  assay	  and	  
protocol,	  as	  described	  earlier.	  	  
	  
3.8 Statistical	  analysis	  
Multivariate	  linear	  regression	  analyses	  were	  used	  to	  scrutinise	  the	  log10	  ATP	  as	  the	  
response	  variable	  using	  two	  models.	  In	  the	  first,	  the	  explanatory	  variables	  were	  gender	  
(0=female,	  1=male);	  age;	  average	  24-­‐hour	  frequency;	  average	  24-­‐hour	  incontinence;	  
number	  of	  stress	  incontinence	  symptoms,	  pain	  symptoms,	  voiding	  symptoms	  and	  OAB	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symptoms;	  the	  presence	  or	  absence	  of	  any	  pyuria	  (0=none,	  1=	  any	  pyuria);	  and	  the	  MSU	  
culture	  result	  (0=negative,	  1=positive).	  	  The	  second	  model	  looked	  more	  closely	  at	  the	  
effect	  of	  the	  degree	  of	  pyuria.	  	  Pyuria	  was	  grouped	  as	  zero	  pyuria,	  pyuria	  1-­‐9	  or	  pyuria	  
≥10,	  subgroups	  that	  are	  currently	  used	  by	  most	  clinicians,	  and	  these	  were	  referenced	  to	  
control	  samples.	  	  The	  sample	  had	  83%	  power	  to	  detect	  a	  .04	  increment	  in	  R2,	  if	  ten	  
predictor	  variables	  were	  included	  in	  the	  regression	  model	  with	  alpha	  =	  0.05.	  	  In	  the	  
laboratory	  experimental	  series,	  paired	  data	  was	  collected	  and	  hence	  a	  paired	  t-­‐test	  was	  
used	  to	  analyse	  the	  difference	  in	  log10	  ATP	  between	  paired	  samples	  stored	  at	  -­‐20°C	  and	  
-­‐80°C;	  paired	  samples	  stored	  with	  and	  without	  boric	  acid;	  and	  paired	  samples	  
centrifuged	  or	  not	  centrifuged.	  The	  diagnostic	  potential	  of	  urinary	  log10	  ATP	  was	  
assessed	  by	  ROC	  plots	  using	  positive	  MSU	  at	  105	  cfu	  ml-­‐1	  of	  a	  pure	  isolate	  of	  a	  known	  
urinary	  pathogen;	  pyuria	  ≥	  10	  wbc	  µl-­‐1	  and	  pyuria	  >	  0	  wbc	  µl-­‐1.	  
	  
3.9 Results	  
Urine	  samples	  from	  75	  healthy	  controls	  and	  340	  patients	  presenting	  with	  LUTS	  were	  
collected.	  The	  patient	  cohort	  was	  grouped	  in	  the	  first	  model;	  with	  pyuria	  (≥1	  wbc	  µl-­‐1)	  or	  
without	  pyuria	  (0	  wbc	  µl-­‐1).	  The	  second	  model	  used	  categorical	  scaling	  to	  compare	  
pyuria	  1-­‐9	  wbc	  µl-­‐1	  (n	  =	  120)	  and	  pyuria	  ≥10	  wbc	  µl-­‐1	  (n	  =	  120)	  with	  a	  baseline	  factor	  of	  
zero	  pyuria	  (0	  wbc	  µl-­‐1).	  The	  demographic	  data	  can	  be	  seen	  in	  Table	  3.1.	  The	  control	  
group	  consisted	  of	  49	  females	  and	  26	  males,	  with	  mean	  age	  38.2yrs	  (95%	  CI	  34.5	  -­‐	  41.8).	  
Within	  the	  LUTS	  group	  there	  were	  314	  females	  and	  26	  males,	  with	  a	  mean	  age	  of	  
58.6yrs	  (95%	  CI	  56.8	  -­‐	  60.4)	  (Table	  1).	  Of	  those	  with	  LUTS,	  33.3%	  had	  only	  OAB	  
symptoms,	  4.1%	  had	  pain	  alone,	  3.7%	  had	  only	  stress	  incontinence	  and	  13.2%	  had	  only	  
voiding	  dysfunction.	  Patients	  had	  a	  median	  of	  3.5	  LUTS	  (quartile	  range	  1	  to	  6).	  The	  
overlap	  of	  symptoms	  is	  illustrated	  in	  Figure	  3.1.	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Table	  3.1	  -­‐	  Demographic	  data	  
	  




Gender	  male	   N	  =	  26	   N	  =	  26	  
Gender	  female	   N	  =	  49	   N	  =	  314	  
No	  Pyuria	   N	  =	  58	  (female	  =	  35,	  male	  =	  23)	   N	  =	  100	  (female	  =	  92,	  male	  =	  8)	  
Any	  Pyuria	   N	  =	  17	  (female	  =	  14,	  male	  =	  3)	   N	  =	  240	  (female	  =	  222,	  male=	  18)	  
	   Mean	   Std	  Deviation	  (sd)	   Mean	   Std	  Deviation	  (sd)	  
Age	  (years)	   38.2	   15.8	   58.6	   16.6	  
	   Mean	   Median	  
	  
sd	   Quartile	  
range	  
Mean	   Median	  
	  
sd	   Quartile	  
range	  
24	  hour	  frequency	   6.2	   6.2	   6.0	  to	  7.0	   6.0	  to	  7.0	   9.2	   8.0	   8.0	  to	  10.0	   6.0	  to	  11.0	  
24	  hour	  
incontinence	  
0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	   0.8	   0.5	   0.5	  to	  1.2	   0.0	  to	  1.0	  
Number	  of	  urgency	  
symptoms	  
0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	   2.8	   2.0	   2.0	  to	  3.6	  	   0.0	  to	  4.0	  
Number	  of	  pain	  
symptoms	  
0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	   0.4	   0.0	   0.2	  to	  0.6	   0.0	  to	  0.0	  
Number	  of	  stress	  inc	  
symptoms	  
0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	   0.3	   0.0	   0.08	  to	  0.5	   0.0	  to	  0.0	  
Number	  of	  voiding	  
symptoms	  
0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	   1.4	   0.0	   1.0	  to	  1.8	   0.0	  to	  2.0	  
Number	  of	  LUTS	   0	   0	   0.0	  to	  0.0	   0.0	  to	  0.0	  
	  





Figure	  3.1-­‐	  Venn	  diagram	  of	  symptom	  analysis	  
A	  four-­‐way	  Venn	  diagram	  illustrating	  the	  overlap	  of	  symptom	  amongst	  the	  patients	  
studied.	  The	  ellipses	  circumscribe	  patients	  who	  had	  one	  or	  more	  symptoms	  in	  the	  





Log10	  transformation	  of	  ATP	  changed	  the	  skewness	  from	  4.2	  to	  -­‐0.3	  and	  kurtosis	  from	  
27.5	  to	  1.1.	  The	  results	  of	  the	  two	  regression	  analyses	  are	  shown	  in	  Table	  3.2.	  It	  can	  be	  
seen	  that	  female	  gender	  was	  associated	  with	  higher	  predictions	  of	  the	  log10	  ATP	  but	  
given	  the	  small	  number	  of	  males,	  the	  limited	  discriminatory	  power	  precludes	  
extrapolation.	  Voiding	  symptoms	  were	  also	  predictive	  of	  higher	  log10	  ATP.,	  Voiding	  
symptoms	  in	  both	  sexes	  have	  been	  reported	  to	  be	  associated	  with	  inflammatory	  
disease	  of	  the	  lower	  urinary	  tract	  (130).	  	  A	  positive	  culture	  result	  predicted	  lower	  log10	  
ATP.	  The	  first	  regression	  model	  shows	  that	  the	  presence	  of	  any	  pyuria	  was	  not	  
predictive	  of	  higher	  log10	  ATP.	  	  The	  second	  regression	  model	  demonstrates	  that	  a	  pyuria	  
≥10	  wbc	  µl-­‐1	  was	  predictive	  of	  a	  higher	  log10	  ATP;	  however,	  lower	  levels	  of	  pyuria	  1-­‐9	  
wbc	  µl-­‐1	  were	  not	  predictive.	  	  These	  data	  demonstrate	  that	  urinary	  ATP	  is	  elevated	  in	  
association	  with	  inflammation	  but	  that	  urinary	  ATP	  lacks	  the	  discriminating	  properties	  
at	  lower	  levels	  of	  pyuria,	  which	  would	  be	  essential	  for	  a	  useful	  clinical	  surrogate	  marker.	  	  
This	  is	  illustrated	  by	  the	  ROC	  analysis	  which	  showed	  an	  area	  under	  the	  curve	  of	  0.6	  for	  a	  
positive	  culture;	  0.5	  for	  pyuria	  >	  0	  wbc	  µl-­‐1	  and	  0.6	  for	  pyuria	  ≥	  10	  wbc	  µl-­‐1	  (Figure	  3.2).	  
These	  data	  imply	  that	  there	  is	  no	  useful	  diagnostic	  role	  for	  this	  assay.	  	  The	  regression	  
analyses	  showed	  that,	  age,	  average	  24-­‐hour	  frequency,	  average	  24-­‐hour	  incontinence,	  
the	  number	  of	  urgency,	  stress	  incontinence,	  and	  pain	  symptoms	  provided	  no	  




Table	  3.2	  -­‐	  Output	  from	  regression	  analysis	  
	  
Model	  1	  Pyuria	  described	  by	  dichotomy	  
	  	   	   	   95%	  Confidence	  Interval	  for	  B	  
	  	   B	  Coefficient	   p	   Lower	  Bound	   Upper	  Bound	  
(Constant)	   -­‐8.026	   .000	   -­‐8.400	   -­‐7.652	  
Age	   .004	   .197	   -­‐.002	   .009	  
Gender	  0	  =	  female,	  1	  =	  male	   -­‐.537	   .001	   -­‐.865	   -­‐.209	  
MSU	  0=negative	  1=positive	   -­‐.346	   .004	   -­‐.582	   -­‐.110	  
Average	  24-­‐hour	  frequency	   -­‐.004	   .743	   -­‐.026	   .019	  
Average	  24-­‐hour	  incontinence	   -­‐.001	   .990	   -­‐.092	   .090	  
Number	  of	  stress	  incontinence	  
symptoms	  
-­‐.065	   .179	   -­‐.161	   .030	  
Number	  of	  voiding	  symptoms	   .124	   .000	   .061	   .187	  
Number	  of	  pain	  symptoms	   .082	   .382	   -­‐.103	   .267	  
Number	  of	  urgency	  symptoms	   -­‐.030	   .163	   -­‐.072	   .012	  
Pyuria	  0=	  none	  1=	  any	   .157	   .107	   -­‐.034	   .349	  
	   	   	   	   	  
Model	  2	  Pyuria	  described	  by	  ordinal	  scale	  
	  	   95%	  Confidence	  Interval	  for	  B	  
	  	   B	  Coefficient	   p	   Lower	  Bound	   Upper	  Bound	  
(Constant)	   -­‐8.058	   .000	   -­‐8.431	   -­‐7.685	  
Age	   .002	   .404	   -­‐.003	   .008	  
Gender	  0	  =	  female,	  1	  =	  male	   -­‐.522	   .002	   -­‐.845	   -­‐.199	  
MSU	  0=negative	  	  1=positive	   -­‐.406	   .001	   -­‐.642	   -­‐.171	  
Average	  24-­‐hour	  frequency	   -­‐.002	   .878	   -­‐.024	   .021	  
Average	  24-­‐hour	  incontinence	   -­‐.024	   .607	   -­‐.114	   .067	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Number	  of	  stress	  incontinence	  
symptoms	  
-­‐.060	   .210	   -­‐.154	   .034	  
Number	  of	  voiding	  symptoms	   .106	   .001	   .043	   .169	  
Number	  of	  pain	  symptoms	   .085	   .356	   -­‐.096	   .266	  
Number	  of	  urgency	  symptoms	   -­‐.024	   .257	   -­‐.066	   .018	  
Pyuria1	  to	  9	  wbc	  µl-­‐1	   .207	   .059	   -­‐.008	   .422	  
Pyuria	  ≥	  10	  wbc	  	  µl-­‐1	   .432	   .000	   .203	   .662	  
	  
Dependent	  variable	  is	  urinary	  log10	  ATP	  concentration	  
	  
	  
Figure	  3.2	  –	  Receiver-­‐operator	  characteristics	  (ROC)	  curve	  for	  urinary	  ATP	  for	  the	  
diagnosis	  of	  UTI.	  The	  ROC	  analysis	  shows	  an	  area	  under	  the	  curve	  of	  0.6	  for	  pyuria	  ≥	  10	  
wbc	  µl-­‐1.	  These	  data	  imply	  that	  there	  is	  no	  useful	  diagnostic	  role	  for	  this	  assay.	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Urinary	  ATP	  decay	  over	  time:	  A	  subgroup	  of	  20,	  randomly	  selected	  patient	  samples	  was	  
used	  to	  plot	  the	  urinary	  ATP	  concentration	  in	  samples	  at	  differing	  time	  points	  after	  
collection;	  0	  hours,	  12	  hours,	  24	  hours,	  48	  hours,	  168	  hours.	  Aliquots	  were	  taken	  at	  
each	  point	  and	  frozen	  at	  -­‐80ºC	  and	  stored	  for	  assays	  in	  batches.	  	  The	  ATP	  concentration	  
fell	  with	  time	  with	  the	  rate	  of	  decline	  dependent	  on	  the	  initial	  concentration,	  as	  
illustrated	  in	  Figure	  3.3,	  where	  the	  time	  course	  of	  each	  sample	  is	  plotted.	  	  	  
	  
Figure	  3.3	  -­‐	  The	  ATP	  decay	  curves	  for	  a	  subset	  of	  20	  urine	  samples	  	  
The	  rate	  of	  decay	  is	  substrate	  concentration	  dependent;	  such	  that	  a	  sample	  with	  a	  
higher	  ATP	  concentration	  shows	  a	  more	  marked	  decay.	  	  It	  is	  therefore	  important	  to	  





Urinary	  ATP	  and	  effect	  of	  storage	  with	  boric	  acid	  preservative:	  Figure	  3.4	  shows	  box	  
plots	  of	  the	  log10	  ATP	  concentration	  at	  each	  time	  point	  comparing	  the	  effect	  of	  boric	  
acid.	  An	  analysis	  of	  20	  paired	  samples	  at	  24-­‐hours	  demonstrated	  the	  significance	  of	  this	  
difference:	  	  mean	  log10	  ATP	  (moles)	  in	  samples	  stored	  without	  boric	  acid	  was	  -­‐6.3	  log10	  
moles	  and	  in	  samples	  stored	  with	  boric	  acid	  was	  -­‐6.5	  log10	  moles	  	  (95%	  CI	  difference	  
0.15	  to	  0.29,	  t=6.2,	  p<.001).	  These	  data	  show	  that	  boric	  acid	  caused	  loss	  of	  ATP.	  
	  
Figure	  3.4	  –	  A	  box	  plot	  showing	  the	  effects	  of	  boric	  acid	  preservative	  on	  urinary	  ATP	  
decay.	  The	  box	  plot	  shows	  a	  subset	  of	  20	  paired	  samples	  to	  test	  the	  effect	  of	  boric	  acid	  
as	  a	  urinary	  preservative	  on	  the	  decay	  of	  urinary	  ATP.	  Urinary	  ATP	  was	  measured	  at	  12	  





Urinary	  ATP	  and	  effect	  of	  storage	  temperature:	  Comparison	  of	  30	  paired	  samples	  of	  
urine	  stored	  at	  -­‐20°C	  and	  -­‐80°C	  showed	  no	  significant	  difference	  in	  ATP	  concentration:	  
mean	  log10	  ATP	  (moles)	  in	  samples	  stored	  at	  -­‐20°C	  was	  -­‐6.7	  log10	  moles	  and	  in	  samples	  
stored	  at	  -­‐80°C	  was	  -­‐6.8	  log10	  moles	  (95%	  CI	  difference	  -­‐0.09	  to	  +0.01	  	  t=-­‐1.7,	  p=.1).	  Thus	  
storage	  at	  -­‐20°C	  for	  8	  weeks	  would	  seem	  reasonable.	  
	  
Urinary	  ATP	  and	  effect	  of	  centrifugation:	  Comparison	  of	  30	  paired	  samples	  of	  urine	  
unspun	  and	  spun	  showed	  that	  the	  supernatant	  urine	  had	  a	  slightly	  lower	  level	  of	  ATP:	  
mean	  log10	  ATP	  (moles	  ml
-­‐1)	  in	  uncentrifuged	  samples	  =	  -­‐6.9	  log10	  moles	  and	  in	  the	  
supernatant	  after	  centrifuge	  mean	  =	  -­‐6.8	  log10	  moles	  (95%	  CI	  difference	  0.03	  to	  0.1,	  t	  =	  
3.5,	  p=.002).	  Whilst	  statistically	  different,	  this	  is	  a	  very	  small	  difference	  and	  of	  little	  
clinical	  significance.	  
	  
3.10 Discussion	  	  
ATP	  has	  been	  proposed	  as	  a	  potential	  clinical	  marker	  for	  acute	  and	  chronic	  urinary	  tract	  
disease	  (33,	  131).	  To	  avoid	  premature	  use,	  when	  assessing	  the	  diagnostic	  potential	  of	  
test,	  it	  is	  important	  to	  assess	  first	  whether	  the	  measure	  explains	  the	  symptoms	  and	  
other	  manifestations	  of	  the	  disease	  of	  interest	  (132).	  The	  data	  published	  here	  
demonstrate	  that	  urinary	  ATP	  shows	  little	  concordance	  with	  the	  clinical	  consequences	  
of	  urinary	  infection	  in	  chronic	  LUTS,	  and	  therefore	  does	  not	  show	  promise	  for	  future	  
development	  of	  a	  diagnostic	  test	  for	  this	  particular	  disease.	  This	  observation	  is	  
confirmed	  in	  the	  ROC	  curves	  that	  explore	  sensitivity	  and	  specificity	  properties.	  
	  
These	  results	  demonstrate	  that	  patients	  with	  LUTS	  and	  any	  pyuria	  do	  not	  manifest	  a	  
significantly	  raised	  urine	  ATP	  concentration.	  It	  is	  only	  when	  there	  is	  a	  high	  pyuria	  of	  
greater	  than	  10	  wbc	  µl-­‐1,	  which	  is	  a	  currently	  used	  marker	  of	  urinary	  infection,	  that	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there	  is	  a	  significantly	  raised	  urinary	  ATP.	  However,	  this	  signal	  was	  not	  a	  discriminating	  
marker	  for	  low	  levels	  of	  lower	  urinary	  tract	  inflammation	  (pyuria	  1-­‐9	  wbc	  µl-­‐1)	  as	  shown	  
by	  our	  second	  regression	  model,	  and	  it	  is	  in	  these	  clinical	  circumstances	  that	  there	  is	  
greatest	  need	  for	  novel	  clinical	  surrogate	  markers.	  	  It	  has	  been	  shown	  that	  low-­‐level	  
pyuria	  (133),	  voiding	  symptoms	  (130),	  overactive	  bladder	  symptoms	  (55)	  and	  pain	  
symptoms	  (134)	  are	  all	  correlated	  with	  urinary	  infection.	  Only	  voiding	  symptoms	  
explained	  a	  small	  amount	  of	  the	  variance	  in	  ATP.	  These	  findings	  are	  therefore	  
discouraging.	  
	  
Counter-­‐intuitively,	  urinary	  ATP	  was	  lower,	  given	  a	  positive	  urine	  culture.	  This	  
unexpected	  result	  may	  reflect	  the	  fact	  that	  there	  were	  so	  few	  positive	  cultures	  (16.9%).	  
Increased	  microbial	  dephosphorylation	  of	  ATP	  to	  adenosine,	  which	  we	  did	  not	  assay,	  
may	  also	  be	  a	  contributing	  factor.	  In	  addition,	  the	  urinary	  ATP	  reflects	  the	  urinary	  
microbial	  biomass	  directly	  post	  void	  and	  there	  may	  be	  significant	  variation	  in	  the	  
urinary	  biomass	  at	  the	  time	  of	  assay	  secondary	  to	  transportation	  and	  processing	  delay.	  	  	  
	  
There	  was	  an	  unbalanced	  sample	  size	  with	  fewer	  control	  participants	  with	  a	  lower	  
average	  age,	  and	  this	  reflects	  the	  common	  difficulty	  of	  finding	  older	  subjects	  without	  
any	  urinary	  tract	  symptoms.	  The	  controls	  in	  this	  experiment	  were	  all	  asymptomatic.	  I	  
did	  control	  for	  these	  differences	  in	  the	  analysis	  but	  would	  nevertheless	  wish	  to	  avoid	  
wide	  inferential	  generalisations.	  The	  essence	  of	  this	  study	  was	  to	  scrutinise	  the	  
discriminating	  properties	  amongst	  patients.	  	  The	  recruitment	  field	  was	  also	  
predominantly	  female	  which	  may	  explain	  the	  gender	  difference.	  The	  small	  numbers	  of	  
males	  were	  nevertheless	  included	  in	  the	  analysis	  as	  the	  model	  was	  sufficiently	  powered	  
for	  this	  variable,	  which	  required	  ≥20	  for	  each	  independent	  variable.	  The	  sample	  was	  
powerful	  enough	  to	  detect	  the	  influence	  of	  voiding	  symptoms,	  pyuria	  and	  culture,	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despite	  the	  wide	  variance.	  	  Urinary	  ATP	  concentrations	  proved	  independent	  of	  age	  and	  
the	  number	  and	  nature	  of	  LUTS	  symptoms,	  other	  than	  voiding	  symptoms.	  The	  
association	  with	  voiding	  symptoms	  was	  not	  surprising	  because	  in	  patients	  with	  chronic	  
LUTS,	  these	  have	  been	  reported	  to	  be	  correlated	  with	  pyuria	  in	  both	  genders,	  in	  clear	  
contrast	  to	  OAB	  and	  pain	  symptoms	  (130).	  	  	  
	  
These	  data	  suggest	  that	  urinary	  ATP	  could	  not	  pick	  out	  low	  levels	  of	  inflammation	  
(pyuria	  1-­‐9	  wbc	  µl-­‐1)	  when	  used	  alone,	  a	  situation	  where	  clinicians	  need	  most	  help.	  	  
Current	  dipstick	  methods	  and	  direct	  urinary	  microscopy	  are	  able	  to	  identify	  pyuria	  when	  
it	  is	  abundant	  (133),	  so	  urinary	  ATP	  would	  offer	  no	  additional	  advantage.	  There	  can	  be	  
little	  doubt	  that	  ATP	  plays	  a	  significant	  role	  in	  the	  pathophysiology	  of	  urinary	  tract	  
disease	  (135,	  136)	  but	  it	  would	  seem	  that	  this	  does	  not	  translate	  into	  a	  useful	  role	  as	  a	  
clinical	  test	  when	  used	  alone.	  
	  
The	  laboratory	  experimental	  series	  showed	  that	  urine	  samples	  should	  be	  processed	  
immediately	  or	  frozen	  and	  stored	  at	  below	  -­‐20°C.	  There	  was	  a	  significant	  urinary	  ATP	  
decay	  with	  time	  when	  samples	  were	  left	  at	  room	  temperature,	  with	  the	  rate	  being	  
substrate	  dependent.	  	  We	  also	  found	  that	  storage	  of	  urine	  at	  -­‐20°C	  is	  adequate	  and	  this	  
therefore	  allows	  for	  wider	  use	  of	  standard	  freezers	  as	  opposed	  to	  the	  specialised	  -­‐80°C	  
devices.	  The	  centrifuge	  studies	  examined	  the	  effect	  of	  removing	  cellular	  material.	  	  The	  
supernatant	  showed	  marginally	  lower	  levels	  of	  ATP.	  	  This	  could	  be	  attributed	  to	  
increased	  ATPase	  activity	  from	  burst	  cells	  or	  it	  may	  have	  resulted	  from	  delayed	  freezing,	  
allowing	  additional	  time	  for	  enzyme	  activity.	  	  Additionally,	  centrifugation	  results	  in	  the	  
removal	  of	  biomass	  and	  hence	  this	  may	  explain	  the	  lower	  levels	  of	  urinary	  ATP.	  This	  
marginal	  difference,	  though	  statistically	  significant,	  may	  not	  be	  clinically	  significant;	  
nevertheless,	  centrifuging	  of	  urine	  prior	  to	  freezing	  or	  analysis	  is	  an	  additional	  labour	  
 76	  
worth	  avoiding.	  Boric	  acid	  proved	  counterproductive	  and	  so	  should	  not	  be	  used	  as	  a	  
preservative.	  
	  
In	  summary	  these	  data	  discourage	  the	  idea	  that	  urinary	  ATP	  should	  be	  developed	  as	  a	  
clinical	  surrogate	  test	  for	  UTI.	  This	  assay	  does	  not	  appear	  more	  effective	  than	  markers	  
used	  in	  current	  clinical	  practice	  (45,	  133).	  However,	  abundant	  urinary	  ATP	  is	  certainly	  
evident	  in	  the	  presence	  of	  significant	  disease	  amongst	  patients	  with	  LUTS	  and	  these	  
data	  do	  encourage	  continued	  interest	  in	  the	  pharmacology	  and	  pathophysiology	  of	  
purinergic	  functions	  in	  the	  bladder.	  	  	  
	  
In	  conclusion,	  urinary	  ATP	  does	  not	  improve	  on	  the	  use	  of	  microscopy	  as	  a	  surrogate	  
marker	  of	  urinary	  tract	  infection	  and	  is	  therefore	  not	  a	  promising	  clinical	  diagnostic	  
marker.	  	  There	  is	  need	  to	  explore	  other	  potential	  markers	  that	  can	  be	  used	  to	  screen	  
LUTS	  patients	  for	  UTI,	  particularly	  applicable	  to	  those	  that	  have	  lower	  levels	  of	  pyuria,	  
where	  significant	  disease	  may	  currently	  be	  overlooked	  (133).	  The	  relevance	  of	  
measuring	  ATP	  to	  study	  the	  pathophysiology	  of	  the	  lower	  urinary	  tract	  is	  still	  very	  
evident	  and	  in	  that	  context	  urine	  is	  a	  useful	  biological	  sample.	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4 Chapter	  4	  –	  The	  cytokine	  response	  in	  OAB	  	  
4.1 Introduction	  
	  Contemporary	  published	  data	  show	  that	  microscopic	  pyuria,	  evaluated	  by	  inspections	  
of	  a	  fresh,	  unspun,	  unstained	  specimen	  of	  urine	  using	  a	  haemocytometer	  remains	  our	  
most	  reliable	  marker	  of	  microbial	  urinary	  infection.	  This	  requires	  a	  microscope	  and	  the	  
accompanying	  skills	  to	  use	  and	  maintain	  the	  instrument.	  Thus,	  urinary	  inflammatory	  
mediators	  offer	  a	  potential	  source	  of	  alternative,	  surrogate	  markers.	  Urinary	  tract	  
infection	  stimulates	  the	  release	  of	  a	  variety	  of	  inflammatory	  mediators	  including	  
platelet-­‐derived	  growth	  factor	  (PDGF),	  tumour	  necrosis	  factor-­‐α	  (TNF-­‐α),	  IL6	  and	  CXCL	  8	  
(84).	  Urinary	  cytokines	  are	  elevated	  in	  patients	  with	  UTI	  and	  epithelial	  cells	  have	  been	  
identified	  as	  early	  producers	  of	  cytokines	  in	  the	  murine	  UTI	  model	  (91)	  (92,	  93)	  (94).	  	  
Uroepithelial	  cell	  lines	  of	  bladder	  and	  kidney	  origin	  constitutively	  make	  IL-­‐6	  and	  respond	  
with	  elevated	  IL-­‐6	  production	  to	  exogenous	  stimuli	  like	  bacteria	  or	  cytokines	  (91,	  95,	  
96).	  Studies	  of	  patients	  with	  UTI	  have	  shown	  rapid	  increases	  in	  urine	  IL6	  levels	  after	  the	  
onset	  of	  infection	  or	  instillation	  of	  bacteria	  into	  the	  urinary	  tract	  but	  serum	  IL6	  levels	  
are	  only	  elevated	  in	  those	  with	  acute	  pyelonephritis	  (97-­‐99).	  Through	  the	  release	  of	  
cytokines,	  epithelial	  cells	  establish	  a	  network	  with	  local	  and	  distant	  host	  cells	  (95).	  Cell	  
recruitment	  follows	  after	  the	  secretion	  of	  chemokines	  like	  IL-­‐8.	  Studies	  have	  shown	  that	  
IL-­‐8	  is	  present	  in	  epithelial	  cells	  of	  the	  healthy	  urinary	  tract	  and	  that	  IL-­‐8	  is	  secreted	  in	  
response	  to	  infection.	  IL-­‐8	  then	  returns	  to	  non-­‐detectable	  levels	  after	  treatment,	  and	  is	  
absent	  from	  normal	  urine	  (100).	  	  There	  is	  very	  little	  information	  on	  inflammatory	  
mediators	  and	  the	  role	  of	  infection	  in	  patients	  with	  overactive	  bladder	  symptoms.	  	  
There	  are	  a	  few	  studies	  that	  have	  looked	  at	  inflammatory	  cytokines	  in	  OAB	  and	  have	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found	  associations	  with	  NGF	  and	  MCP-­‐1	  (109-­‐111,	  137).	  Study	  methods	  have	  included	  
ELISAs,	  whilst	  others	  have	  looked	  at	  microarrays	  and	  found	  inflammatory	  signals	  in	  
patients	  with	  overactive	  bladder	  symptoms.	  These	  studies	  have	  not	  looked	  at	  the	  role	  
of	  infection	  that	  may	  be	  missed	  by	  conventional	  methods	  of	  testing	  within	  these	  
patients.	  	  	  
	  
4.2 Hypothesis	  
Patients	  with	  OAB	  symptoms	  show	  a	  higher	  urinary	  inflammatory	  signal	  as	  compared	  to	  
controls	  with	  higher	  levels	  of	  urinary	  Interleukin	  6	  (IL6),	  CXCL	  8,	  Lactoferrin,	  Tamm-­‐
Horsfall	  Protein	  (THP),	  Monocyte	  Chemoatractant	  Protein-­‐1	  (MCP)	  and	  Nerve	  Growth	  
Factor	  (NGF).	  
	  
4.3 Study	  Design	  	  
A	  prospective	  controlled	  study	  was	  conducted	  to	  test	  the	  hypothesis	  and	  measure	  
levels	  of	  urinary	  Interleukin	  6,	  CXCL	  8,	  Lactoferrin,	  Tamm-­‐Horsfall	  Protein	  (THP),	  
Monocyte	  Chemoatractant	  Protein-­‐1	  (MCP)	  and	  Nerve	  Growth	  Factor	  (NGF)	  in	  patients	  
with	  OAB	  symptoms	  as	  compared	  to	  controls.	  	  
	  
4.4 Ethical	  Approval	  
Studies	  included	  in	  this	  work	  had	  ethical	  approval	  by	  the	  National	  Research	  Ethics	  




4.5 Inclusion	  and	  exclusion	  criteria	  
Subject	  Inclusion	  Criteria	  
1. Adults	  aged	  >=18	  years	  	  
2. Able	  to	  complete	  a	  symptom	  questionnaire	  	  
3. Diagnosed	  with	  OAB	  with	  or	  without	  pyuria	  (≥	  1	  wbc	  µl-­‐1)	  
4. Post-­‐menopausal	  women	  or	  women	  using	  adequate	  contraception	  
	  
Subject	  Exclusion	  Criteria	  
1. Age	  less	  than	  18	  years	  	  
2. Inability	  to	  consent	  	  
3. Pregnant	  women	  or	  women	  planning	  to	  conceive	  
4. Patients	  with	  concurrent	  illnesses	  that	  in	  the	  opinion	  of	  the	  investigator	  are	  
likely	  to	  compromise	  the	  validity	  of	  the	  data	  
	  
The	  study	  groups	  were	  	  
1)	  Female	  adult	  patients	  with	  OAB,	  describing:	  	  
a. Urgency,	  the	  sudden	  compelling	  desire	  to	  urinate,	  a	  sensation	  that	  is	  
difficult	  to	  defer.	  
b. Urinary	  frequency,	  voiding	  eight	  or	  more	  times	  in	  a	  24-­‐hour	  period.	  	  
c. Nocturia,	  the	  need	  to	  wake	  one	  or	  more	  times	  per	  night	  to	  void.	  
d. They	  may	  or	  may	  not	  experience	  urinary	  incontinence.	  
e. With	  or	  without	  pyuria	  (≥1	  wbc	  µL-­‐1)	  and/or	  a	  history	  of	  acute	  symptom	  
exacerbations.	  
	  
2)	  Control	  Group	  -­‐	  Female	  adults	  without	  OAB	  and	  without	  other	  lower	  urinary	  tract	  
symptoms.	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4.6 Study	  Population	  
4.6.1 Recruitment	  
Patients	  with	  OAB	  symptoms	  and	  healthy	  volunteers	  were	  recruited	  as	  described	  in	  
chapter	  2.	  
4.6.2 Consent	  	  
Written	  consent	  was	  obtained	  from	  all	  participating	  individuals	  as	  described	  in	  chapter	  
2.	  
	  
4.7 Safety	  considerations	  	  
There	  were	  no	  safety	  considerations	  for	  patients	  providing	  MSU	  samples	  only.	  	  
	  
4.8 Data	  management	  
Study	  data	  were	  stored	  in	  the	  Department	  of	  Medicine,	  UCL	  Archway	  Campus,	  as	  per	  
Good	  Clinical	  Practice	  (GCP)	  guidance.	  All	  samples	  and	  recoded	  data	  were	  identifiable	  
by	  study	  numbers	  and	  participant	  initials.	  Any	  patient	  identifiable	  data	  was	  stored	  on	  
only	  a	  secure	  NHS	  database,	  which	  was	  protected	  by	  encryption	  and	  daily	  backup.	  
	  
4.9 Study	  Method	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  as	  
described	  in	  chapter	  2.	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4.9.1 Blinding	  	  
Microscopy	  was	  performed	  with	  blinding	  to	  patient	  details	  and	  symptoms	  of	  
participants.	  Samples	  presented	  for	  analysis	  were	  identified	  only	  by	  a	  randomly	  
generated	  four-­‐digit	  study	  number.	  	  Blinding	  was	  ensured	  during	  sample	  processing	  as	  
samples	  were	  only	  identified	  by	  the	  four-­‐digit	  study	  number.	  	  
	  
4.10 Interleukin-­‐6	  (IL6)	  
4.10.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  IL6	  expression	  in	  patients	  with	  OAB	  
symptoms	  was	  undertaken.	  Female	  patients	  with	  symptoms	  of	  OAB	  and	  healthy	  
volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  written	  consent	  was	  obtained.	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  at	  -­‐80°C	  
as	  described	  in	  chapter	  2,	  for	  IL6	  quantification	  using	  a	  high-­‐sensitivity,	  enzyme-­‐linked	  
immunosorbent	  assay	  (ELISA).	  Patients	  and	  controls	  provided	  carefully	  collected	  MSU	  
samples	  and	  aliquots	  of	  spun	  urine	  frozen	  as	  described	  in	  chapter	  2.	  
	  
The	  samples	  were	  thawed	  to	  room	  temperature	  and	  analysed	  in	  batches,	  and	  blinding	  
to	  sample	  details	  and	  symptoms	  ensured.	  The	  Quantikine®	  High	  Sensitivity	  ELISA	  
Human	  IL6	  Immunoassay	  was	  used	  to	  quantify	  IL6	  expression	  in	  urine	  (R&D	  Systems,	  
Abingdon,	  UK),	  with	  a	  limit	  of	  detection	  of	  0.09pg	  ml-­‐1	  with	  an	  inter-­‐	  and	  intra-­‐assay	  
coefficient	  of	  variation	  of	  less	  than	  10%.	  Frozen	  urine	  samples	  under	  went	  only	  one	  
freeze	  thaw	  cycle	  ensuring	  stability	  of	  IL6.	  	  The	  urine	  samples	  were	  thawed	  to	  room	  
temperature	  and	  mixed	  thoroughly	  using	  a	  vortex	  mixer	  (Scientific	  Industries,	  New	  York,	  
USA).	  	  The	  assay	  included	  IL6	  stock	  standard	  at	  a	  concentration	  of	  10	  pg	  ml-­‐1.	  Calibrator	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diluent	  was	  used	  to	  produce	  serial	  dilutions	  ranging	  from	  10	  pg	  ml-­‐1	  to	  0.156	  pg	  ml-­‐1.	  
Calibrator	  diluent	  was	  used	  as	  0	  pg	  ml-­‐1	  standard.	  	  
	  
The	  supplied	  pre	  coated	  96	  well	  microplate	  was	  used	  to	  plate	  the	  IL6	  standards	  and	  
urine	  samples.	  100	  µl	  of	  the	  eight	  IL6	  standards	  were	  plated	  in	  duplicate.	  	  40	  urine	  
samples	  were	  plated	  in	  duplicate	  in	  the	  remaining	  80	  wells	  by	  adding	  100	  µl	  of	  each	  
urine	  sample.	  The	  plate	  was	  then	  covered	  and	  incubated	  at	  room	  temperature.	  	  Binding	  
was	  encouraged	  using	  an	  orbital	  microplate	  shaker	  (0.12”	  orbit)	  set	  at	  500	  ±	  50	  rpm	  for	  
two	  hours.	  	  
	  
After	  the	  2	  hour	  incubation	  the	  well	  contents	  were	  remove	  and	  the	  wells	  washed	  six	  
times	  with	  wash	  solution.	  	  Each	  wash	  was	  carefully	  pipetted	  without	  disruption	  to	  the	  
base	  of	  the	  well.	  In	  a	  second	  incubation,	  200µl	  of	  IL6	  conjugate	  was	  then	  added	  to	  each	  
well,	  and	  the	  plate	  incubated	  for	  a	  further	  two	  hours.	  The	  well	  contents	  were	  washed	  as	  
described	  earlier.	  	  The	  plate	  was	  then	  incubated	  on	  the	  bench	  top,	  after	  addition	  of	  50µl	  
of	  substrate	  solution,	  at	  room	  temperature	  for	  one	  hour.	  Following	  this	  was	  the	  
addition	  of	  50	  µl	  of	  amplifier	  solution	  without	  any	  washing	  and	  a	  colour	  change	  noted.	  	  
The	  plate	  was	  incubated	  on	  the	  bench	  top	  at	  room	  temperature	  for	  30	  minutes.	  	  In	  the	  
final	  step	  50µl	  of	  stop	  solution	  was	  added	  followed	  by	  analysis	  within	  30	  minutes.	  	  
Interleukin-­‐6	  concentration	  was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  
microplate	  reader	  (DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  490	  nm.	  The	  reader	  
produced	  standard	  curves,	  which	  were	  used	  to	  calculate	  concentrates	  for	  each	  well.	  	  
The	  minimum	  detectable	  dose	  (MDD)	  of	  the	  ELISA	  kit	  according	  to	  the	  manufacturers	  
ranges	  from	  0.016-­‐0.110	  pg	  ml-­‐1,	  with	  an	  average	  MDD	  of	  0.039	  pg	  ml-­‐1.	  All	  samples	  
were	  analysed	  in	  duplicate	  to	  test	  the	  inter-­‐assay	  precision	  and	  the	  mean	  value	  was	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taken.	  The	  intra-­‐assay	  precision	  for	  urine	  assays	  suggested	  by	  the	  company	  was	  5.5-­‐
9.8%	  and	  the	  inter-­‐assay	  precision	  for	  this	  experiment	  was	  5.5-­‐11.2%.	  
	  
4.10.2 Statistical	  Analysis	  
The	  power	  to	  test	  the	  null	  hypothesis	  that	  the	  population	  means	  were	  equal	  was	  
calculated.	  The	  criterion	  for	  statistical	  significance	  (alpha)	  was	  set	  at	  0.05.	  The	  test	  was	  
2-­‐tailed.	  It	  was	  found	  that	  a	  sample	  size	  comprising	  20	  controls	  and	  20	  patients	  had	  a	  
80%	  power	  to	  detect	  0.4	  pg	  ml-­‐1	  difference	  in	  IL6	  between	  patients	  and	  controls,	  given	  a	  
population	  standard	  deviation	  of	  0.4	  pg	  ml-­‐1.	  The	  data	  were	  checked	  for	  normality	  using	  
a	  Q-­‐Q	  plot	  and	  found	  to	  be	  satisfactory,	  hence	  parametric	  methods	  were	  used	  for	  




One	  hundred	  and	  eighty	  two	  patients	  (F=179;	  M=33;	  mean	  age	  (years)=60.0;	  sd=17.7)	  
and	  30	  control	  subjects	  (F=11;	  M=19;	  mean	  age	  (years)=25.1;	  sd=9.3)	  were	  included	  in	  
the	  analysis.	  There	  was	  no	  significant	  difference	  in	  urinary	  IL6	  when	  compared	  with	  
gender	  (p=.29,	  95%	  CI	  -­‐0.11	  to	  0.36).	  Urinary	  IL6	  expression	  was	  significantly	  greater	  in	  
patients	  with	  OAB	  symptoms	  compared	  to	  asymptomatic	  controls	  (ANOVA	  F=16;	  







Figure	  4.1	  –	  A	  graph	  to	  show	  the	  mean	  Log	  urinary	  IL6	  and	  95%	  confidence	  interval	  in	  
patients	  with	  OAB	  and	  controls	  
	  
	  
Amongst	  patients,	  pyuria	  was	  associated	  with	  higher	  levels	  of	  IL6,	  although	  patients	  
without	  pyuria	  still	  demonstrated	  greater	  IL6	  expression	  than	  normal	  controls	  (ANOVA	  
F=27.2,	  p<.001),	  shown	  in	  figure	  4.2.	  However	  Bonferroni	  post	  hoc	  analysis	  showed	  a	  
significant	  between	  group	  difference	  when	  comparing	  controls	  with	  OAB	  patents	  with	  
pyuria	  1-­‐	  9	  or	  greater	  than	  10.	  	  There	  was	  no	  significant	  difference	  when	  comparing	  
OAB	  patients	  with	  zero	  pyuria	  and	  pyuria	  1-­‐9.	  	  OAB	  patients	  with	  a	  pyuria	  of	  greater	  
than	  10	  differed	  from	  all	  groups.	  
	  
Despite	  differences	  in	  the	  demographic	  characteristics	  of	  the	  study	  groups,	  these	  
findings	  support	  preliminary	  data	  demonstrating	  cytological	  evidence	  of	  urothelial	  
inflammation	  in	  patients	  with	  OAB	  symptoms.	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Figure	  4.2	  –	  A	  graph	  to	  show	  the	  mean	  log	  urinary	  IL6	  and	  95%	  confidence	  interval	  in	  





We	  found	  a	  correlation	  between	  Log	  IL6	  and	  Log	  pyuria	  (R	  =	  0.46,	  F=59,	  p<.001).	  A	  
linear	  regression	  model	  was	  fitted	  to	  the	  data	  with	  log	  Lactoferrin	  as	  the	  dependant	  
variable	  with	  R	  calculated	  at	  0.46	  (Figure	  4.3)	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There	  are	  significant	  data	  to	  suggest	  that	  a	  variety	  of	  bladder	  epithelial	  cell	  derived	  
mediators	  are	  involved	  in	  the	  elevated	  neutrophil	  response	  in	  the	  bladder	  after	  acute	  
bacterial	  infection	  (88,	  96).	  	  IL6	  has	  shown	  a	  prominent	  role	  in	  patients	  with	  acute	  UTI	  
though	  there	  is	  some	  debate	  about	  the	  pathways	  involved	  (138).	  	  	  It	  is	  thought	  that	  in	  
adaptation	  to	  uropathogenic	  bacterial	  suppression	  of	  an	  inflammatory	  response,	  there	  
may	  be	  multiple	  pathways	  by	  which	  bladder	  epithelial	  cells	  are	  able	  to	  trigger	  response	  
with	  elevated	  IL6	  (95).	  Identifying	  a	  cytokine	  response	  in	  patients	  with	  OAB	  supports	  
the	  premise	  that	  some	  patients	  with	  OAB	  may	  have	  an	  inflammatory	  aetiology	  to	  their	  
condition.	  In	  addition,	  in	  patients	  with	  OAB	  and	  pyuria	  we	  have	  found	  an	  increased	  level	  
of	  urinary	  IL6.	  The	  association	  between	  IL6	  and	  urine	  infection	  in	  the	  literature	  also	  
leads	  us	  to	  postulate	  on	  an	  infective	  aetiology	  in	  these	  patients.	  	  In	  addition,	  there	  is	  
growing	  evidence	  in	  the	  literature	  that	  the	  magnitude	  of	  the	  cytokine	  response	  and	  the	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type	  of	  cytokine	  found	  in	  the	  urine	  is	  influenced	  by	  the	  virulence	  of	  the	  pathogen.	  IL6	  
has	  been	  particularly	  associated	  with	  fimbriae	  (96,	  139).	  The	  findings	  in	  this	  study	  
support	  the	  hypothesis	  that	  OAB	  symptoms	  may	  be	  associated	  with	  a	  urothelial	  
inflammatory	  response,	  which	  may	  be	  secondary	  to	  urine	  infection.	  
	  
4.11 Lactoferrin	  
4.11.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  urinary	  Lactoferrin	  in	  patients	  with	  
OAB	  symptoms	  was	  undertaken.	  Female	  patients	  with	  symptoms	  of	  OAB	  and	  healthy	  
volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  written	  consent	  was	  obtained.	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  at	  -­‐80°C	  
as	  described	  in	  chapter	  2,	  for	  urinary	  Lactoferrin	  quantification	  using	  a	  high	  sensitivity	  
sandwich	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  
	  
Urine	  samples	  underwent	  only	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  Lactoferrin.	  	  
Urine	  samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  
(Scientific	  Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  
to	  ensure	  blinding	  to	  sample	  details	  and	  group.	  The	  Human	  Lactoferrin	  ELISA	  
immunoassay	  was	  used	  to	  quantify	  urinary	  Lactoferrin	  (ICL,	  Portland,	  USA),	  with	  a	  range	  
of	  detection	  of	  3.125ng	  ml-­‐1	  -­‐100ng	  ml-­‐1,	  with	  a	  sensitivity	  average	  of	  0.725ng	  ml-­‐1.	  
Lactoferrin	  standard	  solutions	  were	  prepared	  using	  100	  ng	  ml-­‐1	  stock	  lactoferrin	  
standard	  and	  six	  serial	  dilutions	  using	  calibrator	  diluent.	  This	  produced	  standard	  




Fourteen	  wells	  in	  the	  supplied	  microplate	  were	  filled	  100	  µl	  of	  the	  seven	  Lactoferrin	  
standard	  solutions	  in	  duplicate,	  with	  the	  remaining	  wells	  accommodating	  100	  µl	  of	  each	  
urine	  test	  sample.	  The	  plate	  was	  incubated	  on	  the	  bench	  top	  at	  room	  temperature	  for	  
30	  minutes	  to	  allow	  binding.	  Following	  incubation	  well	  contents	  were	  aspirated	  and	  the	  
wells	  carefully	  filled	  with	  wash	  solution.	  	  This	  was	  then	  carefully	  aspirated	  and	  the	  
process	  repeated	  3	  times.	  
	  
After	  washing,	  100µl	  of	  Enzyme	  Antibody	  Conjugate	  was	  added	  to	  each	  well,	  and	  the	  
plate	  incubated	  for	  a	  further	  30	  minutes.	  The	  well	  contents	  were	  again	  emptied	  and	  
washed	  four	  times.	  One	  hundred	  microlitres	  of	  the	  supplied	  substrate	  solution	  were	  
then	  added	  to	  each	  well,	  and	  the	  plate	  incubated	  on	  in	  a	  dark	  room	  at	  room	  
temperature	  for	  10	  minutes.	  One	  hundred	  microlitres	  of	  the	  supplied	  stop	  solution	  
were	  then	  added	  to	  each	  of	  the	  wells	  and	  analysis	  undertaken	  within	  30	  minutes.	  
Lactoferrin	  concentration	  was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  microplate	  
reader	  (DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  450	  nm.	  The	  reader	  produced	  
standard	  curves,	  fit	  to	  a	  four-­‐parameter	  logistics	  curve,	  which	  were	  used	  to	  calculate	  
concentrates	  for	  each	  well.	  	  All	  samples	  were	  analysed	  in	  duplicate	  to	  test	  the	  inter-­‐
assay	  precision	  and	  the	  mean	  value	  was	  taken.	  	  
	  
4.11.2 Statistical	  Analysis	  
The	  data	  were	  checked	  for	  normality	  using	  a	  Q-­‐Q	  plot	  and	  found	  to	  be	  satisfactory,	  
hence	  parametric	  methods	  were	  used	  for	  analysis.	  Statistical	  analysis	  of	  the	  data	  was	  
conducted	  using	  ANOVA	  at	  the	  95%	  level	  of	  confidence.	  Correlation	  between	  
Lactoferrin	  and	  pyuria	  was	  explored	  using	  a	  regression	  analysis.	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4.11.3 Results	  
Sixty	  five	  patients	  (F=59;	  M=6;	  mean	  age	  (years)=62.3;	  sd=16.9)	  and	  14	  control	  subjects	  
(F=9;	  M=5;	  mean	  age	  (years)=53.6;	  sd=16.9)	  were	  included	  in	  the	  analysis.	  Urinary	  
Lactoferrin	  was	  significantly	  greater	  in	  patients	  with	  OAB	  compared	  to	  asymptomatic	  
controls	  (ANOVA	  F=23.2;	  p<.001,	  (95%	  CI	  -­‐2.1	  to	  -­‐0.87)	  as	  seen	  in	  figure	  4.4.	  	  
	  
Figure	  4.4	  -­‐	  A	  graph	  to	  show	  the	  mean	  Log	  urinary	  Lactoferrin	  and	  95%	  confidence	  
interval	  in	  patients	  with	  OAB	  and	  controls	  
	  
Amongst	  patients,	  only	  3	  patients	  had	  zero	  pyuria,	  21	  had	  pyuria	  1	  –	  9	  and	  41	  had	  
pyuria	  of	  10	  or	  more.	  	  Therefore,	  we	  grouped	  patients	  into	  those	  with	  pyuria	  of	  0-­‐9	  and	  
those	  with	  pyuria	  of	  ≥10.	  Patients	  with	  pyuria	  0-­‐9	  and	  those	  with	  pyuria	  ≥10	  
demonstrated	  greater	  urinary	  Lactoferrin	  when	  compared	  with	  controls	  (ANOVA	  
F=62.8;	  p<.001),	  shown	  in	  figure	  4.5.	  However	  post	  hoc	  analysis	  showed	  a	  significant	  
between	  group	  difference	  when	  comparing	  controls	  with	  OAB	  patents	  with	  pyuria	  ≥10	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but	  no	  significant	  difference	  when	  comparing	  controls	  and	  OAB	  patients	  with	  pyuria	  0-­‐
9.	  
	  
Figure	  4.5	  –	  A	  graph	  to	  show	  the	  mean	  Log	  urinary	  Lactoferrin	  and	  95%	  confidence	  
interval	  in	  patients	  with	  OAB	  pyuria	  0-­‐9	  ,	  OAB	  pyuria	  greater	  than	  or	  equal	  to	  10	  and	  
controls	  	  
	  
We	  found	  a	  correlation	  between	  Log	  Lactoferrin	  and	  Log	  pyuria	  (R	  =	  0.8,	  F=112,	  p<.001).	  
A	  quadratic	  regression	  model	  was	  fitted	  to	  the	  data	  with	  log	  Lactoferrin	  as	  the	  







Figure	  4.6	  –	  A	  graph	  to	  show	  the	  correlation	  between	  Log	  Lactoferrin	  and	  Log	  pyuria	  	  
	  
4.11.4 Discussion	  
These	  data	  demonstrated	  that	  urinary	  Lactoferrin	  levels	  discriminate	  successfully	  
between	  patients	  with	  OAB	  and	  pyuria.	  There	  is	  good	  evidence	  that	  the	  Lactoferrin	  
reflects	  the	  pyuria	  status	  quantitatively	  and	  so	  may	  warrant	  further	  exploration	  in	  
relation	  to	  other	  markers	  of	  inflammation	  and	  infection.	  This	  is	  encouraging	  data	  from	  
this	  small	  pilot	  study	  however	  now	  would	  need	  further	  robust	  evaluation	  with	  a	  range	  
of	  other	  surrogate	  markers	  of	  disease	  and	  quantitative	  measure	  of	  symptoms.	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4.12 CXCL	  8	  	  
4.12.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  urinary	  CXCL	  8	  in	  patients	  with	  OAB	  
symptoms	  was	  undertaken.	  Female	  patients	  with	  symptoms	  of	  OAB	  and	  healthy	  
volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  written	  consent	  was	  obtained.	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  at	  -­‐80°C	  
as	  described	  in	  chapter	  2,	  for	  urinary	  CXCL	  8	  quantification	  using	  a	  high	  sensitivity	  
enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  	  
	  
Urine	  samples	  underwent	  only	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  CXCL	  8.	  	  
Urine	  samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  
(Scientific	  Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  
to	  ensure	  blinding	  to	  sample	  details	  and	  group.	  	  The	  Human	  CXCL	  8	  ELISA	  immunoassay	  
was	  used	  to	  quantify	  urinary	  CXCL	  8	  (R	  and	  D	  systems),	  with	  a	  mean	  minimal	  detection	  
range	  of	  with	  a	  range	  of	  detection	  of	  3.5pg	  ml-­‐1.	  The	  assay	  included	  CXCL8	  stock	  
standard	  at	  a	  concentration	  of	  2000	  pg	  ml-­‐1.	  Calibrator	  diluent	  was	  used	  to	  produce	  
serial	  dilutions	  ranging	  from	  2000	  pg	  ml-­‐1	  to	  31.2	  pg	  ml-­‐1.	  Calibrator	  diluent	  was	  used	  as	  
0	  pg	  ml-­‐1	  standard.	  	  All	  wells	  were	  filled	  with	  100	  µl	  of	  assay	  diluent.	  Sixteen	  wells	  in	  the	  
supplied	  microplate	  were	  filled	  with	  50	  µl	  of	  the	  CXCL	  8	  standard	  solutions	  in	  duplicate,	  
with	  the	  remaining	  wells	  accommodating	  50	  µl	  of	  each	  urine	  test	  sample.	  The	  plate	  was	  
then	  incubated	  at	  room	  temperature	  for	  2	  hours.	  	  
	  
After	  the	  2	  hour	  incubation	  the	  well	  contents	  were	  remove	  and	  the	  wells	  washed	  six	  
times	  with	  wash	  solution.	  	  Each	  wash	  was	  carefully	  pipetted	  without	  disruption	  to	  the	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base	  of	  the	  well.	  In	  a	  second	  incubation,	  100µl	  of	  CXCL	  8	  conjugate	  was	  then	  added	  to	  
each	  well,	  and	  the	  plate	  incubated	  for	  a	  further	  1	  hour.	  The	  well	  contents	  were	  washed	  
as	  described	  earlier.	  	  The	  plate	  was	  then	  incubated	  with	  protection	  from	  light,	  after	  
addition	  of	  200µl	  of	  substrate	  solution,	  at	  room	  temperature	  for	  30	  minutes.	  In	  the	  final	  
step	  50µl	  of	  stop	  solution	  was	  added	  followed	  by	  analysis	  within	  30	  minutes.	  CXCL	  8	  
concentration	  was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  microplate	  reader	  
(DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  450	  nm.	  The	  reader	  produced	  standard	  
curves,	  fit	  to	  a	  four-­‐parameter	  logistics	  curve,	  which	  was	  used	  to	  calculate	  concentrates	  
for	  each	  well.	  	  All	  samples	  were	  analysed	  in	  duplicate	  to	  test	  the	  inter-­‐assay	  precision	  
and	  the	  mean	  value	  was	  taken.	  	  
	  
4.12.2 Statistical	  Analysis	  
The	  data	  was	  assessed	  for	  normality	  using	  a	  Q-­‐Q	  plot	  and	  found	  not	  to	  be	  normally	  
distributed,	  hence	  non-­‐parametric	  methods	  were	  used	  for	  analysis.	  Statistical	  analysis	  
of	  the	  data	  was	  conducted	  using	  Mann	  Whitney	  U	  test	  and	  Kruskall-­‐Wallis	  to	  assess	  for	  
a	  between	  group	  difference.	  
4.12.3 Results	  
Forty	  four	  patients	  (F=41;	  M=3;	  mean	  age	  (years)=53.1;	  sd=18.0)	  and	  12	  control	  subjects	  
(F=6;	  M=6;	  mean	  age	  (years)=40.9;	  sd=16.2)	  were	  included	  in	  the	  analysis.	  Urinary	  CXCL	  
8	  was	  not	  significantly	  different	  when	  comparing	  patients	  with	  OAB	  compared	  to	  








When	  comparing	  urinary	  CXCL	  8	  with	  pyuria	  there	  was	  significantly	  higher	  urinary	  CXCL	  
8	  in	  patients	  with	  pyuria	  greater	  than	  10	  when	  compared	  with	  control,	  pyuria	  zero	  and	  












These	  preliminary	  data	  do	  not	  show	  a	  significant	  difference	  in	  urinary	  CXCL	  8	  when	  
comparing	  normal	  healthy	  controls	  with	  patients	  with	  OAB.	  	  However	  it	  is	  difficult	  to	  
form	  strong	  conclusions	  from	  a	  small	  sample.	  	  In	  addition,	  there	  was	  a	  significant	  
difference	  in	  mean	  age	  between	  controls	  and	  patients	  and	  the	  sample	  size	  was	  small.	  
On	  further	  analysis	  when	  comparing	  urinary	  CXCL	  8	  with	  pyuria	  status	  in	  this	  group	  
there	  was	  significantly	  higher	  urinary	  CXCL	  8	  in	  patients	  with	  pyuria	  ≥10.	  	  However	  
urinary	  CXCL	  8	  lacks	  the	  ability	  to	  differentiate	  between	  controls	  and	  patients	  with	  low	  
levels	  of	  pyuria	  where	  current	  tests	  are	  needed.	  	  Therefore	  based	  on	  this	  small	  study	  
urinary	  CXCL	  8	  does	  not	  show	  potential	  as	  a	  marker	  that	  would	  help	  distinguish	  
between	  patients	  and	  controls.	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4.13 Uromodulin	  /	  Tamm	  Horsfall	  protein	  (THP)	  
4.13.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  urinary	  uromodulin	  in	  patients	  with	  
OAB	  symptoms	  was	  undertaken.	  Patients	  with	  symptoms	  of	  OAB	  and	  healthy	  
volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  written	  consent	  was	  obtained.	  
All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  for	  
pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  at	  -­‐80°C	  
as	  described	  in	  chapter	  2,	  for	  urinary	  Uromodulin	  quantification	  using	  a	  high	  sensitivity	  
enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  	  
	  
Urine	  samples	  underwent	  only	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  Uromodulin.	  	  
Urine	  samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  
(Scientific	  Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  
to	  ensure	  blinding	  to	  sample	  details	  and	  group.	  	  The	  Human	  Uromodulin	  glycoprotein	  
ELISA	  immunoassay	  was	  used	  for	  the	  quantitative	  determination	  of	  Uromodulin	  
Glycoprotein	  (Tamm-­‐Horsfall	  Glycoprotein,	  THP)	  in	  urine	  samples	  (MDbioproducts).	  The	  
sensitivity	  of	  the	  Uromodulin	  ELISA	  is	  described	  as	  typically	  less	  than	  0.75	  ng	  ml-­‐1.	  
Sensitivity	  of	  the	  assay	  was	  defined	  by	  the	  manufacturer	  as	  the	  minimal	  detectable	  
dose	  determined	  by	  adding	  two	  standard	  deviations	  of	  the	  mean	  optical	  density	  value	  
for	  twenty	  replicates	  of	  the	  zero	  standard	  and	  calculating	  the	  corresponding	  
concentration.	  Seven	  standard	  solutions	  were	  prepared	  using	  the	  supplied	  Uromodulin	  
standard	  (2500	  ng	  ml-­‐1)	  and	  assay	  diluent	  to	  produce	  a	  2-­‐fold	  dilution	  series,	  with	  150	  
ng	  ml-­‐1	  standard	  serving	  as	  the	  highest	  standard	  and	  Assay	  Diluent	  serving	  as	  the	  zero	  (0	  




Uromodulin	  Glycoprotein	  Microplate	  containing	  12	  x	  8	  strips	  coated	  with	  polyclonal	  
antibody	  to	  Uromodulin	  Glycoprotein	  was	  used.	  Sixteen	  wells	  in	  the	  supplied	  microplate	  
were	  filled	  with	  50	  µl	  of	  the	  Uromodulin	  standard	  solutions	  in	  duplicate,	  with	  the	  
remaining	  wells	  accommodating	  50	  µl	  of	  each	  urine	  test	  sample.	  The	  plate	  was	  then	  
incubated	  at	  37	  °C	  for	  60	  minutes.	  The	  well	  contents	  were	  then	  emptied	  and	  the	  wells	  
washed	  six	  times	  using	  the	  supplied	  wash	  solution.	  
	  
After	  washing,	  50µl	  of	  Uromodulin	  Conjugate	  were	  added	  to	  each	  well,	  and	  the	  plate	  
incubated	  for	  a	  further	  60	  minutes	  at	  37	  °C.	  The	  well	  contents	  were	  again	  emptied	  and	  
washed	  six	  times.	  Fifty	  microlitres	  of	  the	  supplied	  diluted	  Streptavidin-­‐HRP	  substrate	  
solution	  were	  then	  added	  to	  each	  well,	  and	  the	  plate	  incubated	  for	  30	  minutes	  insuring	  
protection	  from	  light.	  The	  well	  contents	  were	  then	  emptied	  and	  the	  wells	  washed	  six	  
times	  using	  the	  supplied	  wash	  solution.	  	  Fifty	  microlitres	  of	  Substrate	  were	  added	  to	  
each	  well	  and	  incubated	  for	  10	  minutes	  at	  37	  °C	  ensuring	  protection	  from	  light.	  Fifty	  
microlitres	  of	  stop	  solution	  were	  then	  added	  to	  each	  of	  the	  wells	  and	  analysis	  
undertaken	  within	  30	  minutes.	  Uromodulin	  concentration	  was	  determined	  using	  an	  
Opsys	  MR	  fluoresence	  microplate	  reader	  (DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  
450	  nm.	  The	  reader	  produced	  standard	  curves,	  fit	  to	  a	  four-­‐parameter	  logistics	  curve,	  
which	  was	  used	  to	  calculate	  concentrates	  for	  each	  well.	  	  All	  samples	  were	  analysed	  in	  
duplicate	  to	  test	  the	  inter-­‐assay	  precision	  and	  the	  mean	  value	  was	  taken.	  	  
4.13.2 Statistical	  Analysis	  
The	  data	  were	  checked	  for	  normality	  using	  a	  Q-­‐Q	  plot	  and	  found	  to	  be	  satisfactory,	  
hence	  parametric	  methods	  were	  used	  for	  analysis.	  Statistical	  analysis	  of	  the	  data	  was	  
conducted	  using	  ANOVA	  at	  the	  95%	  level	  of	  confidence.	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4.13.3 Results	  
Forty	  six	  patients	  (F=43;	  M=3;	  mean	  age	  (years)=40.9;	  sd=16.2)	  and	  13	  control	  subjects	  
(F=7;	  M=6;	  mean	  age	  (years)=53.1;	  sd=18.0)	  were	  included	  in	  the	  analysis.	  Uromodulin	  
was	  significantly	  different	  when	  comparing	  patients	  with	  OAB	  symptoms	  compared	  to	  
asymptomatic	  controls	  (ANOVA	  F=	  1.38	  p=.246),	  as	  seen	  in	  figure	  4.9.	  	  
	  
Figure	  4.9	  -­‐	  A	  graph	  showing	  mean	  Log	  Uromodulin	  and	  95%	  confidence	  interval	  in	  
patients	  with	  OAB	  symptoms	  and	  healthy	  controls	  
	  
When	  comparing	  Uromodulin	  with	  pyuria	  there	  was	  no	  significant	  difference	  between	  
controls	  or	  patients	  with	  varying	  degrees	  of	  pyuria	  (F=0.686,	  p	  =.418).	  	  
4.13.4 Discussion	  
These	  data	  do	  not	  suggest	  a	  significant	  difference	  in	  Uromodulin	  when	  comparing	  
normal	  healthy	  controls	  with	  patients	  with	  OAB.	  	  However	  it	  is	  difficult	  to	  form	  strong	  
conclusions	  from	  a	  small	  sample.	  	  In	  addition,	  there	  was	  a	  significant	  difference	  in	  mean	  
age	  between	  controls	  and	  patients	  and	  the	  sample	  size	  was	  small.	  On	  further	  analysis	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when	  comparing	  Uromodulin	  with	  pyuria	  status	  there	  was	  no	  significant	  difference	  in	  
Uromodulin	  when	  compared	  to	  controls	  and	  patients	  with	  varying	  amounts	  of	  pyuria.	  
Therefore	  based	  on	  this	  small	  study	  Uromodulin	  does	  not	  show	  potential	  as	  a	  marker	  
that	  discriminates	  between	  controls	  and	  patients	  with	  OAB.	  	  
	  
4.14 Monocyte	  Chemo-­‐attractant	  Protein	  (MCP-­‐1)	  
4.14.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  urinary	  monocyte	  chemo-­‐attractant	  
protein	  (MCP-­‐1)	  in	  patients	  with	  OAB	  symptoms	  was	  undertaken.	  Patients	  with	  
symptoms	  of	  OAB	  and	  healthy	  volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  
written	  consent	  was	  obtained.	  All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  
immediate	  microscopy	  for	  pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  
urine	  were	  frozen	  at	  -­‐80°C,	  as	  described	  in	  chapter	  2,	  for	  urinary	  MCP-­‐1	  quantification	  
using	  a	  high	  sensitivity	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  	  
	  
Urine	  samples	  underwent	  only	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  MCP-­‐1.	  	  
Urine	  samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  
(Scientific	  Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  
to	  ensure	  blinding	  to	  sample	  details	  and	  group.	  	  The	  Quantikine	  Human	  MCP-­‐1	  
Immunoassay	  (R	  and	  D	  systems)	  was	  used	  to	  measure	  human	  MCP-­‐1	  in	  urine.	  The	  
minimum	  detectable	  dose	  (MDD)	  of	  MCP-­‐1	  assay	  was	  defined	  by	  the	  manufacture	  as	  
ranging	  from	  0.57-­‐10.0	  pg	  ml-­‐1.	  The	  mean	  MDD	  was	  1.7	  pg	  ml-­‐1.	  Seven	  standard	  
solutions	  were	  prepared	  using	  the	  supplied	  MCP-­‐1	  standard	  (2000	  pg	  ml-­‐1)	  and	  assay	  
diluent	  to	  produce	  a	  2-­‐fold	  dilution	  series,	  with	  2000	  pg	  ml-­‐1	  standard	  serving	  as	  the	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highest	  standard	  and	  Calibrator	  Diluent	  serving	  as	  the	  zero	  (0	  pg	  ml-­‐1).	  	  Human	  urine	  
samples	  required	  a	  2-­‐fold	  dilution	  using	  Calibrator	  Diluent.	  
	  
A	  microplate	  containing	  12	  x	  8	  strips	  coated	  with	  polyclonal	  antibody	  to	  MCP-­‐1	  was	  
used.	  Sixteen	  wells	  in	  the	  supplied	  microplate	  were	  filled	  with	  200	  µl	  of	  the	  MCP-­‐1	  
standard	  solutions	  in	  duplicate,	  with	  the	  remaining	  wells	  accommodating	  200	  µl	  of	  each	  
diluted	  urine	  test	  sample.	  The	  plate	  was	  then	  incubated	  at	  room	  temperature	  for	  120	  
minutes.	  The	  well	  contents	  were	  then	  aspirated	  and	  the	  wells	  washed	  three	  times	  using	  
400µl	  the	  supplied	  wash	  solution.	  
	  
After	  washing,	  200	  μL	  of	  MCP-­‐1	  Conjugate	  were	  added	  to	  each	  well	  and	  the	  plate	  
incubated	  for	  a	  further	  120	  minutes	  at	  room	  temperature.	  The	  well	  contents	  were	  again	  
emptied	  and	  washed	  three	  times.	  Two	  hundred	  μL	  of	  Substrate	  Solution	  were	  then	  
added	  to	  each	  well	  and	  incubated	  for	  30	  minutes	  at	  room	  temperature	  protecting	  from	  
light.	  Fifty	  microlitres	  of	  stop	  solution	  were	  then	  added	  to	  each	  of	  the	  wells	  with	  a	  
colour	  change	  from	  blue	  to	  yellow	  and	  analysis	  undertaken	  within	  30	  minutes.	  MCP-­‐1	  
concentration	  was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  microplate	  reader	  
(DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  450	  nm.	  The	  reader	  produced	  standard	  
curves,	  fit	  to	  a	  four-­‐parameter	  logistics	  curve,	  which	  was	  used	  to	  calculate	  concentrates	  
for	  each	  well.	  	  All	  samples	  were	  analysed	  in	  duplicate	  and	  the	  mean	  value	  was	  taken.	  
4.14.2 Statistical	  Analysis	  
The	  data	  were	  checked	  for	  normality	  using	  a	  Q-­‐Q	  plot	  and	  found	  to	  be	  satisfactory,	  
hence	  parametric	  methods	  were	  used	  for	  analysis.	  Statistical	  analysis	  of	  the	  data	  was	  




Forty	  one	  female	  patients	  (F=41,	  mean	  age	  (years)=63.3;	  sd=11.3)	  and	  39	  female	  control	  
subjects	  (F=39;	  mean	  age	  (years)=43.8;	  sd=16.2)	  were	  included	  in	  the	  analysis.	  When	  
comparing	  OAB	  patients	  with	  asymptomatic	  controls	  there	  was	  no	  significant	  difference	  
found	  in	  urinary	  MCP-­‐1	  (ANOVA	  F=	  0.11	  p=.740),	  as	  seen	  in	  figure	  4.10.	  	  
	  
Figure	  4.10	  –	  A	  Graph	  to	  show	  the	  mean	  Log	  MCP-­‐1	  and	  95%	  confidence	  intervals,	  in	  
patients	  with	  OAB	  symptoms	  and	  controls	  
	  
4.14.4 Discussion	  
These	  data	  do	  not	  show	  a	  significant	  difference	  in	  urinary	  MCP-­‐1	  between	  controls	  and	  
patients	  with	  OAB	  symptoms.	  	  Limitations	  of	  this	  study	  do	  include	  the	  small	  sample	  size	  
and	  significant	  difference	  in	  age	  between	  patients	  and	  controls	  therefore	  interpretation	  
must	  be	  taken	  with	  caution.	  	  However	  there	  does	  not	  appear	  to	  be	  a	  large	  difference	  in	  
urinary	  levels	  of	  MCP-­‐1	  in	  patients’	  with	  OAB	  compared	  with	  healthy	  controls.	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4.15 Nerve	  Growth	  Factor	  (NGF)	  
4.15.1 Brief	  description	  of	  methods	  
A	  controlled,	  prospective	  cross-­‐sectional	  study	  of	  urinary	  β-­‐Nerve	  Growth	  Factor	  (NGF)	  
in	  patients	  with	  OAB	  symptoms	  was	  undertaken.	  Patients	  with	  symptoms	  of	  OAB	  and	  
healthy	  volunteers	  were	  recruited	  as	  described	  in	  chapter	  2	  and	  written	  consent	  was	  
obtained.	  All	  participants	  provided	  clean	  catch	  MSU	  samples	  and	  immediate	  microscopy	  
for	  pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	  urine	  were	  frozen	  at	  -­‐
80°C,	  as	  described	  in	  chapter	  2,	  for	  urinary	  NGF	  quantification	  using	  a	  high	  sensitivity	  
enzyme-­‐linked	  immunosorbent	  assay	  (ELISA).	  	  
	  
Urine	  samples	  underwent	  only	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  NGF.	  	  Urine	  
samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  (Scientific	  
Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  to	  ensure	  
blinding	  to	  sample	  details	  and	  group.	  Urinary	  NGF	  was	  measured	  using	  NGF	  
Immunoassay	  (Promega)	  with	  a	  minimum	  detection	  of	  7.8	  pg	  ml-­‐1	  and	  less	  than	  3%	  
cross-­‐reactivity	  with	  other	  neurotrophic	  factors.	  A	  standard	  curve	  was	  produced	  using	  1	  
µg	  ml-­‐1	  NGF	  Standard	  and	  serial	  dilutions	  with	  the	  highest	  standard	  250pg	  ml-­‐1	  to	  3.9	  pg	  
ml-­‐1.	  The	  microplate	  was	  coated	  using	  Anti-­‐NGF	  polyclonal	  antibody	  and	  carbonate	  
coating	  buffer	  (pH	  9.7)	  and	  incubated	  overnight	  at	  4°C.	  	  The	  plate	  was	  then	  washed	  
once	  and	  200	  µl	  of	  Block	  Buffer	  were	  added	  to	  each	  well	  and	  incubated	  without	  shaking	  
for	  1	  hour	  at	  room	  temperature.	  	  The	  plate	  was	  washed	  once	  with	  wash	  buffer.	  	  Sixteen	  
wells	  in	  the	  supplied	  microplate	  were	  filled	  with	  100	  µl	  of	  the	  NGF	  standard	  solutions	  in	  
duplicate,	  with	  the	  remaining	  wells	  accommodating	  100	  µl	  of	  each	  diluted	  (1:2)	  urine	  
sample.	  The	  plate	  was	  then	  sealed	  and	  incubated	  at	  room	  temperature	  for	  6	  hours	  at	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37°C.	  The	  well	  contents	  were	  then	  aspirated	  and	  the	  wells	  washed	  five	  times	  using	  
200µl	  wash	  solution.	  
	  
After	  washing,	  100	  μL	  of	  diluted	  Anti-­‐NGF	  monoclonal	  antibody	  were	  added	  to	  each	  
well	  and	  the	  plate	  sealed	  and	  incubated	  overnight	  at	  4°C.	  The	  well	  contents	  were	  again	  
emptied	  and	  washed	  five	  times.	  One	  hundred	  μL	  of	  Anti-­‐Rat	  IgG	  HRP	  conjugate	  were	  
added	  to	  each	  well	  and	  incubated	  for	  2.5	  hours	  at	  room	  temperature.	  The	  well	  contents	  
were	  then	  emptied	  and	  the	  wells	  washed	  five	  times	  using	  wash	  solution.	  	  One	  hundred	  
microlitres	  of	  TMB	  Solution	  were	  added	  to	  each	  well	  and	  incubated	  for	  10	  minutes	  at	  
room	  temperature.	  	  The	  reaction	  was	  stopped	  by	  adding	  100	  µl	  of	  1N	  hydrochloric	  acid	  
to	  each	  well	  and	  a	  blue	  to	  yellow	  colour	  change	  was	  observed.	  	  NGF	  concentration	  was	  
determined	  within	  30	  minutes	  using	  an	  Opsys	  MR	  fluorescence	  microplate	  reader	  
(DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  450	  nm.	  The	  reader	  produced	  standard	  
curves,	  fit	  to	  a	  four-­‐parameter	  logistics	  curve,	  which	  was	  used	  to	  calculate	  concentrates	  
for	  each	  well.	  	  All	  samples	  were	  analysed	  in	  duplicate	  and	  the	  mean	  value	  was	  taken.	  
4.15.2 Statistical	  Analysis	  
The	  data	  were	  checked	  for	  normality	  using	  a	  Q-­‐Q	  plot	  and	  found	  to	  be	  satisfactory,	  
hence	  parametric	  methods	  were	  used	  for	  analysis.	  Statistical	  analysis	  of	  the	  data	  was	  
conducted	  using	  ANOVA	  at	  the	  95%	  level	  of	  confidence.	  
	  
4.15.3 Results	  
Forty	  one	  female	  patients	  (F=41,	  mean	  age	  (years)=63.3;	  sd=11.3)	  and	  39	  female	  control	  
subjects	  (F=39;	  mean	  age	  (years)=43.8;	  sd=16.2)	  were	  included	  in	  the	  analysis.	  When	  
comparing	  OAB	  patients	  with	  asymptomatic	  controls	  there	  was	  no	  significant	  difference	  





Figure	  4.11	  –	  A	  Graph	  to	  show	  the	  mean	  Log	  NGF	  and	  95%	  confidence	  intervals,	  in	  





From	  this	  small	  study	  there	  does	  not	  appear	  to	  be	  a	  difference	  in	  urinary	  NGF	  when	  
comparing	  patients	  with	  controls.	  In	  the	  literature	  there	  has	  been	  suggestion	  that	  NGF	  
may	  have	  potential	  as	  marker	  of	  OAB	  hence	  exploration	  was	  pursued.	  	  These	  studies	  
however	  have	  explored	  NGF	  as	  a	  marker	  of	  detrusor	  overactivity	  but	  it	  is	  well	  
recognised	  that	  there	  may	  be	  other	  causes	  for	  symptoms	  of	  urgency.	  In	  this	  small	  study	  
however	  no	  difference	  was	  seen	  between	  healthy	  controls	  and	  those	  with	  OAB	  
symptoms.	  NGF	  also	  does	  not	  seem	  to	  correlate	  with	  markers	  of	  infection	  such	  as	  
pyuria.	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5 Chapter	  5	  –	  A	  blinded	  observational	  cohort	  study	  of	  the	  
microbiological	  ecology	  associated	  with	  pyuria	  and	  overactive	  
bladder	  symptoms	  	  
	  
5.1 Hypothesis	  
Patients	  with	  symptoms	  of	  OAB	  show	  a	  discriminating	  urinary	  microbiology	  in	  urinary	  
sediment	  when	  compared	  to	  controls.	  
	  
5.2 Background	  	  
The	  bacterial	  ecology	  of	  the	  lower	  urinary	  tract	  in	  patients	  with	  chronic	  LUTS	  remains	  
unexplored.	  Critically,	  the	  relationship	  between	  infection,	  inflammation,	  and	  the	  
generation	  of	  OAB	  has	  not	  been	  scrutinised	  in	  a	  prospective,	  controlled	  study.	  This	  work	  
was	  undertaken	  to	  characterise	  the	  ecology	  of	  the	  lower	  urinary	  tract	  using	  sensitive	  
microbiological	  methods,	  and	  define	  the	  relationship	  between	  infection,	  urothelial	  
inflammation,	  and	  symptom	  generation	  in	  patients	  OAB	  symptoms	  and	  healthy	  
controls.	  
	  
5.3 Study	  Overview	  
Adult	  female	  patients	  with	  OAB	  symptoms,	  and	  asymptomatic	  control	  subjects,	  were	  
assessed	  at	  twelve	  study	  visits,	  scheduled	  every	  four	  weeks.	  At	  each	  visit,	  all	  study	  
participants	  provided	  a	  clean	  catch	  MSU.	  The	  urine	  was	  analysed	  to	  explore	  the	  
microbiology	  of	  the	  lower	  urinary	  tract,	  and	  the	  inflammatory	  and	  immune	  response	  of	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the	  urothelium.	  Demographic	  data	  were	  stored	  in	  a	  secure	  clinical	  database.	  Symptoms	  
were	  assessed	  using	  validated	  questionnaires.	  	  
	  
5.4 Methods	  
5.4.1 Ethical	  review	  
This	  study	  was	  approved	  by	  the	  National	  Research	  Ethics	  Service	  (NRES)	  Committee	  
London;	  East	  Central	  Research	  Ethical	  Committee	  1	  (Reference	  number	  11/H0721/7).	  
5.4.2 Study	  design	  
This	  was	  a	  blinded,	  comparative,	  observational	  cohort	  study	  of	  female	  patients	  OAB	  
symptoms,	  and	  asymptomatic	  control	  subjects	  using	  a	  consilience	  approach	  (figure	  5.1).	  
5.4.3 Study	  Groups	  
Patients	  with	  OAB:	  Twenty	  female	  patients	  who	  describe	  OAB	  symptoms,	  included	  
urinary	  urgency,	  with	  or	  without	  urge	  incontinence.	  	  
	  
Asymptomatic	  controls:	  Twenty	  healthy	  female	  adults	  with	  no	  urinary	  symptoms	  
including:	  urinary	  urgency,	  urinary	  incontinence,	  perception	  of	  increased	  urinary	  
frequency,	  voiding	  problems,	  or	  pain	  attributed	  to	  the	  urinary	  tract.	  
	  
All	  participants	  provided	  written,	  informed	  consent,	  and	  completed	  the	  ICIQ	  LUTS,	  
Urgency	  and	  Pain	  questionnaire.	  	  Women	  who	  were	  pregnant	  or	  planning	  pregnancy	  
were	  not	  eligible	  for	  inclusion.	  Any	  participants	  with	  an	  illness	  that	  in	  the	  opinion	  of	  the	  
chief	  investigator	  may	  have	  compromised	  the	  validity	  of	  the	  data	  were	  excluded.	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5.4.4 Recruitment	  of	  participants	  
Patient	  and	  control	  subjects	  were	  recruited	  as	  described	  previously	  in	  chapter	  2.	  
Additional	  participants	  were	  recruited	  to	  accommodate	  a	  patient	  dropout	  rate	  of	  up	  to	  
40%.	  
5.4.5 Data	  Management	  	  
Study	  data	  were	  stored	  in	  the	  Department	  of	  Medicine,	  UCL	  Archway	  Campus,	  as	  per	  
Good	  Clinical	  Practice	  (GCP)	  guidance.	  All	  samples	  and	  recoded	  data	  were	  identifiable	  
by	  study	  numbers	  and	  participant	  initials.	  Any	  patient	  identifiable	  data	  was	  stored	  on	  
only	  a	  secure	  NHS	  database,	  which	  was	  protected	  by	  encryption	  and	  daily	  backup.	  
5.4.6 Study	  visits	  and	  processes	  
Written,	  informed	  consent	  was	  obtained	  at	  the	  first	  visit,	  prior	  to	  any	  study	  related	  
procedures,	  and	  eligibility	  checked.	  Participants	  attended	  twelve	  study	  visits	  in	  total,	  
scheduled	  every	  4	  weeks.	  	  
	  
Patients	  and	  control	  subjects	  provided	  MSU	  samples	  using	  the	  clean-­‐catch	  method,	  
described	  in	  chapter	  2.	  All	  samples	  were	  subject	  to	  analysis	  as	  outlined	  below.	  All	  
participants	  completed	  symptom	  questionnaires.	  	  
5.4.7 Primary	  outcome	  measure	  
The	  primary	  outcome	  measure	  was	  the	  total	  log	  bacterial	  colony	  forming	  units	  of	  all	  
isolates	  obtained	  from	  culture	  of	  the	  urinary	  sediment.	  
5.4.8 Secondary	  Outcome	  measures	  
The	  secondary	  outcome	  measures	  included	  the	  assessment	  of	  urothelial	  inflammation	  




Microscopic	  pyuria	  count	  	  
Urothelial	  cell	  count	  	  
Urothelial	  cells	  demonstrating	  associated	  bacteria	  
Routine	  urine	  culture	  in	  hospital	  laboratory	  
ICIQ-­‐LUTS	  symptoms	  score	  	  
Whittington	  urgency	  score	  	  
Whittington	  pain	  score	  
	  
Figure	  5.1	  –	  Study	  Design	  	  
	  
5.5 Sample	  size	  calculation	  
A	  sample	  size	  of	  20	  participants	  in	  each	  group	  provided	  83%	  power	  to	  detect	  a	  
significant	  difference	  in	  log	  bacterial	  growth	  with	  alpha	  of	  0.05.	  	  This	  was	  calculated	  
from	  pilot	  data	  where	  the	  log	  bacterial	  count	  standard	  deviation	  was	  2	  and	  mean	  
differcne	  was	  0.5.	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5.6 Statistical	  Analysis	  
The	  primary	  analysis	  was	  to	  determine	  the	  difference	  in	  total	  log	  colony	  forming	  units	  
ml-­‐1	  of	  bacterial	  growth	  between	  patients	  and	  control	  subjects.	  The	  secondary	  analyses	  
were	  to	  explore	  the	  relationship	  between	  bacterial	  growth,	  lower	  urinary	  tract	  
symptoms	  and	  function,	  and	  markers	  of	  urothelial	  inflammation	  and	  immune	  
activation.	  The	  primary	  outcome	  data	  were	  assessed	  for	  normality	  using	  Q-­‐Q	  plots,	  and	  
non-­‐parametric	  methods	  of	  analysis	  employed	  if	  the	  data	  were	  not	  normally	  
distributed.	  Data	  from	  patients	  and	  controls	  were	  pooled	  to	  compare	  the	  performance	  
of	  routine	  culture	  methods	  against	  the	  results	  of	  urinary	  sediment	  culture.	  	  
	  
The	  secondary	  analyses	  were	  undertaken	  using	  the	  general	  linear	  models	  (GLM)	  
repeated	  measures	  procedure	  in	  SPSS.	  Bacterial	  growth	  was	  designated	  the	  dependent	  
variable,	  and	  other	  measures	  entered	  as	  independent	  variables	  in	  the	  model.	  The	  
analyses	  were	  undertaken	  with	  the	  supervision	  of	  a	  statistician	  familiar	  with	  the	  analysis	  
of	  multilevel	  models	  in	  SPSS.	  	  	  	  
	  
The	  secondary	  analyses	  were	  conducted	  to	  evaluate	  the	  relationship	  between	  markers	  
of	  urothelial	  inflammation,	  bacterial	  growth,	  urinary	  symptoms,	  and	  lower	  urinary	  tract	  
function.	  In	  addition,	  culture	  of	  the	  spun	  urinary	  sediment	  was	  used	  to	  determine	  the	  
bacterial	  growth	  and	  routine	  laboratory	  cultures	  reported	  as	  positive	  or	  negative.	  The	  
secondary	  analyses	  were	  undertaken	  using	  the	  linear	  mixed-­‐effects	  models	  procedure	  
in	  SPSS.	  Data	  were	  assessed	  for	  normality	  using	  Q-­‐Q	  plots	  and	  log-­‐transformed	  where	  
necessary.	  Data	  that	  were	  normally	  distributed	  were	  analysed	  using	  parametric	  




Between	  April	  2011	  and	  September	  2013,	  24	  female	  patients	  with	  OAB	  (mean	  age=63;	  
sd=11)	  and	  22	  asymptomatic	  control	  subjects	  (mean	  age	  59;	  sd	  =	  9)	  were	  recruited.	  
Both	  groups	  were	  matched	  for	  menopausal	  status	  and	  BMI.	  There	  was	  1	  drop-­‐out	  from	  
the	  patient	  group	  and	  1	  drop-­‐out	  from	  the	  control	  group.	  The	  results	  below	  are	  from	  
the	  pooled	  data	  analysis	  of	  282	  patient	  visits	  and	  253	  control	  visits.	  	  
In	  order	  to	  examine	  the	  differences	  between	  patients	  and	  controls	  linear	  mixed-­‐effects	  
models	  procedure	  was	  used	  to	  analyse	  the	  longitudinal	  data	  with	  the	  group	  
classification	  (Patient/Control)	  as	  an	  independent	  factor.	  Within	  the	  model	  the	  fixed	  
effect	  was	  the	  group	  number	  and	  the	  dependant	  variables	  were	  selected	  in	  turn	  as	  LUTS	  
score,	  urgency	  score,	  pain	  score,	  total	  bacterial	  growth	  on	  sediment	  culture,	  log	  pyuria	  
and	  log	  epithelial	  cell	  shedding.	  Visit	  number	  was	  selected	  as	  the	  repeated	  effect.	  These	  
six	  analyses	  (table	  5.1)	  showed	  that	  group	  status	  (Patient/Control)	  was	  a	  significant	  
predictor	  of	  total	  symptoms	  (Estimate	  of	  coefficient	  =	  -­‐16.11,	  p<.0001);	  of	  pain	  
(Estimate	  of	  coefficient	  =	  -­‐1.44,	  p=.001);	  	  Pyuria	  (log	  pyuria)	  (Estimate	  of	  coefficient	  =	  -­‐
0.57,	  p<.0001);	  epithelial	  cell	  shedding	  (log	  epithelial	  cell	  count)	  (Estimate	  of	  coefficient	  
=	  -­‐0.30,	  p<.0001)	  and	  Log	  colony	  counts	  (Estimate	  of	  coefficient	  =	  -­‐1.07,	  p<.0001).	  	  
	  
Table	  5.1	  –	  Linear	  mixed	  models	  analysis	  with	  Group	  as	  the	  fixed	  effect	  
Dependent	  variable	  	   Parameter	  estimate*	  	   Significance	  
LUTS	  score	   -­‐16.11	  (95%	  CI	  =	  -­‐19.1	  to	  -­‐13.1;	  t=	  -­‐10.8;	  df	  =	  43.8)	   P<.0001	  
Urgency	   -­‐6.95	  (95%	  CI	  =	  -­‐8.65	  to	  -­‐5.24;	  t=	  -­‐8.21;	  df	  =	  44.1)	   P<.0001	  
Pain	   -­‐1.44	  (95%	  CI	  =	  -­‐2.23	  to	  -­‐0.64;	  t=	  -­‐3.65;	  df	  =	  44.1)	   P<.0001	  
Bacterial	  growth§	   	  -­‐1.08(95%	  CI=-­‐1.55	  to	  -­‐0.60;	  t=-­‐4.57;	  df=41.3)	   P<.0001	  
Pyuria	  count†	   -­‐0.57	  (95%	  CI=-­‐0.75	  to	  -­‐0.37;	  t=-­‐6.37;	  df=41.7)	   p<.0001	  
Epithelial	  count*	   -­‐0.30	  (95%	  CI=-­‐0.44	  to	  -­‐0.15;	  t=-­‐4.21;	  df=43.1)	   p<.0001	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  by	  controls	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compared	  with	  patients	  subjects	  during	  the	  study;	  §Bacterial	  growth:	  log	  cfu	  ml-­‐1;	  †Pyuria	  count:	  
wbc	  ul-­‐1;	  *Epithelial	  count:	  epc	  ul-­‐1;	  	  
	  
The	  linear	  mixed-­‐effects	  models	  procedure	  was	  used	  to	  achieve	  a	  multiple	  regression,	  
with	  the	  independent	  variables	  selected	  as;	  group	  number	  (Patient/Control),	  total	  LUTS	  
score,	  urgency	  score,	  pain	  score,	  log	  total	  microbial	  growth	  and	  log	  epithelial	  cell	  
shedding	  (table	  5.2).	  The	  dependant	  variable	  was	  selected	  to	  be	  log	  pyuria.	  Visits	  were	  
selected	  as	  the	  repeated	  effects.	  The	  variables	  that	  predicted	  log	  pyuria	  were	  group	  
number,	  total	  LUTS	  score,	  log	  bacterial	  growth	  (Estimate	  of	  coefficient	  0.14,	  p<.0001)	  
and	  log	  epithelial	  cell	  shedding	  (Estimate	  of	  coefficient	  0.25,	  p<.0001)	  and	  similarly	  the	  
predictors	  of	  log	  bacterial	  growth	  were	  group	  and	  log	  pyuria	  (table	  5.3).	  	  
	  
Table	  5.2	  –	  Multiple	  mixed	  models	  analysis	  with	  log	  pyuria	  as	  the	  dependant	  variable	  
Parameter	   Parameter	  estimate*	  	   Significance	  
Group	   -­‐0.35	  (95%	  CI	  =	  -­‐0.09	  to	  -­‐0.54;	  t=	  -­‐4.76;	  df	  =	  47.5)	   P<.0001	  
LUTS	  score	   0.13	  (95%	  CI	  =	  0.02	  to	  0.01	  ;	  t=	  2.89;	  df	  =	  363.6)	   P<.0001	  
Bacterial	  growth§	   	  0.14	  (95%	  CI=0.17	  to	  0.11;	  t=8.96;	  df=483.8)	   P<.0001	  
Epithelial	  count*	   0.25	  (95%	  CI=-­‐0.35	  to	  -­‐0.15;	  t=5.10;	  df=474.9)	   p<.0001	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  log	  pyuria;;	  
§Bacterial	  growth:	  log	  cfu	  ml-­‐1;	  †Pyuria	  count:	  wbc	  ul-­‐1;	  *Epithelial	  count:	  epc	  ul-­‐1;	  	  
	  
	  
Table	  5.3	  –	  Multiple	  mixed	  models	  analysis	  with	  log	  bacterial	  growth	  as	  the	  
dependant	  variable	  
Parameter	   Parameter	  estimate*	  	   Significance	  
Group	   -­‐0.73	  (95%	  CI	  =	  -­‐0.21	  to	  -­‐1.26;	  t=	  -­‐2.79;	  df	  =	  76.57)	   P<.007	  
Pyuria	  count†	   0.96	  (95%	  CI	  =	  01.15	  to	  0.77;	  t=	  9.90;	  df	  =	  403.43)	   P<.0001	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  log	  pyuria;	  




From	  the	  pooled	  analysis,	  in	  contrast	  to	  controls,	  patients	  demonstrated	  significantly	  
greater	  bacterial	  growth	  characterised	  by	  culture	  of	  the	  centrifuged	  urinary	  sediment	  
(Z=-­‐5.981,	  p<.0001)	  (figure	  5.2).	  	  The	  median	  log	  total	  colony	  counts	  in	  the	  patient	  
group	  were	  2.30	  (interquartile	  range	  1.54)	  and	  1.50	  (interquartile	  range	  2.01)	  in	  the	  
control	  group.	  The	  patient	  group	  also	  showed	  significantly	  higher	  levels	  of	  urinary	  
leucocyte	  excretion	  and	  increased	  clue	  cell	  shedding	  (β=1.48,	  df=1,	  p<.0001)	  (figure	  
5.3).	  	  In	  the	  control	  group	  the	  mean	  clue	  cell	  proportion	  was	  0.01,	  median	  0.00	  
(sd=0.057,	  interquartile	  range=0.00)	  and	  in	  the	  patient	  group	  mean	  clue	  cell	  proportion	  



























Within	  the	  patient	  group	  9.72%	  had	  a	  positive	  routine	  culture	  compared	  with	  0.40%	  in	  
the	  control	  group.	  93.4%	  of	  patients	  had	  a	  positive	  spun	  sediment	  culture	  (>	  0	  cfu	  ml-­‐1)	  
which	  was	  significantly	  higher	  when	  compared	  to	  controls	  where	  70.1%	  had	  a	  positive	  
sediment	  culture	  (χ2=51.33,	  p<.0001).	  The	  microbial	  diversity	  was	  distinctly	  different	  
between	  patients	  and	  controls.	  	  In	  patient	  cultures,	  recognised	  uropathogens	  
predominated	  (Figure	  5.4).	  
	  





Figure	  5.5	  shows	  the	  distribution	  of	  microbes	  isolated	  from	  controls	  and	  patients.	  	  	  
Using	  multinomial	  logistic	  regression,	  with	  the	  microbes	  entered	  into	  the	  model	  as	  
factors	  and	  the	  dependant	  variable	  being	  the	  group	  (Patient/Control),	  E	  Coli	  and	  other	  
coliforms	  and	  no	  growth	  proved	  significant	  predictors	  of	  the	  group	  (χ2	  =	  82.8,	  p<.0001).	  
	  
	  







Figure	  5.6	  –	  A	  graph	  to	  show	  the	  proportionate	  distribution	  between	  patients	  and	  
controls	  of	  each	  organism	  genus	  
	  
	  
Figure	  5.6	  shows	  a	  proportionate	  occurrence,	  between	  controls	  and	  patients,	  of	  each	  
organism	  genus.	  Thus	  the	  column	  pairs	  add	  to	  1	  in	  each	  case.	  There	  is	  a	  distinct	  
variation	  in	  bacteria	  found	  between	  patients	  and	  controls.	  	  It	  can	  be	  suggested	  that	  
some	  of	  the	  bacterial	  genus	  found	  in	  patients	  occurred	  less	  frequently	  in	  controls.	  	  
	  
Spearman	  analysis	  demonstrated	  the	  following	  correlations:	  LUTS	  symptoms	  and	  pyuria	  
(R	  =	  0.50),	  urgency	  and	  pyuria	  (R	  =0.44),	  pyuria	  and	  epithelial	  cell	  shedding	  (R=	  0.41).	  	  
When	  analysing	  the	  longitudinal	  data,	  patients	  consistently	  showed	  a	  higher	  log	  




Figure	  5.7	  –	  Mean	  Log	  bacterial	  growth	  in	  patients	  and	  controls	  at	  each	  visit	  	  
	  
Patients	  also	  showed	  a	  significantly	  higher	  mean	  log	  pyuria	  when	  compared	  to	  controls	  
at	  each	  visit.	  	  




Mean	  urinary	  ATP	  was	  found	  to	  be	  significantly	  different	  between	  patients	  and	  controls	  
across	  each	  visit	  (figure	  5.9).	  The	  variances	  were	  considerable,	  but	  a	  difference	  was	  still	  
evident	  though	  the	  random	  noise.	  
	  





This	  analysis	  of	  the	  pooled	  data	  would	  suggest	  that	  patients	  and	  controls	  appear	  to	  
demonstrate	  differences	  in	  bacterial	  ecology,	  and	  differences	  in	  the	  expression	  of	  
microscopic	  pyuria	  and	  clue	  cells.	  The	  patient	  group	  was	  also	  found	  to	  be	  carrying	  a	  
quantitatively	  greater	  bacterial	  load	  although	  a	  diagnostic	  quantitative	  threshold	  is	  not	  
proposed.	  The	  analysis	  of	  the	  longitudinal	  data	  shows	  a	  fair	  correlation	  between	  
symptoms	  and	  pyuria,	  specifically	  urgency	  and	  pyuria	  and	  pyuria	  and	  evidence	  of	  
epithelial	  cell	  shedding.	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The	  number	  of	  participants	  that	  completed	  the	  study	  in	  the	  patient	  and	  control	  arm,	  
taking	  into	  consideration	  dropouts,	  maintained	  statistical	  power.	  The	  study	  groups	  were	  
matched	  for	  key	  demographics	  including	  age,	  menopausal	  status	  and	  BMI.	  Other	  
demographics	  were	  not	  controlled	  for.	  The	  primary	  outcome	  measure	  of	  bacterial	  
growth	  (cfu	  ml-­‐1)	  found	  through	  quantitative	  culture	  of	  the	  spun	  urinary	  sediment	  
demonstrated	  greater	  bacterial	  growth	  amongst	  patients	  when	  compared	  to	  controls.	  
This	  was	  in	  contrast	  to	  the	  routine	  laboratory	  culture,	  which	  did	  not	  show	  a	  significant	  
difference	  in	  positive	  cultures	  between	  the	  two	  groups.	  These	  results	  highlight	  the	  
inaccuracy	  of	  using	  standard	  culture	  techniques,	  constrained	  by	  diagnostic	  thresholds.	  
These	  findings	  provide	  yet	  more	  evidence	  of	  the	  inaccuracy	  of	  fixed	  culture	  thresholds	  
in	  the	  exploration	  of	  UTI.	  	  
	  
The	  common	  bacterial	  isolates	  found	  on	  spun	  sediment	  in	  patients	  were	  different	  to	  the	  
predominant	  bacterial	  isolates	  from	  controls.	  	  This	  supports	  work	  in	  the	  literature	  by	  
Khasriya	  et	  al	  (140).	  	  E.	  coli	  was	  the	  most	  prevalent	  species	  amongst	  patients,	  followed	  
by	  Enterococcus	  faecalis.	  Proteus,	  KES	  and	  pseudomonas	  were	  also	  found	  more	  
commonly	  within	  the	  patient	  group	  as	  compared	  with	  the	  control	  group.	  Amongst	  
control	  subjects,	  Staphylococcus,	  streptococcus,	  Citrobacter	  and	  lactobacillus	  were	  
more	  commonly	  found.	  	  
	  
These	  data	  suggest	  that	  E.coli	  is	  the	  most	  prevalent	  organism	  found	  on	  culture	  amongst	  
patients,	  which	  is	  similar	  to	  studies	  that	  have	  looked	  at	  patients	  with	  acute	  UTI	  (60).	  	  
Escherichia	  coli	  are	  found	  in	  the	  perineum	  and	  vagina	  and	  are	  thought	  to	  ascend	  and	  
enter	  the	  urinary	  tract	  (141).	  	  Murine	  models	  have	  shown	  Uropathogenic	  E.	  coli	  to	  use	  
Type	  1	  pilus	  to	  attach	  to	  bladder	  umbrella	  cells	  leading	  to	  invasion	  and	  formation	  of	  
 120	  
IBCs	  (50,	  74).	  	  The	  bacteria	  are	  able	  to	  release	  toxins	  that	  cause	  damage	  to	  the	  host	  and	  
allows	  colonisation	  of	  the	  urothelium,	  a	  source	  of	  nutrients	  and	  iron	  for	  the	  bacteria	  
(142)	  (143).	  	  The	  second	  most	  prevalent	  bacterium	  found	  in	  the	  patient	  cultures	  was	  
Enterococcus	  faecalis.	  Studies	  have	  show	  that	  Enterococcus	  faecalis	  is	  able	  to	  cause	  
damage	  through	  the	  release	  of	  exotoxins	  (144).	  More	  recently	  Horsley	  et	  al	  (101)	  has	  
shown	  good	  evidence	  of	  intracellular	  colonisation	  by	  Enterococcus	  faecalis	  of	  urothelial	  
cells	  using	  confocal	  microscopy.	  	  
	  
Proteus	  spp.	  are	  thought	  to	  be	  opportunistic	  organisms	  and	  most	  commonly	  seen	  in	  
urinary	  tract	  infection	  particularly	  associated	  with	  long-­‐term	  catheterisation	  (145).	  
Studies	  have	  also	  found	  that	  Proteus	  mirabilis	  is	  a	  key	  organism	  in	  biofilm	  formation	  
associated	  with	  urinary	  catheters,	  causing	  chronic	  infection	  (146).	  	  The	  virulence	  
properties	  of	  Proteus	  bacilli	  stem	  from	  flagella-­‐mediated	  motility,	  both	  swimming	  and	  
swarming	  (147)	  .	  	  A	  review	  by	  Schaffer	  et	  all	  described	  how	  this	  organism	  uses	  a	  diverse	  
set	  of	  virulence	  factors	  to	  colonise	  the	  urinary	  tract,	  including	  urease	  and	  stone	  
formation,	  fimbriae	  and	  adhesins,	  iron	  and	  zinc	  acquisition,	  proteases	  and	  toxins	  and	  
biofilm	  formation(148).	  	  
	  
The	  potential	  for	  an	  organism	  to	  cause	  disease	  is	  thought	  to	  be	  dependant	  on	  its	  
virulence	  factors.	  	  These	  can	  be	  inherent	  to	  the	  bacteria	  and	  can	  also	  include	  host	  
factors.	  Such	  virulence	  properties	  include	  Type-­‐1Pilli	  expressed	  by	  E.coli	  or	  the	  ability	  to	  
swarm	  by	  Proteus	  spp.	  Other	  factors	  include	  the	  ability	  to	  produce	  harmful	  toxins	  and	  
the	  ability	  form	  intracellular	  bacterial	  communities	  and	  biofilm	  formation.	  Some	  






The	  majority	  of	  patient	  cultures,	  as	  well	  as	  some	  control	  cultures	  demonstrated	  
polymicrobial	  growth.	  Whilst	  mixed	  growth	  cultures	  have	  historically	  been	  associated	  
with	  contamination	  from	  poor	  sampling,	  this	  was	  been	  strongly	  challenged	  (150,	  151).	  
Wolcott	  et	  al	  suggested	  that	  a	  polymicrobial	  growth	  and	  co-­‐existent	  of	  certain	  species	  
of	  bacteria	  may	  offer	  a	  survival	  advantage	  (152).	  	  
	  
Urothelial	  clue	  shedding	  has	  been	  described	  as	  an	  immune	  response.	  	  Murine	  and	  
human	  studies	  have	  shown	  increased	  cell	  shedding	  in	  response	  to	  infection	  (75,	  76,	  
153).	  This	  study	  found	  that	  the	  patient	  group	  showed	  increased	  proportions	  of	  urinary	  
clue	  cells,	  which	  may	  be	  a	  reflection	  of	  increased	  immune	  activation	  in	  response	  to	  a	  
higher	  bacterial	  load.	  Conversely	  lower	  proportions	  of	  clue	  cells	  in	  the	  control	  group	  
may	  also	  suggest	  little	  contamination	  via	  the	  clean-­‐catch	  MSU	  sampling	  method.	  This	  
study	  showed	  increased	  colonisation	  of	  shed	  urothelial	  cells	  in	  patients	  with	  LUTS	  
compared	  with	  controls	  which	  supports	  work	  in	  other	  studies	  (154).	  
	  
The	  assessment	  of	  bacterial	  adhesion	  to	  urothelial	  cells	  could	  have	  been	  affected	  by	  the	  
sampling	  method.	  Bacterial	  contamination	  from	  the	  lower	  genital	  tract	  could	  have	  
contributed	  to	  this.	  	  However	  the	  immediate	  refrigeration	  of	  urine	  and	  the	  processing	  
of	  these	  samples	  within	  one	  hour	  of	  collection	  reduced	  this	  risk.	  	  Whilst	  one	  could	  argue	  
that	  the	  MSU	  sampling	  method	  could	  contribute	  to	  contamination,	  this	  was	  appear	  to	  




In	  the	  longitudinal	  study	  there	  was	  a	  significant	  difference	  in	  the	  microbial	  growth	  and	  
pyuria	  in	  the	  patient	  group	  compared	  with	  the	  control	  group.	  	  It	  can	  be	  suggested	  that	  
there	  was	  both	  an	  increased	  immune	  response,	  which	  may	  be	  related	  to	  bacterial	  
growth.	  	  There	  is	  clearly	  a	  complex	  relationship	  between	  inflammation	  and	  bacterial	  
proliferation	  that	  needs	  further	  exploration,	  the	  start	  of	  which	  has	  been	  this	  work.	  
However	  there	  was	  also	  polymicrobial	  growth	  found	  in	  the	  control	  subjects,	  which	  does	  
not	  trigger	  a	  host	  response.	  	  	  	  
	  
A	  possible	  explanation	  for	  this	  may	  be	  Quorum	  sensing,	  which	  describes	  intracellular	  
communication	  between	  bacteria.	  This	  process	  allows	  microbes	  to	  communicate	  and	  
may	  allow	  modification	  of	  individual	  genes	  influencing	  population	  density	  and	  bacterial	  
composition	  (155)	  (156).	  Increase	  in	  bacterial	  populations	  offers	  advantages	  over	  the	  
host	  through	  virulence	  factors	  and	  the	  ability	  to	  scavenge	  nutrients.	  Bacteria	  use	  
quorum	  sensing	  to	  coordinate	  behaviours	  including	  biofilm	  formation,	  virulence,	  and	  
antibiotic	  resistance.	  	  This	  process	  is	  based	  on	  the	  local	  density	  of	  the	  bacterial	  
population.	  Quorum	  sensing	  can	  occur	  within	  a	  single	  bacterial	  species	  as	  well	  as	  
between	  diverse	  species.	  	  It	  is	  thought	  that	  this	  process	  is	  an	  indicator	  of	  population	  
density	  or	  the	  diffusion	  rate	  of	  the	  cell's	  immediate	  environment.	  The	  mechanism	  of	  
action	  is	  thought	  to	  be	  through	  secretion	  of	  secrete	  signalling	  molecules,	  called	  
autoinducers	  by	  the	  bacteria.	  Common	  signalling	  molecules	  include	  oligopeptides	  in	  
Gram-­‐positive	  bacteria,	  N-­‐acyl	  homoserine	  lactones	  (AHL)	  in	  Gram-­‐negative	  bacteria,	  
and	  a	  family	  of	  autoinducers	  known	  as	  autoinducer-­‐2	  (AI-­‐2)	  in	  both	  Gram-­‐negative	  and	  
Gram-­‐positive	  bacteria.	  These	  bacteria	  also	  have	  a	  receptor	  that	  can	  specifically	  detect	  
the	  signalling	  molecule	  (inducer).	  When	  the	  inducer	  binds	  the	  receptor,	  it	  activates	  
transcription	  of	  certain	  genes,	  including	  those	  for	  inducer	  synthesis.	  There	  is	  a	  low	  
likelihood	  of	  a	  bacterium	  detecting	  its	  own	  secreted	  inducer.	  Thus,	  in	  order	  for	  gene	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transcription	  to	  be	  activated,	  the	  cell	  must	  encounter	  signalling	  molecules	  secreted	  by	  
other	  cells	  in	  its	  environment.	  As	  the	  population	  of	  bacterial	  grows,	  the	  concentration	  
of	  the	  inducer	  passes	  a	  threshold,	  leading	  to	  the	  production	  of	  more	  inducer.	  	  This	  
forms	  a	  positive	  feedback	  loop,	  and	  the	  receptor	  becomes	  fully	  activated	  (157).	  
Activation	  of	  the	  receptor	  induces	  the	  up-­‐regulation	  of	  other	  specific	  genes,	  causing	  all	  
of	  the	  cells	  to	  begin	  transcription	  at	  approximately	  the	  same	  time.	  This	  coordinated	  
behaviour	  of	  bacterial	  cells	  can	  be	  useful	  in	  a	  variety	  of	  situations.	  
	  
These	  insights	  may	  start	  to	  explain	  the	  complex	  relationship	  between	  bacterial	  
expansion	  and	  pyuria.	  Some	  organisms	  that	  pose	  potent	  virulence	  factors	  might	  attack	  
their	  host	  at	  lower	  cell	  densities	  than	  microbes	  with	  lesser	  pathogenic	  potential.	  
Quorum	  sensing	  systems	  are	  not	  exclusively	  for	  intra-­‐species	  communication.	  Bacteria	  
from	  different	  species	  produce	  universal	  AI	  molecules	  (158,	  159).	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6 Chapter	  6	  –	  The	  urinary	  cytokine	  and	  inflammatory	  response	  in	  
relation	  to	  symptoms	  of	  OAB	  
6.1 Hypothesis	  
Patients	  with	  symptoms	  of	  overactive	  bladder	  show	  varying	  urinary	  inflammatory	  
signals	  in	  relations	  to	  their	  symptoms.	  
6.1.1 Aims	  
To	  explore	  the	  variation	  in	  urinary	  IL6	  and	  Lactoferrin	  in	  relation	  to	  changes	  in	  pyuria,	  
microbial	  growth	  and	  symptoms	  in	  patients	  with	  OAB.	  	  
	  
6.2 Study	  design	  and	  Methods	  	  
6.2.1 Ethical	  review	  
This	  study	  was	  approved	  by	  the	  National	  Research	  Ethics	  Service	  (NRES)	  Committee	  
London;	  East	  Central	  Research	  Ethical	  Committee	  1	  (Reference	  number	  11/H0721/7).	  
6.2.2 Study	  design	  
This	  was	  a	  blinded,	  comparative,	  observational	  cohort	  study	  of	  female	  patients	  with	  
OAB	  symptoms,	  and	  asymptomatic	  control	  subjects.	  
6.2.3 Study	  Groups	  
Female	  patients	  who	  described	  OAB	  symptoms,	  including	  urinary	  urgency,	  with	  or	  
without	  urge	  incontinence.	  Asymptomatic	  controls:	  healthy	  female	  adults	  with	  no	  
urinary	  symptoms	  including:	  urinary	  urgency,	  urinary	  incontinence,	  perception	  of	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increased	  urinary	  frequency,	  voiding	  problems,	  or	  pain	  attributed	  to	  the	  urinary	  tract.	  
Recruitment	  was	  as	  described	  in	  chapter	  2.	  
	  
Subject	  Inclusion	  Criteria	  
9. Adults	  Women	  aged	  >=18	  years	  	  
10. Able	  to	  complete	  a	  symptom	  questionnaire	  	  
11. Diagnosed	  with	  OAB	  with	  or	  without	  pyuria	  (≥	  1	  wbc	  µl-­‐1)	  
12. Post-­‐menopausal	  women	  or	  women	  using	  adequate	  contraception	  
	  
Subject	  Exclusion	  Criteria	  
9. Age	  less	  than	  18	  years	  	  
10. Inability	  to	  consent	  	  
11. Pregnant	  women	  or	  women	  planning	  to	  conceive	  
12. Patients	  with	  concurrent	  illnesses	  that	  in	  the	  opinion	  of	  the	  investigator	  are	  
likely	  to	  compromise	  the	  validity	  of	  the	  data	  
	  
The	  study	  groups	  were:	  
1)	  Female	  adult	  patients	  with	  OAB,	  describing:	  	  
f. Urgency,	  the	  sudden	  compelling	  desire	  to	  urinate,	  a	  sensation	  that	  is	  
difficult	  to	  defer.	  
g. Urinary	  frequency,	  voiding	  eight	  or	  more	  times	  in	  a	  24-­‐hour	  period.	  	  
h. Nocturia,	  the	  need	  to	  wake	  one	  or	  more	  times	  per	  night	  to	  void.	  
i. They	  may	  or	  may	  not	  experience	  urinary	  incontinence.	  




2)	  Female	  adults	  without	  OAB	  and	  without	  other	  lower	  urinary	  tract	  symptoms.	  
	  
6.2.4 Recruitment	  of	  participants	  and	  consent	  
Patients	  were	  recruited	  from	  urological	  clinics	  at	  the	  Department	  of	  Medicine,	  
University	  College	  London	  Archway	  Campus.	  The	  patients	  who	  expressed	  interest	  were	  
given	  written	  information	  regarding	  the	  study	  and	  then	  contacted	  two	  weeks	  later	  and	  
if	  agreeable,	  invited	  for	  an	  initial	  visit	  where	  written	  informed	  consent	  was	  obtained.	  
Control	  subjects	  were	  recruited	  from	  the	  staff	  at	  the	  Whittington	  Hospital	  and	  
University	  College	  London.	  	  
	  
6.2.5 Data	  Management	  	  
Study	  data	  were	  stored	  in	  the	  Department	  of	  Medicine,	  UCL	  Archway	  Campus,	  as	  per	  
Good	  Clinical	  Practice	  (GCP)	  guidance.	  All	  samples	  and	  recoded	  data	  were	  identifiable	  
by	  study	  numbers	  and	  participant	  initials.	  Any	  patient	  identifiable	  data	  was	  stored	  on	  
only	  a	  secure	  NHS	  database,	  which	  was	  protected	  by	  encryption	  and	  daily	  backup.	  	  	  
	  
6.2.6 Study	  visits	  and	  processes	  
Written,	  informed	  consent	  was	  taken	  at	  the	  first	  visit,	  prior	  to	  any	  study	  related	  
procedures,	  and	  eligibility	  checked.	  Participants	  attended	  twelve	  study	  visits	  in	  total,	  
scheduled	  every	  4	  weeks.	  The	  study	  design	  can	  be	  seen	  in	  figure	  6.1.	  All	  participants	  
completed	  symptom	  questionnaires	  including	  ICIQ-­‐FLUTS,	  Whittington	  urgency	  score	  
and	  Whittington	  pain	  score.	  Patients	  and	  control	  subjects	  provided	  MSU	  samples	  using	  
the	  clean-­‐catch	  method.	  All	  samples	  were	  subject	  to	  analysis	  by	  blinded	  researchers.	  	  	  
Immediate	  microscopy	  for	  pyuria	  and	  epithelial	  cells	  was	  performed.	  	  Aliquots	  of	  spun	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urine	  were	  frozen	  at	  -­‐80°C.	  	  These	  process	  and	  methods	  are	  all	  described	  in	  detail	  in	  
chapter	  2.	  	  
	  
6.2.7 Primary	  outcome	  measure	  
The	  primary	  outcome	  measure	  was	  urinary	  IL6	  and	  urinary	  Lactoferrin	  in	  patients	  with	  
OAB	  symptoms	  and	  asymptomatic	  controls.	  	  	  
	  
6.2.8 Secondary	  Outcome	  measures	  
The	  secondary	  outcome	  measures	  included	  the	  assessment	  of	  urothelial	  inflammation	  
and	  immune	  activation,	  routine	  microbiological	  assessment	  and	  lower	  urinary	  tract	  
symptoms.	  	  
	  
Microscopic	  pyuria	  count	  	  
Urothelial	  cell	  count	  	  
Urothelial	  cells	  demonstrating	  associated	  bacteria	  
Microbial	  growth	  using	  enhanced	  sediment	  culture	  
ICIQ-­‐LUTS	  symptoms	  score	  	  
Whittington	  urgency	  score	  	  








Figure	  6.1	  –	  Study	  Design	  	  
	  
	  
6.3 Additional	  Methods	  
6.3.1 	  Quantification	  of	  Urinary	  IL6	  	  
The	  samples	  were	  thawed	  to	  room	  temperature	  and	  analysed	  in	  batches,	  and	  blinding	  
to	  sample	  details	  and	  symptoms	  ensured.	  The	  Quantikine®	  High	  Sensitivity	  ELISA	  
Human	  IL6	  Immunoassay	  was	  used	  to	  quantify	  urinary	  IL6	  (R&D	  Systems,	  Abingdon,	  
UK),	  with	  a	  limit	  of	  detection	  of	  0.09pg	  ml-­‐1	  with	  an	  inter-­‐	  and	  intra-­‐assay	  coefficient	  of	  
variation	  of	  less	  than	  10%.	  Frozen	  urine	  samples	  under	  went	  only	  one	  freeze	  thaw	  cycle	  
ensuring	  stability	  of	  IL6.	  	  The	  urine	  samples	  were	  thawed	  to	  room	  temperature	  and	  
mixed	  thoroughly	  using	  a	  vortex	  mixer	  (Scientific	  Industries,	  New	  York,	  USA).	  	  The	  assay	  
included	  IL6	  stock	  standard	  at	  a	  concentration	  of	  10	  pg	  ml-­‐1.	  Calibrator	  diluent	  was	  used	  
to	  produce	  serial	  dilutions	  ranging	  from	  10	  pg	  ml-­‐1	  to	  0.156	  pg	  ml-­‐1.	  Calibrator	  diluent	  
was	  used	  as	  0	  pg	  ml-­‐1	  standard.	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The	  supplied	  pre	  coated	  96	  well	  microplate	  was	  used	  to	  plate	  the	  IL6	  standards	  and	  
urine	  samples.	  100	  µl	  of	  the	  eight	  IL6	  standards	  were	  plated	  in	  duplicate.	  	  40	  urine	  
samples	  were	  plated	  in	  duplicate	  in	  the	  remaining	  80	  wells	  by	  adding	  100	  µl	  of	  each	  
urine	  sample.	  The	  plate	  was	  then	  covered	  and	  incubated	  at	  room	  temperature.	  	  Binding	  
was	  encouraged	  using	  an	  orbital	  microplate	  shaker	  (0.12”	  orbit)	  set	  at	  500	  ±	  50	  rpm	  for	  
two	  hours.	  	  
	  
After	  the	  2	  hour	  incubation	  the	  well	  contents	  were	  remove	  and	  the	  wells	  washed	  six	  
times	  with	  wash	  solution.	  	  Each	  wash	  was	  carefully	  pipetted	  without	  disruption	  to	  the	  
base	  of	  the	  well.	  In	  a	  second	  incubation,	  200µl	  of	  IL6	  conjugate	  was	  then	  added	  to	  each	  
well,	  and	  the	  plate	  incubated	  for	  a	  further	  two	  hours.	  The	  well	  contents	  were	  washed	  as	  
described	  earlier.	  	  The	  plate	  was	  then	  incubated	  on	  the	  bench	  top,	  after	  addition	  of	  50µl	  
of	  substrate	  solution,	  at	  room	  temperature	  for	  one	  hour.	  Following	  this	  was	  the	  
addition	  of	  50	  µl	  of	  amplifier	  solution	  without	  any	  washing	  and	  a	  colour	  change	  noted.	  	  
The	  plate	  was	  incubated	  on	  the	  bench	  top	  at	  room	  temperature	  for	  30	  minutes.	  	  In	  the	  
final	  step	  50µl	  of	  stop	  solution	  was	  added	  followed	  by	  analysis	  within	  30	  minutes.	  	  
Interleukin-­‐6	  concentration	  was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  
microplate	  reader	  (DYNEX	  Technologies,	  Worthing,	  UK),	  set	  at	  490	  nm.	  The	  reader	  
produced	  standard	  curves,	  which	  were	  used	  to	  calculate	  concentrates	  for	  each	  well.	  	  
The	  minimum	  detectable	  dose	  (MDD)	  of	  the	  ELISA	  kit	  according	  to	  the	  manufacturers	  
ranges	  from	  0.016-­‐0.110	  pg	  ml-­‐1,	  with	  an	  average	  MDD	  of	  0.039	  pg	  ml-­‐1.	  All	  samples	  
were	  analysed	  in	  duplicate	  to	  test	  the	  inter-­‐assay	  precision	  and	  the	  mean	  value	  was	  
taken.	  The	  intra-­‐assay	  precision	  for	  urine	  assays	  suggested	  by	  the	  company	  was	  5.5-­‐





6.3.2 Quantification	  of	  Urinary	  Lactoferrin	  
Urine	  samples	  underwent	  one	  freeze	  thaw	  cycle	  to	  ensure	  stability	  of	  Lactoferrin.	  	  Urine	  
samples	  were	  thawed	  to	  room	  temperature	  and	  mixed	  using	  a	  vortex	  mixer	  (Scientific	  
Industries,	  New	  York,	  USA).	  Samples	  were	  only	  identifiable	  by	  study	  numbers	  to	  ensure	  
blinding	  to	  sample	  details	  and	  group.	  The	  Human	  Lactoferrin	  ELISA	  immunoassay	  was	  
used	  to	  quantify	  urinary	  Lactoferrin	  (ICL,	  Portland,	  USA),	  with	  a	  range	  of	  detection	  of	  
3.125ng	  ml-­‐1	  -­‐100ng	  ml-­‐1,	  with	  a	  sensitivity	  average	  of	  0.725ng	  ml-­‐1.	  Lactoferrin	  standard	  
solutions	  were	  prepared	  using	  100	  ng	  ml-­‐1	  stock	  lactoferrin	  standard	  and	  six	  serial	  
dilutions	  using	  calibrator	  diluent.	  This	  produced	  standard	  solutions	  between	  100ng	  ml-­‐1	  
and	  3.125ng	  ml-­‐1,	  and	  calibrator	  diluent	  was	  used	  as	  zero	  standard.	  
	  
Fourteen	  wells	  in	  the	  supplied	  microplate	  were	  filled	  100	  µl	  of	  the	  seven	  Lactoferrin	  
standard	  solutions	  in	  duplicate,	  with	  the	  remaining	  wells	  accommodating	  100	  µl	  of	  each	  
urine	  test	  sample.	  The	  plate	  was	  incubated	  on	  the	  bench	  top	  at	  room	  temperature	  for	  
30	  minutes	  to	  allow	  binding.	  Following	  incubation	  well	  contents	  were	  aspirated	  and	  the	  
wells	  carefully	  filled	  with	  wash	  solution.	  	  This	  wsa	  then	  carefully	  aspirated	  and	  the	  
process	  repeated	  3	  times.	  
	  
After	  washing,	  100µl	  of	  Enzyme	  Antibody	  Conjugate	  were	  added	  to	  each	  well,	  and	  the	  
plate	  incubated	  for	  a	  further	  30	  minutes.	  The	  well	  contents	  were	  again	  emptied	  and	  
washed	  four	  times.	  One	  hundred	  microlitres	  of	  the	  supplied	  substrate	  solution	  was	  then	  
added	  to	  each	  well,	  and	  the	  plate	  incubated	  in	  a	  dark	  room	  at	  room	  temperature	  for	  10	  
minutes.	  One	  hundred	  microlitres	  of	  the	  supplied	  stop	  solution	  were	  then	  added	  to	  
each	  of	  the	  wells	  and	  analysis	  undertaken	  within	  30	  minutes.	  Lactoferrin	  concentration	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was	  determined	  using	  an	  Opsys	  MR	  fluorescence	  microplate	  reader	  (DYNEX	  
Technologies,	  Worthing,	  UK),	  set	  at	  450	  nm.	  The	  reader	  produced	  standard	  curves,	  fit	  to	  
a	  four-­‐parameter	  logistics	  curve,	  which	  was	  used	  to	  calculate	  concentrates	  for	  each	  
well.	  	  All	  samples	  were	  analysed	  in	  duplicate	  to	  test	  the	  inter-­‐assay	  precision	  and	  the	  
mean	  value	  was	  taken.	  	  
	  
6.4 Sample	  size	  calculation	  
The	  study	  was	  powered	  to	  detect	  a	  clinically	  significant	  difference	  between	  groups	  in	  
terms	  of	  microbial	  culture	  colony	  count.	  For	  any	  surrogate	  marker	  of	  inflammation	  or	  
infection	  we	  should	  expect	  discriminatory	  power	  at	  least	  as	  effective	  as	  colony	  counts.	  
This	  study	  was	  therefore	  powered	  to	  function	  within	  those	  strictures.	  	  Pilot	  data	  
demonstrated	  that	  the	  standard	  deviation	  of	  the	  log	  bacterial	  count	  was	  2	  (sd=2.0),	  and	  
the	  standardised	  mean	  difference	  in	  log	  bacterial	  counts	  was	  0.5	  (f=0.5).	  A	  sample	  size	  
of	  20	  subjects	  in	  each	  group	  would	  provide	  83%	  power	  to	  detect	  a	  significant	  difference	  
in	  log	  bacterial	  growth	  at	  the	  5%	  level	  (α=0.05).	  
	  
6.5 Statistical	  Analysis	  
The	  primary	  statistical	  analysis	  was	  to	  determine	  the	  difference	  in	  urinary	  IL6	  and	  
Lactoferrin	  in	  patients	  compared	  to	  controls.	  The	  secondary	  analyses	  were	  to	  explore	  
the	  relationship	  between	  these	  urinary	  markers	  of	  inflammation	  and	  bacterial	  growth,	  
lower	  urinary	  tract	  symptoms	  and	  function.	  	  The	  primary	  outcome	  data	  were	  assessed	  
for	  normality	  using	  Q-­‐Q	  plots,	  and	  parametric	  methods	  of	  analysis	  used	  as	  the	  data	  
were	  normally	  distributed.	  Data	  from	  patients	  and	  controls	  were	  pooled	  to	  compare	  the	  
performance	  of	  urine	  cytokines	  in	  relation	  to	  pyuria,	  bacterial	  growth	  by	  enhanced	  
sediment	  culture	  and	  symptoms,	  in	  patients	  and	  controls.	  A	  linear	  mixed-­‐effects	  models	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analysis	  was	  used	  to	  analyse	  the	  data	  to	  take	  into	  account	  the	  repeated	  measures.	  This	  
was	  undertaken	  using	  the	  linear	  mixed-­‐effects	  models	  procedure	  in	  SPSS.	  Urinary	  IL6	  
and	  Lactoferrin	  were	  designated	  as	  the	  dependent	  variables,	  and	  other	  measures	  
entered	  as	  independent	  covariates	  in	  the	  model.	  The	  analysis	  was	  undertaken	  with	  the	  
supervision	  of	  a	  statistician	  familiar	  with	  the	  analysis	  of	  multilevel	  models	  in	  SPSS.	  	  
	  
6.6 Results	  
Between	  April	  2011	  and	  September	  2013,	  24	  female	  patients	  with	  OAB	  (mean	  age=63;	  
sd=11)	  and	  22	  asymptomatic	  control	  subjects	  (mean	  age	  59;	  sd	  =	  9)	  were	  recruited.	  
Both	  groups	  were	  matched	  for	  menopausal	  status	  and	  BMI.	  There	  was	  1	  drop-­‐out	  from	  
the	  patient	  group	  and	  1	  drop-­‐out	  from	  the	  control	  group.	  These	  results	  are	  from	  the	  
pooled	  data	  from	  144	  OAB	  patient	  visits	  and	  136	  control	  visits.	  	  
	  
The	  linear	  mixed-­‐effects	  models	  procedure	  was	  used	  to	  analysis	  the	  longitudinal	  data	  
and	  explores	  the	  relationship	  between	  urinary	  IL6	  and	  urgency	  score,	  pain	  score,	  LUTS	  
score,	  pyuria	  and	  microbial	  growth	  on	  enhanced	  sediment	  culture.	  In	  the	  first	  model	  the	  
independent	  covariate	  was	  the	  group	  (0	  or	  1	  /	  control	  or	  patient),	  the	  dependant	  
variable	  IL6	  and	  the	  repeated	  variables	  were	  indexed	  on	  visit	  number.	  There	  was	  a	  
significant	  difference	  in	  urinary	  IL6	  between	  patients	  and	  controls	  (Table	  6.1).	  	  
	  
Table	  6.1	  –	  Linear	  mixed	  models	  analysis	  with	  IL6	  as	  the	  dependant	  variable	  
Parameter	   Parameter	  estimate*	  	   Significance	  
Group	  
16.1	  (Mean	  =	  -­‐0.24	  95%	  CI	  =	  -­‐0.31	  to	  -­‐0.57;	  t=	  -­‐6.8;	  
df	  =	  42.2	  )	  
P<.0001	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  group	  (control	  =	  0	  
and	  patient	  =	  1)	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In	  the	  second	  model	  the	  dependant	  variable	  was	  log	  IL6	  and	  the	  independent	  covariates	  
were	  the	  group	  number	  (0/1),	  urgency	  score,	  pain	  score,	  LUTS	  score,	  log	  pyuria	  and	  log	  
total	  microbial	  growth.	  The	  repeated	  variables	  were	  indexed	  on	  visit	  number.	  Table	  6.2	  
shows	  the	  results;	  it	  can	  be	  seen	  that	  pyuria	  count	  (log10	  wbc	  µl
-­‐1)	  proved	  a	  significant	  
predictor	  of	  IL6	  however	  total	  bacterial	  growth	  (log10	  CFU	  ml
-­‐1),	  epithelial	  cell	  count	  
(log10	  epc	  µl
-­‐1)	  and	  the	  symptoms	  scores	  did	  not.	  
	  
Table	  6.2	  -­‐	  Mixed	  models	  analysis	  with	  IL6	  as	  the	  dependant	  variable	  	  
Dependent	  variable	  	   Parameter	  estimate*	  	   Significance	  
Group	   0.12	  (F	  =	  2.34;	  sd	  =	  0.03;	  df	  =	  57.4)	   P=.13	  
LUTS	  score	   0.09	  (F	  =	  0.24;	  sd	  =	  0.02;	  df	  =	  79.0)	   P=.63	  
Urgency	   0.08	  (F	  =	  0.16;	  sd	  =	  0.02;	  df	  =	  213.2)	   P=.69	  
Pain	   0.16	  (F	  =	  0.76;	  sd	  =	  0.04;	  df	  =	  182.4)	   P=0.39	  
Bacterial	  growth§	   0.08	  (F	  =	  2.64;	  sd	  =	  0.02;	  df	  =	  227.9)	   P=.11	  
Pyuria	  count†	   0.18	  (F	  =	  64.4;	  sd	  =	  0.04;	  df	  =	  237.0)	   P=<.0001	  
Epithelial	  count*	   0.13	  (F	  =	  0.05;	  sd	  =	  0.03;	  df	  =	  227.9)	   P=.106	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  by	  patients	  
compared	  with	  control	  subjects	  during	  the	  study;	  §Bacterial	  growth:	  log	  cfu	  ml-­‐1;	  †Pyuria	  count:	  wbc	  
ul-­‐1;	  *Epithelial	  count:	  epc	  ul-­‐1;	  	  
	  
	  
Mean	  urinary	  IL6	  was	  found	  to	  be	  significantly	  higher	  in	  patients	  when	  compared	  with	  
controls	  across	  each	  visit	  (figure	  6.2).	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Figure	  6.2	  –	  Mean	  Log	  IL6	  in	  patients	  and	  controls	  at	  each	  visit.	  
	  
The	  linear	  mixed-­‐effects	  models	  procedure	  was	  used	  to	  analyse	  the	  longitudinal	  data	  
and	  explore	  the	  relationship	  between	  urinary	  Lactoferrin	  and	  urgency	  score,	  pain	  score,	  
LUTS	  score,	  pyuria	  and	  microbial	  growth	  on	  enhanced	  sediment	  culture.	  In	  the	  first	  
model	  the	  independent	  covariate	  was	  the	  group	  (0	  or	  1	  /	  control	  or	  patient),	  the	  
dependant	  variable	  Lactoferrin,	  and	  the	  repeated	  variables	  were	  indexed	  on	  visit	  
number.	  	  There	  was	  a	  significant	  difference	  in	  urinary	  Lactoferrin	  between	  patients	  and	  
controls	  (table	  6.3).	  	  
	  
Table	  6.3	  –	  Linear	  mixed	  models	  analysis	  with	  Lactoferrin	  as	  the	  dependant	  variable	  
Parameter	   Parameter	  estimate*	  	   Significance	  
Group	  
51.8	  (Mean	  =	  -­‐1.27	  95%	  CI	  =	  -­‐1.10	  to	  -­‐1.44;	  t=	  -­‐6.8;	  
df	  =	  42.7	  )	  
P<.0001	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  group	  (control	  =	  0	  




A	  multiple	  mixed-­‐effects	  models	  analysis	  was	  performed	  where	  the	  dependant	  variable	  
was	  log	  Lactoferrin	  and	  the	  independent	  covariates	  were	  the	  group	  number	  (0/1),	  LUTS	  
score,	  urgency	  score,	  pain	  score,	  log	  total	  microbial	  growth	  and	  log	  pyuria.	  Table	  6.4	  
shows	  the	  results	  for	  each	  of	  these	  parameters.	  	  The	  predictors	  of	  Lactoferrin	  proved	  to	  
be	  the	  total	  bacterial	  growth	  (log10	  CFU	  ml
-­‐1),	  pyuria	  count	  (log10	  wbc	  µl
-­‐1)	  however	  
epithelial	  cell	  (log10	  wbc	  µl
-­‐1)	  count	  and	  symptoms	  did	  not.	  	  
	  
Table	  6.4	  -­‐	  Mixed	  models	  analysis	  with	  Lactoferrin	  as	  the	  dependant	  variable	  	  
Dependent	  variable	  	   Parameter	  estimate*	  	   Significance	  
Group	   0.10	  (F	  =	  25.19;	  sd	  =	  0.03;	  df	  =	  70.6)	   P=<.0001	  
LUTS	  score	   0.14	  (F	  =	  1.67;	  sd	  =	  0.02;	  df	  =	  180.0)	   P=.198	  
Urgency	   0.11	  (F	  =	  0.08;	  sd	  =	  0.02;	  df	  =	  228.1)	   P=.782	  
Pain	   0.07	  (F	  =	  3.89;	  sd	  =	  0.04;	  df	  =	  178.3)	   P=.050	  
Bacterial	  growth§	   0.27	  (F	  =	  4.54;	  sd	  =	  0.02;	  df	  =	  201.5)	   P=.034	  
Pyuria	  count†	   0.25	  (F	  =	  56.65;	  sd	  =	  0.04;	  df	  =	  179.4)	   P=<.0001	  
Epithelial	  count*	   0.11	  (F	  =	  0.001;	  sd	  =	  0.03;	  df	  =	  187.7)	   P=.970	  
	  
*Parameter	  estimate:	  Increase	  in	  magnitude	  of	  dependent	  variable	  demonstrated	  by	  patients	  
compared	  with	  control	  subjects	  during	  the	  study;	  §Bacterial	  growth:	  log	  cfu	  ml-­‐1;	  †Pyuria	  count:	  wbc	  
ul-­‐1;	  *Epithelial	  count:	  epc	  ul-­‐1;	  	  
	  
Mean	  urinary	  Lactoferrin	  was	  found	  to	  be	  significantly	  higher	  in	  the	  patient	  group	  when	  





Figure	  6.3–	  Mean	  Log	  Lactoferrin	  in	  patients	  and	  controls	  at	  each	  visit.	  
	  
Between	  log	  pyuria	  and	  log	  bacterial	  growth	  there	  was	  a	  correlation	  of	  0.61.	  There	  was	  
a	  correlation	  of	  0.63	  between	  log	  IL6	  and	  log	  pyuria.	  	  A	  similar	  correlation	  of	  0.67	  was	  
found	  between	  log	  pyuria	  and	  log	  Lactoferrin.	  	  Between	  log	  IL6	  and	  log	  Lactoferrin	  there	  
was	  a	  correlation	  of	  0.58.	  
	  
6.7 Discussion	  
This	  is	  first	  prospective	  study	  that	  has	  addressed	  the	  role	  of	  infection	  and	  inflammation	  
in	  the	  generation	  of	  OAB	  symptoms.	  	  From	  cross-­‐sectional	  data	  there	  is	  a	  growing	  body	  
of	  evidence	  that	  bacterial	  infection	  may	  play	  a	  role	  in	  the	  LUTS	  and	  OAB.	  In	  this	  study	  
the	  patient	  group	  and	  control	  were	  matched	  for	  age,	  BMI	  and	  menopause	  status	  and	  
statistical	  power	  was	  maintained	  given	  the	  sample	  size.	  There	  was	  a	  significant	  
difference	  in	  the	  microbial	  growth,	  pyuria,	  urinary	  IL6	  and	  Lactoferrin	  in	  the	  patient	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group	  compared	  with	  the	  control	  group.	  	  In	  the	  longitudinal	  study	  there	  was	  a	  
significant	  difference	  in	  the	  microbial	  growth	  and	  pyuria	  in	  the	  patient	  group	  compared	  
with	  the	  control	  group.	  	  
	  
Urinary	  IL6	  had	  an	  association	  with	  pyuria.	  Increased	  urinary	  IL6	  secretion	  has	  been	  
demonstrated	  in	  prospective	  studies	  of	  acute	  UTI	  (93).	  Bacteria	  are	  able	  to	  trigger	  an	  
innate	  immune	  response	  by	  activating	  epithelial	  cells.	  Like	  other	  mucosal	  surfaces,	  the	  
lining	  of	  the	  urinary	  tract	  contains	  receptors	  capable	  of	  recognizing	  intruding	  pathogens	  
by	  pathogen	  associated	  molecular	  patterns	  (PAMPS).	  Of	  the	  various	  immune	  
surveillance	  molecules	  the	  Toll-­‐like	  receptor	  (TLR)	  family	  is	  the	  best	  characterized.	  
Mechanisms	  proposed	  involve	  bacterial	  adherence	  and	  TLR4	  signalling.	  In	  vivo	  studies	  
where	  there	  has	  been	  a	  bacterial	  challenge	  to	  urothelial	  cells,	  a	  rapid	  cytokine	  response	  
was	  observed,	  with	  production	  of	  interleukin-­‐1beta	  (IL-­‐1beta),	  IL-­‐6,	  and	  IL-­‐8.	  In	  this	  
study	  type	  1-­‐fimbriated	  E.	  coli	  activated	  IL-­‐6	  and	  IL-­‐8	  production	  more	  efficiently	  than	  
the	  non-­‐fimbriated	  (Samuelsson	  2004).	  IL-­‐6	  is	  detected	  in	  the	  urine	  at	  the	  time	  of	  
diagnosis	  in	  most	  patients	  with	  bacteria	  in	  the	  urinary	  tract,	  however,	  IL-­‐6	  was	  only	  
detected	  in	  the	  serum	  of	  symptomatic	  patients	  (91)	  .	  These	  observations	  suggested	  that	  
the	  cytokine	  response	  during	  UTI	  could	  have	  local	  and	  systemic	  components.	  Epithelial	  
cells	  are	  thought	  to	  be	  responsible	  for	  the	  local	  cytokine	  response	  (88,	  100,	  160).	  
Studies	  have	  shown	  that	  IL6	  production	  increases	  neutrophil	  migration	  and	  activation	  of	  
IL8	  (161,	  162).	  	  Adhering	  bacteria	  and	  isolated	  P	  fimbriae	  stimulate	  higher	  levels	  of	  IL-­‐6	  
production	  in	  cells	  that	  express	  the	  globoseries	  of	  glycolipids	  such	  as	  kidney	  epithelial	  
cells.	  Uroepithelial	  cells	  also	  respond	  to	  stimulation	  by	  cytokines;	  IL-­‐1alpha	  and	  
TNFalpha	  induce	  the	  secretion	  of	  IL-­‐6	  and	  IL-­‐8	  and	  the	  upregulation	  of	  mRNAs	  for	  IL-­‐





Further	  data	  from	  prospective	  studies	  of	  UTI	  are	  needed	  to	  improve	  our	  understanding	  
of	  its	  role	  in	  infection.	  There	  is	  a	  complex	  regulation	  of	  the	  production	  of	  Interleukin-­‐6	  
by	  membrane-­‐bound	  and	  soluble	  receptors,	  which	  are	  modulated	  by	  a	  host	  of	  other	  
influences	  (164).	  	  Strains	  of	  UPEC	  have	  developed	  strategies	  to	  evade	  immune	  response	  
by	  suppressing	  cytokine	  reactions	  to	  infection	  (149,	  165,	  166).	  Whilst	  the	  onset	  of	  acute	  
bacterial	  cystitis	  appears	  to	  be	  associated	  with	  an	  increase	  in	  urinary	  IL6	  secretion	  (93),	  
this	  study	  would	  suggest	  it	  has	  a	  role	  in	  chronic	  infection.	  	  	  
	  
Urinary	  Lactoferrin	  was	  associated	  with	  pyuria	  and	  microbial	  growth.	  	  Lactoferrin	  is	  a	  
functional	  protein	  of	  the	  transferring	  family.	  	  It	  is	  part	  of	  our	  innate	  immune	  defence	  at	  
mucosal	  surfaces.	  Lactoferrin’s	  primary	  role	  is	  to	  sequester	  free	  iron.	  	  Iron	  is	  a	  nutrient	  
essential	  for	  bacterial	  growth	  and	  survival.	  	  Hence	  in	  doing	  so,	  Lactoferrin	  competes	  
directly	  with	  bacteria	  and	  removes	  an	  essential	  substrate	  needed	  for	  bacterial	  growth	  
(167).	  	  	  It	  can	  therefore	  be	  proposed	  that	  when	  there	  is	  an	  increase	  in	  bacterial	  load,	  
urinary	  Lactoferrin	  would	  be	  elevated.	  It	  has	  also	  been	  proposed	  that	  the	  antibacterial	  
action	  of	  Lactoferrin	  is	  explained	  by	  the	  presence	  of	  specific	  receptors	  on	  the	  cell	  
surface	  of	  microorganisms.	  The	  mechanism	  for	  this	  is	  via	  binding	  to	  the	  
lipopolysaccharide	  (LPS)	  of	  the	  bacterial	  wall	  and	  the	  oxidation	  of	  the	  bacteria	  via	  
formation	  of	  peroxides.	  This	  affects	  the	  membrane	  permeability	  and	  results	  in	  the	  
cellular	  lysis	  (167).	  
	  
Lactoferrin	  has	  other	  antibacterial	  mechanisms	  not	  related	  to	  iron,	  such	  as	  stimulation	  
of	  phagocytosis.	  	  However	  it	  is	  thought	  that	  the	  dominant	  mechanism	  of	  action	  is	  via	  its	  
iron	  binding	  properties	  and	  interaction	  with	  LPS	  of	  the	  bacterial	  cell	  wall	  (168,	  169).	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Lactoferrin’s	  binding	  to	  the	  bacteria	  wall	  is	  associated	  with	  the	  specific	  peptide	  
lactoferricin,	  which	  is	  located	  at	  the	  N-­‐lobe	  of	  Lactoferrin	  and	  is	  produced	  by	  in	  vitro	  
cleavage	  of	  Lactoferrin	  with	  trypsin	  (170,	  171).	  The	  antimicrobial	  action	  of	  Lactoferrin	  
has	  also	  been	  reported	  via	  targeting	  H+-­‐ATPase	  and	  interference	  with	  proton	  
translocation	  in	  the	  cell	  membrane,	  resulting	  in	  a	  lethal	  effect	  in	  vitro,	  as	  well	  as	  
preventing	  attachment	  (172).	  	  
	  
Bortner	  et	  al.	  (1989)	  proposed	  that	  this	  iron-­‐independent	  Lactoferrin	  killing	  was	  a	  result	  
of	  a	  direct	  interaction	  of	  Lactoferrin	  with	  the	  bacterial	  surface	  (173).	  	  Lactoferrin	  has	  
been	  shown	  to	  interact	  with	  LPS	  of	  the	  Gram-­‐negative	  bacterial	  membrane	  of	  E.	  coli,	  
with	  the	  release	  of	  the	  LPS	  from	  the	  membrane	  (174).	  	  However,	  this	  release	  was	  
blocked	  by	  addition	  of	  Ca2+	  and	  Mg2+	  ions,	  suggesting	  the	  importance	  of	  these	  divalent	  
cations	  as	  modulators	  for	  the	  antimicrobial	  activity	  of	  Lactoferrin	  (173).	  Lactoferrin	  
sensitive	  strains	  of	  Legionella	  pneumophila	  were	  protected	  from	  killing	  by	  addition	  of	  
calcium	  chloride,	  magnesium	  nitrate	  and	  magnesium	  chloride,	  however	  addition	  of	  
sodium	  chloride	  had	  no	  effect	  (173).	  Kalmar	  et	  al	  showed	  that	  Mg2+	  ions	  decreased	  
Lactoferrin	  killing,	  whereas	  the	  addition	  of	  Ca2+	  or	  K+	  ions	  had	  no	  affect	  on	  the	  
antimicrobial	  activity	  of	  Lactoferrin	  (175).	  
	  
Studies	  have	  suggested	  that	  Lactoferrin	  binds	  to	  the	  isolated	  lipid	  A	  portion	  of	  LPS	  
(174).	  The	  N-­‐terminal	  region	  of	  Lactoferrin,	  which	  includes	  the	  lactoferricin	  peptide	  
sequence,	  was	  shown	  to	  be	  involved	  in	  the	  binding	  of	  intact	  Lactoferrin	  to	  the	  LPS	  of	  E.	  
coli	  055B5	  (176).	  Lactoferrin	  has	  also	  been	  shown	  to	  interact	  reversibly	  with	  porins	  of	  
the	  E.	  coli	  membrane.	  	  However	  these	  porins	  may	  be	  shielded	  from	  attack	  by	  the	  
polysaccharide	  portion	  of	  the	  LPS	  hence	  decreasing	  antibacterial	  activity	  (177).	  	  The	  
susceptibility	  of	  the	  bacteria	  to	  Lactoferrin	  is	  thought	  to	  be	  dependent	  on	  their	  growth	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phase	  since	  bacteria	  are	  more	  susceptible	  to	  killing	  by	  Lactoferrin	  when	  in	  early	  phase	  
(173,	  175).	  The	  binding	  of	  Lactoferrin	  to	  these	  bacteria	  was	  temperature	  sensitive	  with	  
no	  binding	  at	  4°C.	  Although	  binding	  was	  shown	  to	  be	  independent	  of	  killing,	  a	  decrease	  
in	  the	  pH	  of	  the	  media	  increased	  the	  sensitivity	  of	  the	  bacteria	  (173).	  	  Lactoferrin	  has	  
also	  been	  shown	  to	  modulate	  the	  activity	  of	  known	  antibacterial	  agents	  such	  as	  
lysozyme	  and	  antibiotics,	  with	  the	  potential	  of	  working	  synergistically	  (178,	  179).	  	  
	  
These	  data	  are	  the	  first	  prospective	  study	  using	  a	  consilience	  approach,	  to	  demonstrate	  
an	  association	  between	  bacterial	  infection,	  markers	  of	  urothelial	  inflammation	  and	  the	  
overactive	  bladder	  symptoms.	  	  This	  work	  has	  helped	  to	  explore	  the	  role	  of	  infection	  and	  
inflammation	  in	  patients	  with	  symptoms	  of	  overactive	  bladder,	  however	  more	  work	  is	  
needed	  to	  improve	  our	  understanding	  of	  the	  precise	  mechanisms	  involved	  in	  the	  
generation	  of	  such	  symptoms.	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7 Chapter	  7	  –	  General	  Discussion	  and	  Conclusions	  
	  
Exclusion	  of	  a	  urinary	  tract	  infection	  is	  a	  universal	  mandatory	  first	  step	  in	  the	  
management	  of	  patients	  with	  lower	  urinary	  tract	  symptoms.	  	  Serious	  concerns	  have	  
been	  raised	  about	  the	  performance	  of	  current	  diagnostic	  tests	  commonly	  used	  to	  
exclude	  UTI	  (40,	  42,	  43,	  48,	  180,	  181).	  These	  tests	  have	  been	  found	  to	  perform	  so	  poorly	  
that	  we	  should	  doubt	  whether	  urinary	  infection	  was	  ever	  reliably	  excluded	  in	  the	  
studies	  that	  characterised	  OAB.	  Thus	  it	  is	  appropriate	  to	  re-­‐visit	  this	  common	  condition	  
and	  scrutinise	  it	  carefully	  for	  evidence	  of	  infection	  or	  inflammation	  that	  may	  have	  been	  
missed	  in	  the	  past.	  A	  role	  for	  infection	  in	  the	  generation	  of	  LUTS	  and	  OAB	  symptoms	  has	  
been	  postulated	  in	  recent	  times	  (101,	  102,	  182,	  183).	  This	  study	  explored	  the	  presence	  
of	  infection	  and	  inflammation	  in	  patients	  with	  LUTS	  and	  OAB	  symptoms.	  	  Data	  were	  
collected	  using	  a	  comparative	  method	  that	  included	  asymptomatic	  normal	  controls.	  
These	  were	  used	  to	  determine	  whether	  patients	  with	  OAB	  symptoms	  demonstrated	  
evidence	  of	  urinary	  infection	  or	  inflammation	  that	  would	  be	  missed	  by	  usual	  routine	  
testing.	  The	  relationship	  between	  bacterial	  infection,	  urinary	  inflammation	  and	  OAB	  
symptoms	  was	  also	  explored	  as	  part	  of	  a	  consilience	  approach.	  Since	  urinary	  ATP	  has	  
been	  promoted	  as	  a	  potential	  test	  for	  OAB	  and	  for	  UTI,	  this	  proposition	  was	  
investigated.	  However,	  there	  was	  no	  intention	  of	  exploring	  any	  of	  the	  other	  markers	  as	  
potential	  clinical	  tests.	  	  The	  history	  of	  this	  subject	  contains	  numerous	  examples	  of	  the	  
problems	  of	  co-­‐opting	  a	  novel	  pathological	  observation	  in	  order	  to	  design	  a	  clinical	  test.	  




7.1 Limitations	  and	  weaknesses	  	  
Patients	  with	  overactive	  bladder	  symptoms	  were	  recruited	  along	  with	  controls	  to	  
explore	  the	  presence	  of	  infection	  and	  inflammation	  using	  a	  number	  of	  independent	  
markers	  of	  infection.	  Symptoms	  were	  measured	  using	  three	  different	  validated	  tools	  
but	  quality	  of	  life	  (QOL)	  was	  not	  included.	  Lower	  urinary	  tract	  symptoms	  and	  OAB	  
symptoms	  are	  more	  common	  in	  females	  although	  significant	  numbers	  of	  men	  also	  
suffer.	  In	  the	  longitudinal	  study	  only	  female	  patients	  were	  included.	  Although	  the	  total	  
number	  of	  patient	  samples	  was	  large,	  the	  numbers	  were	  insufficient	  to	  permit	  any	  sub-­‐
group	  analyses.	  
	  
All	  patients	  and	  controls	  provided	  clean	  catch	  midstream	  urine	  samples.	  The	  use	  of	  
catheter	  sampling	  in	  subjects	  would	  have	  been	  unacceptable,	  particularly	  as	  the	  data	  
were	  collected	  prospectively	  over	  multiple	  visits.	  Clear	  direction	  and	  a	  specific	  protocol	  
were	  used	  to	  minimise	  contamination	  however	  some	  contamination	  may	  have	  
occurred.	  	  
	  
The	  culture	  methods	  used	  in	  this	  work	  were	  favourable	  for	  growth	  of	  aerobic	  
uropathogens.	  	  Culture	  conditions	  and	  techniques	  for	  detection	  of	  fastidious	  and	  
anaerobic	  organisms	  were	  not	  used	  and	  this	  may	  have	  influenced	  the	  findings.	  	  In	  
addition,	  the	  majority	  of	  bacteria	  were	  identified	  to	  genus	  level.	  Species	  detection	  by	  
ribotyping	  and	  API	  testing	  were	  not	  performed.	  The	  use	  of	  culture	  methods	  limits	  the	  
detection	  of	  viable	  but	  non-­‐culturable	  organisms	  (VBNC).	  	  Alternative	  methods	  of	  
molecular	  testing	  using	  16s	  ribotyping	  were	  considered.	  However	  this	  method	  limits	  
quantification	  of	  bacteria,	  which	  was	  possible	  using	  culture	  techniques.	  	  In	  addition,	  
molecular	  methods	  can	  also	  produce	  a	  plethora	  of	  organisms	  with	  no	  information	  on	  
their	  pathogeneric	  properties	  or	  whether	  they	  are	  alive.	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7.2 Urinary	  ATP	  as	  a	  marker	  of	  infection	  	  
There	  is	  now	  much	  evidence	  to	  show	  that	  the	  current	  tests	  used	  to	  exclude	  UTI	  are	  not	  
adequate.	  The	  problems	  affect	  the	  culture	  methods	  used	  to	  exclude	  UTI	  and	  the	  
surrogate	  tests;	  dipsticks	  and	  even	  microscopy	  for	  pyuria.	  The	  current	  gold	  standard	  
used	  in	  most	  UK	  laboratories	  continues	  to	  be	  microbial	  culture	  of	  a	  single	  known	  urinary	  
pathogen	  of	  more	  then	  105	  cfu	  ml-­‐1.	  	  This	  threshold	  first	  purposed	  by	  Kass	  (1957)	  for	  
women	  with	  clinical	  pyelonephritis,	  suffers	  from	  spectrum	  bias	  and	  should	  not	  be	  used	  
to	  screen	  all	  patients	  with	  LUTS	  (38,	  40).	  	  In	  addition,	  there	  is	  now	  much	  evidence	  for	  
polymicrobial	  infection	  as	  opposed	  to	  infection	  from	  a	  single	  predominate	  organism	  
(41,	  150,	  184).	  It	  is	  now	  well	  recognised	  that	  the	  threshold	  used	  to	  define	  acute	  
infection	  of	  the	  lower	  urinary	  tract	  is	  much	  too	  high	  (46,	  48,	  180,	  185,	  186).	  Hence	  use	  
of	  these	  tests	  in	  patients	  with	  chronic	  infection	  needs	  to	  be	  interpreted	  with	  caution	  
(47).	  Very	  few	  studies	  have	  looked	  at	  the	  use	  of	  dipsticks	  and	  culture	  in	  patients	  with	  
chronic	  LUTS	  (187-­‐189).	  There	  is	  much	  work	  need	  to	  explore	  alternative	  methods	  to	  
screen	  for	  infection	  in	  patients	  with	  LUTS.	  ATP	  has	  been	  proposed	  as	  a	  potential	  clinical	  
marker	  for	  acute	  and	  chronic	  urinary	  tract	  disease	  (37,	  124,	  190).	  Optimum	  clinical	  
sampling	  methods	  were	  reviewed	  along	  with	  whether	  urinary	  ATP	  explains	  the	  
symptoms	  and	  markers	  of	  infection.	  This	  study	  finds	  that	  urinary	  ATP	  showed	  little	  
concordance	  with	  the	  clinical	  consequences	  of	  urinary	  infection	  in	  chronic	  LUTS,	  and	  
therefore	  does	  not	  show	  promise	  for	  future	  development	  of	  a	  diagnostic	  test	  for	  this	  
particular	  disease.	  Urinary	  ATP	  was	  found	  lacking	  and	  did	  not	  improve	  on	  fresh	  
microscopy	  of	  urine	  to	  screen	  for	  infection.	  There	  is	  need	  to	  explore	  other	  potential	  
markers	  that	  can	  be	  used	  to	  screen	  for	  infection	  in	  LUTS	  patients,	  particularly	  applicable	  
to	  those	  that	  have	  lower	  levels	  of	  pyuria,	  where	  significant	  disease	  may	  currently	  be	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overlooked.	  Abundant	  urinary	  ATP	  is	  certainly	  evident	  in	  the	  presence	  of	  significant	  
disease	  amongst	  patients	  with	  LUTS	  and	  these	  data	  do	  encourage	  continued	  interest	  in	  
the	  pharmacology	  and	  pathophysiology	  of	  purinergic	  functions	  in	  the	  bladder.	  	  	  
	  
7.3 The	  cytokine	  response	  in	  OAB	  	  
The	  proposed	  relationship	  between	  urinary	  infection	  and	  the	  generation	  of	  OAB	  
symptoms	  has	  been	  suggested	  from	  cross-­‐sectional	  studies.	  The	  literature	  has	  a	  range	  
of	  potential	  biomarkers	  for	  OAB	  but	  none	  have	  been	  reviewed	  in	  relation	  to	  chronic	  
infection	  and	  the	  generation	  of	  OAB	  symptoms.	  	  This	  is	  the	  first	  study	  to	  explore	  urinary	  
IL6,	  CXCL	  8,	  Lactoferrin,	  Tamm-­‐Horsfall	  Protein	  (THP),	  Monocyte	  Chemoatractant	  
Protein-­‐1	  (MCP)	  and	  Nerve	  Growth	  Factor	  (NGF)	  in	  patients	  with	  OAB	  symptoms,	  as	  
compared	  to	  asymptomatic	  controls,	  in	  relation	  to	  other	  markers	  of	  inflammation.	  
Urinary	  IL6	  and	  Lactoferrin	  showed	  a	  significant	  difference	  between	  patients	  and	  
controls.	  Levels	  of	  urinary	  IL6	  and	  Lactoferrin	  varied	  in	  relation	  to	  pyuria	  and	  total	  
microbial	  growth	  suggesting	  a	  correlation	  between	  inflammation	  and	  bacterial	  infection	  
in	  a	  symptomatic	  population.	  The	  methods	  used	  in	  this	  work	  were	  hypothesis	  driven.	  	  
Others	  have	  conducted	  similar	  work	  but	  used	  micro-­‐array	  methods	  to	  screen	  very	  large	  
numbers	  of	  potential	  markers.	  Such	  an	  approach	  is	  susceptible	  to	  numerous	  Type	  2	  
errors	  because	  probability	  favours	  the	  occurrence	  of	  chance	  correlations	  unrelated	  to	  
causative	  associations.	  This	  problem	  is	  best	  avoided	  by	  adopting	  a	  hypothesis-­‐based	  
approach	  that	  scrutinises	  a	  limited	  number	  of	  plausible	  candidates.	  I	  selected	  this	  panel	  
of	  cytokines	  on	  my	  understanding	  of	  the	  pathophysiology	  being	  studied	  and	  used	  
conventional	  empirical	  science	  to	  prove	  or	  refute	  a	  hypothesis.	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7.4 Urinary	  infection	  and	  inflammation	  in	  OAB	  	  
The	  current	  diagnostic	  tests	  used	  to	  screen	  for	  infection	  are	  clearly	  inadequate	  and	  
urinary	  infection	  is	  being	  missed	  through	  use	  of	  fixed	  diagnostic	  thresholds.	  	  Using	  new	  
culture	  techniques	  looking	  at	  the	  urinary	  sediment,	  there	  was	  a	  distinct	  difference	  
found	  in	  the	  urinary	  ecology	  between	  patients	  with	  OAB	  symptoms	  and	  matched	  
controls.	  	  This	  was	  supported	  by	  evidence	  of	  urothelial	  inflammation	  through	  
examination	  of	  pyuria,	  epithelial	  cell	  shedding	  and	  urinary	  cytokines.	  Whilst	  
quantitative	  differences	  in	  bacterial	  growth	  were	  observed,	  there	  was	  additionally	  a	  
difference	  in	  the	  organisms	  found	  in	  those	  with	  symptoms;	  with	  recognised	  
uropathogens	  including	  E.	  coli	  and	  Enterococcus	  spp.	  isolated	  more	  frequently.	  Routine	  
urine	  culture	  did	  not	  detect	  these	  differences.	  These	  ecological	  findings	  were	  associated	  
with	  evidence	  of	  increased	  urothelial	  inflammation	  amongst	  patients,	  implying	  that	  
these	  microbes	  might	  be	  more	  than	  harmless	  contaminants.	  
	  
The	  proposed	  relationship	  between	  urinary	  infection	  and	  the	  generation	  of	  OAB	  
symptoms	  was	  studied.	  An	  observational	  cohort	  study	  was	  undertaken	  with	  patients	  
and	  controls	  matched	  for	  key	  demographic	  characteristics	  and	  monitored	  at	  twelve	  
study	  visits	  over	  a	  one-­‐year	  period.	  Pyuria	  and	  epithelial	  cell	  shedding	  was	  associated	  
with	  increased	  bacterial	  colony	  counts	  and	  increasing	  pyuria	  was	  associated	  with	  a	  rise	  
in	  bacterial	  load.	  Increasing	  pyuria	  was	  associated	  with	  elevated	  levels	  of	  urinary	  ATP,	  
Lactoferrin	  and	  IL6,	  indicative	  of	  urothelial	  distress	  and	  inflammation,	  although	  the	  
strength	  of	  these	  relationships	  varied.	  
	  
Increasing	  pyuria	  was	  associated	  with	  deterioration	  in	  total	  symptoms,	  epithelial	  cell	  
shedding	  and	  microbial	  growth.	  These	  relationships	  were	  independent	  of	  routine	  
culture	  status.	  These	  controlled,	  prospective	  data	  are	  the	  first	  to	  demonstrate	  a	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significant	  association	  between	  bacterial	  infection,	  urothelial	  inflammation	  and	  the	  
presence	  of	  OAB	  symptoms.	  These	  data	  suggest	  that	  the	  treatment	  of	  presumed	  
bacterial	  infection	  in	  the	  presence	  of	  pyuria	  might	  confer	  significant	  symptomatic	  
benefit.	  	  
	  
7.5 Further	  work	  	  
The	  approach	  to	  the	  diagnosis	  of	  UTI	  needs	  to	  be	  revised	  and	  the	  disease	  should	  no	  
longer	  be	  viewed	  as	  a	  categorical	  dichotomy	  of	  positive	  or	  negative.	  Rather	  than	  
pursuing	  new	  diagnostics,	  to	  define	  the	  presence	  or	  absence	  of	  the	  condition,	  we	  might	  
achieve	  greater	  success	  by	  applying	  Bayesian	  models	  and	  think	  in	  terms	  of	  	  	  
probabilities	  when	  judging	  our	  approach	  to	  the	  treatment	  of	  patients.	  Bayesian	  
methods	  feed	  on	  broad	  knowledge	  and	  a	  deeper	  understanding	  of	  the	  interaction	  
between	  bacteria	  and	  host.	  Biology	  always	  forms	  continua	  and	  is	  inimical	  to	  
categorisation.	  Nowadays	  we	  have	  the	  technology	  needed	  to	  deal	  with	  numerous	  
probability	  distributions	  that	  are	  relevant	  to	  a	  particular	  pathology.	  It	  is	  the	  norm	  for	  
data	  to	  be	  entered	  onto	  computer	  systems.	  There	  is	  no	  reason	  why	  probability	  
calculations	  that	  incorporate	  all	  of	  the	  available	  data	  so	  that	  richer	  analysis	  of	  diagnoses	  
and	  treatment	  decisions	  can	  be	  achieved.	  	  
	  
Studies	  to	  explore	  the	  prevalence	  of	  atypical	  bacterial	  infection	  in	  these	  patients	  would	  
compliment	  this	  work.	  The	  longitudinal	  data	  from	  this	  study	  indicate	  that	  patients	  with	  
OAB	  symptoms	  demonstrate	  evidence	  of	  bacterial	  infection	  and	  hence	  intervention	  




7.6 Conclusions	  	  
The	  hypothesis	  that	  ‘Bacterial	  infection	  of	  the	  lower	  urinary	  tract	  goes	  undetected	  by	  
routine	  diagnostic	  testing	  and	  contributes	  to	  the	  generation	  of	  lower	  urinary	  tract	  
symptoms	  in	  patients	  with	  symptoms	  of	  overactive	  bladder’	  was	  successfully	  tested	  and	  
the	  results	  support	  this	  hypothesis.	  
	  
The	  aims	  of	  the	  study	  were:	  
	  
1.	   To	  explore	  the	  urinary	  inflammatory	  response	  in	  patients	  with	  symptoms	  of	  
overactive	  bladder.	  
	  
Bacterial	  infection	  of	  the	  lower	  urinary	  tract	  goes	  undetected	  by	  routine	  diagnostic	  
testing	  and	  there	  is	  evidence	  of	  urinary	  infection	  and	  inflammation	  in	  patients	  with	  
symptoms	  of	  OAB	  that	  is	  significantly	  different	  to	  asymptomatic	  controls.	  	  
	  
2.	   To	  determine	  the	  relationship	  between	  urothelial	  inflammation,	  manifested	  by	  
pyuria,	  epithelial	  shedding	  and	  microbial	  growth,	  and	  symptom	  variation	  in	  patients	  
with	  symptoms	  of	  overactive	  bladder.	  
	  
Patients	  with	  OAB	  show	  a	  difference	  in	  pyuria	  and	  epithelial	  cell	  shedding	  when	  
compared	  to	  controls.	  	  Patients	  with	  OAB	  show	  significantly	  higher	  microbial	  growth	  
when	  compared	  to	  controls.	  	  When	  explored	  further	  by	  qualitative	  analysis	  the	  bacterial	  
ecology	  in	  patients	  with	  OAB	  is	  distinctly	  different	  to	  controls.	  
	  
3.	   To	  determine	  the	  urinary	  cytokine	  and	  inflammatory	  response	  in	  relation	  to	  
symptom	  exacerbation	  in	  OAB.	  
 148	  
	  
Urinary	  IL6	  and	  Lactoferrin	  were	  found	  to	  be	  significantly	  higher	  in	  patients	  with	  OAB	  
symptoms	  as	  compared	  to	  controls.	  These	  markers	  varied	  in	  accordance	  with	  pyuria,	  
microbial	  growth	  and	  epithelial	  cell	  shedding.	  	  These	  markers	  may	  provide	  promise	  in	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Participant Information Sheet - Patient 
Short title: Immunology of Cystitis and OAB 
 
A blinded observational cohort study of the immunological changes 
associated with chronic cystitis and overactive bladder symptoms in 
women. 
 
Version 2.0,  21st February 2011 
 
We would like to invite you to take part in our research study.  Before you decide 
we should like you to understand why the research is being done and what it 
would involve for you. One of our team will go through the information sheet with 
you and answer any questions you have. We suggest that this should take about 
20 minutes. Talk to others about the study if you wish.  
  
Part 1 tells you the purpose of this study and what will happen to you if you take 
part.   
 
Part 2 gives you more detailed information about the conduct of the study.   
 
Ask us if there is anything that is not clear.  Take time to decide whether or not 
you wish to take part. 
  
Participant Information Sheet – Part 1 
 
 
What is the purpose of the project?  
 
Many people suffer with Overactive Bladder, causing symptoms such as needing 
to rush to the toilet, passing urine frequently (more than 8 times per day and 
once at night) and urinary incontinence (leaking from the bladder). Additionally 
there may be problems with bladder emptying and with recurrent urinary 
Department of Medicine 
1st Floor, Clerkenwell Building 
Archway Campus 
Highgate Hill 
London N19 5LW 
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infection. We recognise that the symptoms are very unpleasant and that the 
urine infections are particularly disruptive.   
 
We have been working with patients who suffer from bladder troubles for many 
years. We have discovered that many of those people with overactive bladder 
symptoms and those with recurrent urine infection demonstrate a previously 
unrecognised inflammatory reaction in the urine that is evident provided that the 
urine is examined very fresh by a light microscope. When these specimens are 
sent to the ordinary laboratory more than half are reported as not showing 
infection, termed culture negative. We have developed a better method for 
analysing the samples that uses very sensitive microbiological methods and 
found that we can identify bacterial infection in over 80%.  
 
We have some evidence that our affected patients are not suffering from 
recurrent urine infection but from the same chronic infection, going on for months 
or years, which from time to time becomes acutely worse for periods. What is 
more, we believe that the bacteria are living inside the cells of the bladder where 
they are protected from immune and antibiotic attack so that treatment has to 
use methods that are different to those used to treat ordinary urinary infection.  
 
We seek to find out whether this is definitely the case in patients with overactive 
bladder. We want to know whether such infections may be adding to the 
problems that affect the bladder. We also want to find out whether treating 
people with antibiotics that we know the bacteria to be sensitive to makes a 
difference to a person’s symptoms. We are also interested in studying newer and 
more sensitive markers of infection. 
 
Why have I been invited? 
 
We hope to include 90 participants in this study which include a mixture of 
people with overactive bladder and others with no bladder symptoms. You have 
been chosen as you: 
• Are female 
• Have symptoms of overactive bladder 
• May or may not have signs of infection in the urine 
 
Do I have to take part?  
 
It is up to you if you decide whether or not to take part. It is up to you to decide to 
join the study. We will describe the study and go through this information sheet. 
If you agree to take part, we will then ask you to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive.  
 
What will happen to me if I take part?  
 
If you decide to take part in the project the research clinician will arrange to see 
you. You will be asked some questions about your bladder symptoms. Your 
answers will be recorded in your confidential research record and stored on a 
computer. This will take about 30 minutes. The computer record is closely 
guarded by the NHS security system so there is no unauthorised access to your 
record.  
 
A urine specimen will be taken by the midstream method. Part of it will be sent to 
the laboratory to check for any bacteria in your urine and another portion will be 
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looked at under the microscope to detect small ‘white blood cells,’ which can 
signify an infection in the urine. Sometimes, tests that look for bacteria in the 
laboratory can come back as negative and looking for white blood cells under the 
microscope is another way to look for infection that may otherwise have been 
missed. We should like to record the results of these in your research recorded. 
The urine will also be used to examine the inflammatory reaction that is occurring 
in your bladder.  A blood sample will also be taken and a skin allergy test 
performed.  These will be required only once throughout the study. 
 
Once we have entered you into the study we should like to review you once a 
month for a year when we shall check your symptoms and obtain a urine sample. 
During this time you will be treated for your symptoms and if there are any signs 
of infection in the urine you will be offered treatment with antibiotics.  As the 
bacteria tend to hide within bladder cells you may need to be on antibiotics for 6-
9 months and will be closely monitored.  This is standard treatment for patients in 
our clinic.  
 
A key inconvenience is that you will need to visit the centre once each month. 





All participants will need to have a blood test at their initial visit. This will involve 
the researcher taking a small blood sample of 20mls from a vein in your arm.  
This may cause some mild bruising of the area which will usually resolve in a few 
days. 
 
Allergy Skin Test 
 
Candida skin tests will be performed on all participants at visit 2.  This is a test 
commonly used to analyse the participants immune response.  This will involve 
having a small injection on the inner side of your lower arm.  The injection site 
will be marked with indelible ink. 48 hours later you will need to come back and 
the site will be checked for signs of redness and this will be measured.  Two 
small skin biopsies (3mm each in size) will be taken under local anaesthetic.  
The local anaesthetic numbs the small area of skin from where the biopsies are 
taken so that it is not painful.  The numbness can last upto 1 hour. This test will 




If you are in the group patients with overactive bladder, we shall ask you to 
undergo a flexible cystoscopy and biopsy at some time but only once. This will 
allow us to examine your bladder more thoroughly and ascertain the degree of 
inflammation that might be affecting your bladder.  If you are in the control group 
you will NOT need to have this procedure done.  
 
Who will perform my procedure?  
 
A doctor trained in urology, surgery of the bladder, will perform the procedure.  
 
What is the procedure? 
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A doctor will insert an instrument called a cystoscope into your bladder via the 
water pipe (urethra). The instrument is a very fine and soft telescopic lens and 
attached to this is a light source and some sterile water to fill the bladder so that 
the lining can be inspected. A local anaesthetic gel is used to numb and lubricate 
the urethra to make the passage into the bladder as comfortable as possible.  
 
Some patients may experience slight discomfort during the procedure but the 
majority do not. If you do feel uncomfortable at any time you should inform the 
doctor performing the examination immediately.  
 
Once the instrument is in place, the examination will take only a few minutes to 
complete.  
 
Once the inspection is completed, the instrument will be removed, and you will 
be informed of the findings and the need for any further management.  
  
A nurse will remain with you whilst the treatment is taking place and will explain 
anything you do not understand.  
 
Are there any serious or frequently occurring risks? 
 
There are potential complications with any procedure. Although these are rare, it 
is important that you are aware of them and have the opportunity to discuss them 
with your doctor.  
 
Common  
Mild burning or bleeding on passing urine for a short period after the cystoscopy.  
 
Occasional  
Infection of the bladder requiring antibiotics. We shall be giving you a course of 
antibiotic treatment lasting one day at the time of the procedure 
 
Rare  
Delayed bleeding requiring removal of clots or further surgery. Injury to the 
urethra causing delayed scar formation. Difficulties in passing urine after the 
procedure requiring temporary insertion of a catheter.  
 
What does the bladder biopsy entail? 
 
When you have the cystoscopy the doctor will take a very small sample of 
bladder tissue (about 1-2mm) in addition to any that may be needed as part of 
your normal clinical care. It feels like a sharp scratch in your bladder, which is 
uncomfortable. The biopsy site from your bladder may bleed but it will stop 
bleeding by itself. There is no need to do anything to the area of the biopsy site 
to stop bleeding, as the sample of bladder tissue taken is very small and shallow. 
Whilst bladder biopsies are a common feature of normal patient care, this biopsy 
would be over and above those involved in normal care. 
 
Expenses and Payments 
 
We shall be able to reimburse you for travel expenses incurred from attending 
study assessments and for additional food and drink arising from this travel. We 
should be grateful for receipts describing the expenses for our auditors. We are 





It would not be advisable for you to participate in this study if you are already a 




It would not be advisable for you to participate in this study if you are pregnant or 
planning to become pregnant during the study period. Unless you are post-
menopausal and not had a period for more than 2 years, a urine pregnancy test 
will be preformed on all participants at the beginning of the study and before the 
cystoscopy.  
 
What will I have to do?  
 
You will have to: 
1. Give your consent  
2. Attend the hospital for your scheduled visits once each month 
3. Provide urine specimens at your visits.  





Day Identification and visit Actions 
Pre-study contact Informal recruitment process and 
participant sent information sheet 
Contact at around day -14 Participant contacted to set date of 
screening visit 
Day 0 Visit 1 1. Informed consent 
2. Urine Pregnancy test 
3. Participant completes 3 
questionnaires 
4. Midstream urine (MSU) 
sample obtained 
5. Urine stored for analysis 
6. Blood sample taken 
Visit 2 at 1 month  
 
1. Participant completes 3 
questionnaires 
2. MSU sample obtained 
3. Urine stored for analysis 
4. At Visit 2 a skin test will be 
preformed  
Visit 3 at 1 month and 2 days 
 
Skin test reviewed  
2 x 3mm skin biopsies taken 
Visits 4 – 14 (every month) 
 
1. Participant completes 3 
questionnaires 
2. MSU sample obtained 
3. Urine stored for analysis 
Additional visits every two to three 
days over the period of acute 
worsening of symptoms 
1. Participant completes 3 
questionnaires 
2. MSU sample obtained 





1. Participant completes 3 
questionnaires 
2. Urine Pregnancy test 
3. MSU sample obtained 
4. Urine stored for analysis  
5. Flexible cystoscopy and 
bladder biopsy  
 
 
What about my current treatments for other conditions?  
 
You will be able to continue all of your normal treatments and these will not be 
affected by this study. 
  
What are the alternatives to participating in the study?  
 
It is entirely your decision if you wish to take part in the study and it will not affect 
your future care if you do not wish to do so. If you do not wish to take part you 
will have your assessment in the usual way and your condition will be managed 
as is done routinely by your consultant.   
 
What are the possible disadvantages and risks of taking part?  
 
You will be seen more often than would be normal in this clinic. However, you 
will be seen outside of the clinic and will not have to wait as in an ordinary clinic. 
We shall do our best to book you in line with your convenience. We shall ask to 
perform a cystoscopy and bladder biopsy and that is explained in a separate part 
of this information package. 
 
If you ever experience a sudden worsening of your bladder symptoms we would 
like to see you immediately, on the same day, so as to get these resolved 
quickly. This could be inconvenient but it could also be very advantageous to 
you. 
 
What are the possible benefits of taking part? 
 
There may not be any benefit, however, you will have access to unusually close 
monitoring of your bladder symptoms.  
 
What happens when the research study stops?  
 
We shall be pleased to continue with your normal clinical care in the usual 
ways. 
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the trial or any 
possible harm you might suffer will be addressed. The detailed information 
concerning this is given in Part 2 of this information sheet. If you have any 
concerns or complaints you should contact your study doctor in the first instance. 
 
Will my taking part in the study be kept confidential?  
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Yes. We will follow ethical and legal practice and all information about you 





Name Professor James Malone-Lee  Tel. Number: 020 7288 5589 
 
Your Research Fellow  
Name Dr Kiren Gill     Tel. Number: 020 7288 3009 
 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before 
making any decision. 
 
Participant Information Sheet – Part 2 
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes 
available about the disease area that is being studied.  If this happens, your 
research doctor or nurse will tell you about it, and discuss with you whether you 
want to continue in the study.  
If you decide to withdraw your research doctor will make arrangements for your 
care to continue.   
If you decide to continue you will be asked to sign an updated consent form.  
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study.  He/she will explain the 
reasons and arrange for your care to continue.  
If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
 
What will happen if I don’t want to carry on with the study?  
 
You are free to withdraw from the study at any time before and after 
signing the consent form without needing to give any explanations. The 
study may be ended at any time with or without your consent. 
 
Should you wish to leave the study we shall offer you a general check-up and the 
option of continued outpatient follow-up.  
 
Unless you wish otherwise, the data collected from you up to the point at which 
you leave the study will be used in the analysis. 
 
What if there is a problem?  
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Every care will be taken to ensure your safety during the course of the study. If 
you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions. Please contact 




In the event that something does go wrong and you are harmed as a result of 
taking part in the approved research study UCL, the Research Sponsor, has 
indemnity (insurance) arrangements in place for non-negligent harm. If you are 
harmed and this is due to someone’s negligence then you may have grounds for 
legal action for compensation against the Trust but you may have to pay your 
legal costs.   
 
Every care will be taken in the course of this clinical trial.  However in the unlikely 
event that you are injured by taking part, compensation may be available. 
 
If you suspect that the injury is the result of the Sponsor’s (University College 
London) or the hospital's negligence then you may be able to claim 
compensation.  After discussing with your study doctor, please make the claim in 
writing to Professor Malone-Lee who is the Chief Investigator for the clinical trial 
and is based at Department of Medicine, Clerkenwell Building, Highgate Hill, 
London N19 5LW. The Chief Investigator will then pass the claim to the 
Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the costs of 
the legal action initially, and you should consult a lawyer about this. 
 
Participants may also be able to claim compensation for injury caused by 
participation in this clinical trial without the need to prove negligence on the part 
of University College London or another party. You should discuss this possibility 
with your study doctor in the same way as above.  
 
Complaints  
If you have any questions about your rights as a research subject or have 
a complaint about the way in which the study has been carried out, please 
contact: Ms Senga Steel, Assistant Director of Nursing, Whittington 
Hospital NHS Trust, Magdala Avenue, London N19 5NF; Tel 020 7288 
3405 
If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure.  Details can be obtained from the 
hospital or from the Department of Health website: http://www.dh.gov.uk.  
You may obtain the necessary guidance from the hospital Patient Advice 
and Liaison Service (PALS), Whittington Hospital, Tel 020 7288 5956 or 
020 7288 5957  
 
Will my taking part in this study be kept confidential?  
 
If you consent to take part in this study, the records obtained while you 
are in this study as well as related health records will remain strictly 
confidential at all times. The information will be held securely on paper 
and electronically at the hospital site managing this research under the 
provisions of the 1998 Data Protection Act. Your name will not be passed 
to anyone else outside the research team or the Sponsor (UCL), who is 
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not involved in the trial. You will be allocated a trial number, which will be 
used as a code to identify you on all trial forms. Any information about you 
which leaves the hospital will have your name and address removed so 
that you cannot be recognised (if it is applicable to your research). 
 
Your records will be available to people authorised to work on the trial but 
may also need to be made available to people authorised by the Sponsor, 
which is the organisation responsible for ensuring that the study is carried 
out correctly.  By signing the consent form you agree to this access for the 
current study and any further research that may be conducted in relation 
to it, even if you withdraw from the current study.  
 
If you withdraw consent from further study treatment, unless you object, your 
data and samples will remain on file and will be included in the final study 
analysis. 
 
In line with the regulations, at the end of the study your data will be securely 
archived for a minimum of 15 years. Arrangements for confidential destruction 
will then be made.  
 
Will my GP be informed of my involvement? 
 
With your permission, your GP, and other doctors who may be treating you, will 
be notified that you are taking part in this study. 
 
What will happen to any samples I give?  
 
A urine specimen will be taken and part of it will be sent to the hospital laboratory 
to check for any bacteria in your urine and another portion will be looked at under 
the microscope to detect small ‘white blood cells,’ which can signify an infection 
in the urine. Two bladder biopsies will be taken at the time of your cystoscopy. 
One will be sent to the hospital laboratory for analysis and the other specimen 
will be analysed by the researcher.  Samples will not be labelled with information 
that can directly identify you, and will only be labelled with the study number that 
has been allocated to you. A portion of the urine samples will be frozen and 
stored for further analysis of inflammation chemicals and bacterial proteins. We 
think that it may play an important role in the development of over-active bladder 
symptoms. The anonymised samples will be stored in a monitored freezer in a 
secure laboratory in the Department of Medicine, Clerkenwell Building. The 
samples will be analysed by researchers within the Division of Medicine at UCL. 
Once analysed the urine sample will be disposed of as per UCL regulations. 
 
Will any genetic tests be done? 
 
No genetic tests will be done.  
 
What will happen to the results of the research?  
 
The results of the study may be published in scientific journals so that other 
researchers working on improving treatments for people with troublesome 
bladder symptoms and incontinence will benefit from our knowledge. You will not 
be identified of any publications and we shall provide you in any case with a 
report of the results of the trial. 
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Who is organising and funding the research?  
 
This study is organised by the Department of Medicine at the Whittington 
Hospital. We are currently making applications for research funds to support this 
programme and are funded this work from our own resources at this time. The 
study is sponsored by University College London.  
 
Who has reviewed the study?  
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests.  This study has been 
reviewed and given favourable opinion by East Central London Research Ethics 
Committee (1).  
 
Further information and contact details  
 
You are encouraged to ask any questions you wish, before, during or after your 
treatment. If you have any questions about the study, please speak to your study 
nurse or doctor, who will be able to provide you with up to date information about 
the drug(s)/procedure(s) involved. If you wish to read the research on which this 
study is based, please ask your study nurse or doctor. If you require any further 
information or have any concerns while taking part in the study please contact 
one of the following people: 
 
Your Doctor 
Name Professor James Malone-Lee  Tel. Number: 020 7288 5589 
 
Your Research Fellow  
Name Dr Kiren Gill     Tel. Number: 020 7288 3009 
 
If you decide you would like to take part then please read and sign the consent 
form. You will be given a copy of this information sheet and the consent form to 
keep. A copy of the consent form will be filed in your patient notes, one will be 
filed with the study records and one may be sent to the Research Sponsor. 
 
You can have more time to think this over if you are at all unsure. 
 



















A blinded observational cohort study of the immunological changes 
associated with  Chronic Cystitis and Overactive Bladder symptoms in 
women 
 
Study Number:        Participant Identification Number for this trial:  
 
Name of Researcher:   
 
1. I confirm that I have read and understand the information sheet 
dated.................... (version............) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by individuals from the 
sponsor of the trial (University College London), from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my 
records.  
 
4. I agree to my GP being informed of my participation in the study.  
 




           
Name of Patient    Date    Signature  
 
 
           
Name of Person    Date    Signature  
taking consent  
 
Department of Medicine 
1st Floor, Clerkenwell Building 
Archway Campus 
Highgate Hill 
London N19 5LW 
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Name of Chief Investigator  Date    Signature  
(if different to the person taking consent)  
 






































ICIQ	  FLUTS	  Long	  Form	  August	  2004	  
Copyright	  ©	  “ICIQ	  Group”	  





ICIQ	  FLUTS	  Long	  Form	  
Whittington	  Urgency	  Score	  




This	  questionnaire	  combines	  with	  ICIQ-­‐FLUTS	  Long	  Form	  with	  the	  Whittington	  
Urgency	  Score	  and	  the	  Whittington	  Bladder	  Pain	  Score.	  This	  long	  form	  of	  the	  
questionnaire	  contains	  important	  questions	  about	  voiding	  ability	  that	  are	  
germane	  to	  the	  occurrence	  of	  urine	  infection
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We	  should	  be	  grateful	  if	  you	  would	  answer	  the	  following	  questions,	  thinking	  about	  
how	  you	  have	  been,	  on	  average,	  over	  the	  PAST	  FOUR	  WEEKS.	  
	  
1.	  Please	  write	  your	  date	  of	  birth____________________________________________
	   	  
	  
2A.	  How	  often	  do	  you	  pass	  urine	  during	  the	  day?	  
	  
One	  to	  six	  times	   0	   	  
Seven	  to	  eight	  times	   1	   	  
Nine	  to	  ten	  times	   2	   	  
Eleven	  to	  twelve	  times	   3	   	  
Thirteen	  times	  or	  more	  times	   4	   	  
	  
2B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
3A.	  During	  the	  night,	  how	  many	  times	  do	  you	  have	  to	  get	  up	  to	  urinate,	  on	  average?	  
	  
None	   0	   	  
One	   1	   	  
Two	   2	   	  
Three	   3	   	  
Four	  or	  more	   4	   	  
	  
3B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
4A.	  Do	  you	  have	  a	  sudden	  need	  to	  rush	  to	  the	  toilet	  to	  urinate?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
4B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	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4C.	  If	  you	  do	  experience	  urgency,	  a	  sudden	  need	  to	  rush	  to	  the	  toilet	  to	  urinate,…...	  
	  
	   Tick	  if	  Yes	  
Does	  cold	  weather	  make	  matters	  worse?	   	  
Does	  the	  sound	  of	  running	  water	  cause	  urgency?	   	  
Does	  putting	  a	  key	  in	  your	  door	  or	  nearing	  home	  cause	  urgency?	   	  
Does	  getting	  out	  of	  bed	  in	  the	  morning	  cause	  urgency	   	  
Does	  fatigue	  or	  anxiety	  make	  mattes	  worse?	   	  
	  
5A.	  Does	  urine	  leak	  before	  you	  can	  get	  to	  the	  toilet?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
5B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
5C.	  If	  you	  do	  experience	  urge	  incontinence,	  a	  urine	  leak	  before	  you	  can	  get	  to	  the	  
toilet,…...	  
	  
	   Tick	  if	  Yes	  
Does	  the	  sound	  of	  running	  water	  cause	  incontinence?	   	  
Does	  putting	  a	  key	  in	  your	  door	  or	  nearing	  home	  cause	  incontinence?	   	  
Does	  getting	  out	  of	  bed	  in	  the	  morning	  cause	  incontinence?	   	  
	  
6A.	  Do	  you	  have	  pain	  in	  your	  bladder?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
6B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	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6C.	  If	  you	  do	  experience	  bladder	  pain,…...	  
	  
	   	   Tick	  if	  Yes	  
Do	  you	  experience	  discomfort	  or	  pain	  on	  bladder	  filling?	   	  
Is	  there	  pain	  or	  discomfort	  in	  or	  over	  the	  pubic	  area?	   	  
	   Is	  this	  pain	  or	  discomfort	  relieved	  completely	  by	  passing	  
urine?	  
	  
	   Is	  this	  pain	  or	  discomfort	  partially	  relieved	  by	  passing	  urine?	   	  
	   Is	  this	  pain	  or	  discomfort	  unrelieved	  by	  passing	  urine?	   	  
Is	  there	  bladder	  pain	  or	  discomfort	  whilst	  passing	  urine?	   	  
Is	  there	  pain	  or	  discomfort	  after	  passing	  urine?	   	  
Is	  there	  pain	  in	  your	  back	  over	  your	  kidneys?	   	  
Is	  there	  pain	  referred	  to	  or	  felt	  in	  the	  genitals?	   	  
Is	  there	  pain	  on	  the	  left	  or	  right	  side	  of	  the	  lower	  abdomen?	   	  
Is	  there	  general	  abdominal	  pain?	   	  
Is	  there	  pain	  radiating	  down	  your	  legs?	   	  
	  
7A.	  How	  often	  do	  you	  leak	  urine?	  
	  
Never	   0	   	  
Once	  or	  less	  per	  week	   1	   	  
Two	  or	  three	  times	  per	  week	   2	   	  
Once	  per	  day	   3	   	  
Several	  times	  per	  day	   4	   	  
	  
7B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
8A.	  Does	  urine	  leak	  when	  you	  are	  physically	  active,	  exert	  yourself,	  cough	  or	  sneeze?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
8B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	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9A	  Do	  you	  ever	  leak	  for	  no	  obvious	  reason	  and	  without	  feeling	  that	  you	  want	  to	  go?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
9B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
10	  How	  much	  urinary	  leakage	  occurs?	  
	  
No	  leakage	   0	   	  
Drops/pants	  damp	   1	   	  
Dribble/pants	  wet	   2	   	  
Floods,	  soaking	  through	  to	  outer	  clothing	   3	   	  
Floods	  running	  down	  legs	  onto	  the	  floor	   4	   	  
	  
11A.	  Is	  there	  a	  delay	  before	  you	  cant	  start	  to	  urinate?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
11B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
12A.	  Do	  you	  have	  to	  strain	  to	  urinate?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
12B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
13A.	  Do	  you	  stop	  and	  start	  more	  than	  once	  while	  you	  urinate?	  
	  
Never	   0	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Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
13B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
14A.	  Do	  you	  leak	  urine	  when	  you	  are	  asleep?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
14B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
15A.	  Would	  you	  say	  that	  the	  strength	  of	  you	  urinary	  stream	  is………..?	  
	  
Not	  reduced	   0	   	  
Reduced	  a	  little	   1	   	  
Quite	  reduced	   2	   	  
Reduced	  a	  great	  deal	   3	   	  
No	  steam	   4	   	  
	  
15B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
16.	  Have	  you	  ever	  blocked	  up	  completely	  so	  that	  you	  could	  not	  urinate	  at	  all	  and	  had	  
to	  have	  a	  catheter	  to	  drain	  the	  bladder?	  
	  
No	   0	   	  
Yes,	  once	   1	   	  
Yes,	  twice	   2	   	  
Yes,	  more	  than	  twice	   3	   	  
	  
 191	  
17A.	  Do	  you	  have	  a	  burning	  feeling	  when	  you	  urinate?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
17B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
18A.	  How	  often	  do	  you	  feel	  that	  your	  bladder	  has	  not	  emptied	  properly	  after	  you	  have	  
urinated?	  
	  
Never	   0	   	  
Occasionally	   1	   	  
Sometimes	   2	   	  
Most	  of	  the	  time	   3	   	  
All	  of	  the	  time	   4	   	  
	  
18B.	  How	  much	  does	  this	  bother	  you?	  
(Please	  ring	  a	  number	  between	  0	  (not	  at	  all)	  and	  10	  (a	  great	  deal)	  
	  
	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   	  
Not	  at	  all	   	   	   	   	   	   	   	   	   	   A	  great	  deal	  
	  
19.	  Can	  you	  stop	  the	  flow	  of	  urine	  if	  you	  try	  while	  you	  are	  urinating?	  
	  
Yes,	  easily	   0	   	  
Yes,	  with	  difficulty	   1	   	  






9.5 Whittington	  Urgency	  score	  
	  
Whittington	  Urgency	  Score	  
Please	  enter	  date	  of	  completion:	  	   dd-­‐mmm-­‐yy	  
We	  should	  be	  grateful	  if	  you	  would	  answer	  the	  following	  questions,	  thinking	  
about	  how	  you	  are	  at	  the	  moment.	  Please	  put	  a	  circle	  around	  your	  response	  for	  
each	  question.	  
	  
Score	  0	  for	  none	  
Score	  1	  for	  some	  
Score	  2	  for	  much	  	  
	  
	  
Do	  you	  experience	  urgency?	  
That	  is	  having	  to	  hurry	  in	  order	  to	  pass	  urine	  
None	   Some	   Much	  
Do	  you	  experience	  urge	  incontinence?	  
That	  is	  hurrying	  to	  pass	  urine	  and	  not	  making	  it	  in	  
time	  
None	   Some	   Much	  
Does	  cold	  weather	  make	  your	  bladder	  symptoms	  
worse?	  
None	   Some	   Much	  
Do	  you	  find	  that	  running	  water	  from	  a	  tap	  causes	  
urinary	  urgency?	  
None	   Some	   Much	  
Do	  you	  find	  that	  running	  water	  from	  a	  tap	  causes	  
incontinence?	  
None	   Some	   Much	  
Do	  you	  find	  that	  putting	  a	  key	  in	  the	  front	  door	  
when	  returning	  home	  causes	  urinary	  urgency?	  
None	   Some	   Much	  
Do	  you	  find	  that	  putting	  a	  key	  in	  the	  front	  door	  
when	  returning	  home	  causes	  urinary	  
incontinence?	  
None	   Some	   Much	  
Do	  you	  find	  that	  on	  getting	  up	  from	  bed	  in	  the	  
morning	  you	  experience	  urgency?	  
None	   Some	   Much	  
Do	  you	  find	  that	  on	  getting	  up	  from	  bed	  in	  the	  
morning	  you	  experience	  urge	  incontinence?	  
None	   Some	   Much	  
Does	  anxiety	  or	  fatigue	  make	  your	  symptoms	  
worse?	  
None	   Some	   Much	  




9.6 Whittington	  Pain	  score	  
	  
Whittington	  Pain	  Score	  
	  
Please	  enter	  date	  of	  completion:	  	   dd-­‐mmm-­‐yy	  
	  
We	  should	  be	  grateful	  if	  you	  would	  answer	  the	  following	  questions,	  thinking	  





Score	  1	  for	  yes	  




Do	  you	  experience	  pain	  or	  discomfort	  on	  bladder	  filling?	   Yes	   No	  
Do	  you	  experience	  pain	  or	  discomfort	  in	  or	  over	  the	  pubic	  
area?	  
Yes	   No	  
Do	  you	  experience	  burning	  or	  pain	  when	  passing	  urine?	   Yes	   No	  
Do	  you	  experience	  pain	  in	  your	  back	  over	  your	  kidneys?	   Yes	   No	  
Do	  you	  experience	  pain	  in	  the	  genitals?	   Yes	   No	  
Do	  you	  experience	  pain	  on	  the	  left	  or	  right	  side	  of	  the	  lower	  
abdomen?	  
Yes	   No	  
Do	  you	  experience	  general	  abdominal	  pain	  or	  discomfort?	   Yes	   No	  
Do	  you	  experience	  pain	  radiating	  down	  your	  legs?	   Yes	   No	  




9.7 Instructions	  on	  clean	  catch	  MSU	  
	  
Midstream	  Urine	  Specimen	  
	  
For	  correct	  test	  results,	  follow	  instructions	  carefully.	  
A	  jug,	  a	  plastic	  container	  and	  a	  wet	  gauze	  will	  be	  given	  to	  you	  
	  
Cleansing	  before	  collecting	  the	  urine	  specimen	  
	  
1. Squeeze	  and	  rub	  some	  alcohol	  gel	  onto	  your	  hands	  once	  you	  are	  in	  the	  
toilet.	  	  There	  are	  alcohol	  gel	  bottles	  in	  each	  toilet.	  
	  
2. Thoroughly	  cleanse	  the	  entire	  genital	  area	  using	  the	  special	  gauze	  that	  is	  
in	  the	  jug.	  
	  
•  Females	  –	  hold	  the	  outer	  edges	  of	  labia	  apart	  and	  cleanse	  from	  
front	  to	  back	  with	  the	  gauze.	  	  One	  wipe	  only!	  
	  
•  Males	  –	  retract	  foreskin	  if	  not	  circumcised	  and	  wipe	  the	  end	  of	  	  
the	  penis	  with	  the	  gauze.	  	  One	  wipe	  only!	  
	  
Please	  do	  not	  throw	  the	  gauze	  into	  the	  toilet	  bowl.	  	  Throw	  it	  into	  the	  yellow	  
bin	  which	  is	  on	  the	  floor	  of	  the	  toilet	  
	  
Collecting	  the	  urine	  specimen	  
	  
•  Females	  –	  continue	  to	  hold	  labia	  apart	  while	  urinating	  
	  
•  Males	  –	  continue	  to	  retract	  foreskin	  while	  urinating	  
	  
1. Urinate	  (pee)	  a	  small	  amount	  of	  urine	  into	  the	  toilet.	  
2. Then	  without	  stopping,	  catch	  some	  urine	  into	  the	  bowl	  by	  passing	  
it	  into	  the	  urine	  stream.	  
3. As	  the	  stream	  comes	  to	  the	  end	  move	  the	  bowl	  away	  and	  urinate	  
(pee)	  the	  rest	  into	  the	  toilet	  
4. Put	  the	  lid	  on	  the	  jug	  and	  bring	  it	  to	  a	  member	  of	  staff.	  
	  
Wash	  hands	  after	  collecting	  the	  urine	  specimen.	  
	  
	  
	  
